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Abstract
The problems of high dimensionality and heterogeneity of data always raise
lots of challenges in computational biology and chemistry. As the size of data
sets increase, as well their complexity, dimensionality reduction and advanced
analytics will gain its importance. The past 10 years or so, data integration has
become an active area of research in the field of machine learning, bioinformatics
and chemoinformatics.
Several dimensionality reduction and data integration methods are currently
available for analyzing and classifying biological data. In the first part of
this thesis, we concentrate on dimensionality reduction techniques such as
the Generalized Eigenvalue Decomposition (GEVD) and Robust Principal
Component Analysis (RPCA). We will investigate the generalized eigenvalue
decomposition (GEVD) in a maximum likelihood setting, in which we employ
a technique relying on the generalization of the singular value decomposition
(SVD). We will elaborate the similarity between maximum likelihood estimation
via a generalized eigenvalue decomposition (MLGEVD) and generalized ridge
regression. This relationship reveals an important mathematical property of
GEVD in which one of the matrices acts as prior information in the model
development. Later we present GEVD for the integration of microarray and
literature information. Then robust PCA (RPCA) is applied on a weighted
matrix for the identification of differentially expressed genes of colon cancer.
In the second part of the thesis, we propose a data-driven bandwidth selection
criterion for kernel PCA (KPCA), which is a non-linear dimensionality reduction
technique. We center our discussion on feature selection/transformation
techniques in medical diagnostics. We show how to build stable, robust and
interpretable classifiers on non-linearly separable data.
In the third part of the thesis we investigate a machine learning approach,
a weighted LS-SVM classifier to integrate two data sources. This algorithm
offers a single mathematical framework for data integration and classification
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problems, hence providing solutions for many real bioinformatics applications.
Finally, based on PCA, we define new chemical descriptors from the connection-
table of chemical compounds. In addition, we develop a new machine learning
approach for the identification of biofilm inhibitors of Salmonella Typhimurium
and Pseudomonas aeruginosa. Here, PCA converts the connection-table of
each compound into a structural descriptor of two vectors: one corresponding
to atoms and the other to bonds. As a supervised classification algorithm,
a weighted least squares support vector machine is used in which a table
enumerating the atoms is weighted against a table enumerating the bonds. We
apply this framework to a given experimental data set on activity of collection
of compounds against Salmonella and Pseudomonas biofilms. This trained
model predicts the activity of new compounds on these biofilms.
Beknopte samenvatting
Hoge dimensionaliteit en heterogeniteit van data vergroten de uitdagingen in
computationele biologie en chemie. Naarmate de grootte en de complexiteit van
de datasets vergroot, zullen dimensie reductie en geavanceerde analytics steeds
belangrijker worden. In de laatste 10 jaar is data integratie een actief research
onderwerp geworden in machine learning, bioinformatics en chemoinformatics.
Verschillende dimensie reductie en data integratie methoden zijn op dit moment
beschikbaar om biologische data te analyseren en classificeren. In het eerste
deel van de thesis gaan we ons concentreren op dimensie reductie technieken
zoals Generalized Eigenvalue Decomposition (GEVD) and Robust Principal
Component Analysis (RPCA). We onderzoeken de generalized eigenvalue
decomposition (GEVD) techniek in een maximum likelihood setting waarbij we
gebruik maken van een techniek gebaseerd op de generalisatie van de singular
value decomposition (SVD). We gaan in op de gelijkenis tussen maximum
likelihood estimation via een generalized eigenvalue decomposition (MLGEVD)
en generalized ridge regression. Dit verband toont een belangrijke wiskundige
eigenschap van GEVD waar een van de matrices zich voordoet als prior
information in de ontwikkeling van het model. Later gaan we GEVD voorstellen
als integratie techniek van microarray data en literatuur informatie. Daarna
wordt Robuste PCA toegepast op een gewogen matrix voor de identificatie van
verschillend uitgedrukte genen van darmkanker.
In het tweede deel van de thesis stellen we een data-gedreven selectie
criterium voor voor kernel PCA (KPCA). KPCA is een niet-lineaire dimensie
reductie techniek. We focussen onze discussie op feature selectie/transformatie
technieken in medische diagnostistiek. We tonen hoe een stabiele, robuste en
interpreteerbare classifier te maken op niet lineair scheidbare data.
In het derde deel van de thesis onderzoeken we een machine learning aanpak,
een gewogen LS-SVM classifier, om twee data bronnen te integreren. Dit
algoritme biedt een enkel wiskundig raamwerk voor data integratie en classificatie
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problemen, dus het voorziet oplossingen voor vele echte toepassingen in
bioinformatics. Tenslotte, gebaseerd op PCA, gaan we nieuwe chemische
beschrijvingen definiëren uit de aansluittabel van chemische verbindingen.
Daarnaast ontwikkelen we een nieuwe machine learning aanpak voor de
identificatie van biofilm remmers van Salmonella Typhimurium en Pseudomonas
aeruginosa. Hier zal PCA de aansluittabel van elke verbinding converteren
in een gestructureerde beschrijving van twee vectoren: een corresponderend
met de atomen en de andere met verbindingen. Als gesuperviseerd classificatie
algoritme wordt een gewogen least squares support vector machine gebruikt
waarbij een tabel die de atoomaantallen weergeeft gewogen wordt tegen een
tabel die de verbindingen weergeeft. We passen dit raamwerk toe op een gegeven
experimentele dataset over de activiteit van een verzameling van verbindingen
van Salmonella versus Pseudomonas biofilms. Dit getrainde model voorspelt de
activiteit van nieuwe verbindingen op deze biofilms.
Glossary
AD Applicability Domain
ALM Augmented Lagrange Multipliers
AUC Area Under the Curve
CacyBP Calcyclin Binding Protein
cDNA Complementary DNA
CRC Colorectal Cancer
CTL Cytotoxic T cells
DEG Differentially Expressed Genes
DNA Deoxyribonucleic acid
EDMD Early-early Stage Duchenne Muscular Dystrophy
eIF Eukaryotic initiation factor
ER Estrogen Receptor
EVD Eigenvalue Decomposition
FDA Fisher Discriminant Analysis
FN False Negatives
FP False Positives
GEV Generalized Eigenvectors
GEVD Generalized Eigenvalue Decomposition
GO The Gene Ontology
GSVD Generalized Singular Value Decomposition
HER2 Human Epidermal Growth Factor Receptor 2
HGF Hepatocyte growth factor
HLA Human Leukocyte Antigen
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IALM Inexact ALM
ITTACA Integrated Tumor Transcriptome Array and
Clinical data Analysis Database
KPCA Kernel PCA
Lasso Least Absolute Shrinkage and Selection Opera-
tor
LOO Leave-One-Out
LOO-CV Leave-One-Out cross validation
LS-SVM Least Squares Support Vector Machines
MLGEVD Maximum Likelihood estimation via Generalized
Eigenvalue Decomposition
MLPCA Maximum Likelihood Principal Component
Analysis
mRNA Messenger RNA
NCI National Cancer Institute
NSC Nearest Shrunken Centroids
OAZ1 Ornithine Decarboxylase
PAM Prediction Analysis of Microarrays
PCA Principal Component Analysis
PR Progesterone Receptor
QP Quadratic Programming
QSAR Quantitative Structure Activity Relationships
RBF Radial Basis Function
RNA Ribonucleic Acid
ROC Receiver Operating Characteristic
RPCA Robust PCA
RPL41 Ribosomal Protein L41
RPs Ribosomal Proteins
rRNAs Ribosomal RNAs
SRF Serum Response Factor
SVD Singular Value Decomposition
SVM Support Vector Machines
Glossary ix
TCTP Translationally Controlled Tumor Protein
TLS Total Least Squares
TN True Negatives
TP True Positives
Tra1 Tumor Rejection Antigen1
UC Ulcerative Colitis
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Chapter 1
Introduction
Bioinformatics and chemoinformatics have evolved at the interface between
chemistry, biology and information technology. In many areas of biological
and chemical science, the huge amount of data and information produced
by high-throughput technologies such as microarray can only be processed
and analyzed using computational techniques. Predictive informatics methods
employ statistical techniques to mine this data for hidden correlations and
to retrieve molecules, genes or patterns with specific properties or desirable
biological activities from large datasets. Furthermore, many of these problems
are so complex that they require informatics methods for solving them.
Informatics methods have been especially valuable in drug design/development
and personalized medicine, but are also increasingly employed in several other
disciplines governed by complex systems. This calls for an interdisciplinary
approach to studying these problems.
1.1 Data Integration and Dimensionality Reduction
Techniques
Data integration is the process of integrating data from multiple sources into
meaningful and valuable information. The process has an important role
in several situations, including business and scientific domains. The data
integration aims at combining selected data sources which form one single
comprehensive view of data sources. There are varieties of applications that
benefit from data integration. In the area of business intelligence, integrated
data sources can be used for querying and reporting on business activities,
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for statistical analysis, data mining, and machine learning in order to enable
forecasting, decision making, and predictions. Data integration in the life
sciences becomes a more complex challenge considering the current “data
explosion” [69]. A lot of theoretical work dealing with data integration and
numerous open problems remain unsolved, mainly on resolving semantic conflicts
between heterogeneous data sources [67].
In the last few years, machine learning techniques have been successfully applied
to many application areas such as information retrieval [151], image processing
[114], computational biology, and chemistry. To understand and explore the
real datasets, we often apply machine learning techniques such as clustering or
classification in a high dimensional space. However, developing these machine
learning models on large data sets can be very time-consuming because of its high
dimensionality. Dimensionality reduction is the most important technique in
unsupervised learning [43], to get a meaningful structure or previously unknown
patterns in the multivariate data.
1.1.1 Data Integration and Dimensionality Reduction in Life
Sciences
Data integration in the life sciences is an important area of research, but it is a
difficult task. The current advancement in science and technology gives rise to
an increasingly wide range of data sources, which in turn must be combined to
get an integrated single view of the biological systems. Indeed, the increasing
importance of computational biology, the science of using biological data to
develop algorithms and relations among various biological systems, emphasizes
the importance of data integration in the life sciences.
In the post-genomic era [116], modern biology has generated tremendous
information by biological high-throughput technologies, such as proteomics
and transcriptomics. This omics data can be very useful, but the real challenge
is to analyze all this data, as a whole, after integrating it [153]. Data integration
helps us get a comprehensive view of different, heterogeneous and distributed
biomedical data sources. Data integration solutions can be very useful in
biomedical information retrieval, clinical diagnosis, system biology, drug design
etc [153].
The data integration plays [199] an important role in the growth of data-driven
knowledge discovery in life sciences. The integration of diverse data helps
the biologists to get the interesting patterns or behavior from the data or
perform comparative analyses among different biological systems. The effective
integration of information from different biological data sources is considered as
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the pre-requisite for many computational biology/bioinformatics research and
has advantages in a wide range of use cases such as analysis and understanding
of omics data, biomarker discovery, and analysis of pathways for drug discovery.
The problem of high dimensionality can be approached with the use of dimension-
ality reduction methods. Principal component analysis (PCA), singular value
decomposition (SVD), eigenvalue decomposition (EVD), generalized singular
value decomposition (GSVD) and generalized eigenvalue decomposition (GEVD)
are commonly used, dimensionality reduction techniques, for the analysis of
high-dimensional data such as genomics, proteomics data etc.
Application Areas
The following sections provide a brief description of the application areas of life
sciences which we discuss throughout the thesis: microarray data analysis [29],
an introduction to quantitative structure–activity relationship (QSAR) models
[75] and clinical data analysis.
Microarray Data Analysis
Microarray technology has become one of the crucial tools that many biologists
use to monitor genome-wide expression levels of genes in a given organism.
Microarrays may be used to measure gene expression in many ways, but one of
the most popular applications is to compare the expression of a set of genes
from a cell maintained in a particular condition (Test Cells) to the same set of
genes from a reference cell maintained under normal conditions (Control Cells)
[173]. Figure 1.1 gives a general picture of the experimental steps involved in
microarray data.
The following procedures, we quote from [29]. First, RNA is extracted from
the cells, which reverse transcribed into cDNA by using an enzyme reverse
transcriptase and nucleotides labeled with different fluorescent dyes (red and
green). Once the samples have been differently labeled, they are allowed to
hybridize onto the same glass slide. Following the hybridization step, the spots
in the hybridized microarray are excited by a laser and scanned to detect
the red and green dyes. The amount of fluorescence emitted upon excitation
corresponds to the amount of bound nucleic acid. If the gene was expressed to
the same extent in both conditions, one would find the spot to be yellow, and
if the gene was not expressed in both conditions, the spot would be black. At
the end of the experimental stage, we get an image of the microarray, in which
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Figure 1.1: The general picture of the experimental steps involved in microarray
analysis
each spot representing a gene with fluorescence value indicating the relative
expression level of that gene.
The microarray is scanned following hybridization and an image file is normally
generated. Then the image is analyzed to identify spots. In the case of
microarrays, the spots are arranged in an orderly manner into sub-arrays or pen
groups, which makes spot identification straightforward. After identifying areas
corresponding to sub-arrays, an area within the sub-array must be selected to
get a measure on the spot and background intensity. The relative expression
level of a gene can be measured as the amount of red or green light emitted
after excitation [9]. The most common metric used to relate this information is
called expression ratio. It is denoted here as Tk and defined as
Tk = Rk/Gk
For each gene k on the array, where Rk represents the spot intensity metric for
the test sample and Gk represents the spot intensity metric for the reference
sample. The processed data, after the normalization procedure (total intensity
normalization or Mean log centering), can then be represented in the form of a
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matrix, often called gene expression matrix. Each row in the matrix corresponds
to a particular gene and each column could either correspond to an experimental
condition or a time at which expression of the genes has been measured. The
expression levels of a gene across different experimental conditions are named
as the gene expression profile, and the expression levels of all genes under an
experimental condition are named as the sample expression profile.
Quantitative structure–activity relationship (QSAR) models
Molecular descriptors are numerical values that characterize the properties of
chemical compounds. Descriptors are frequently divided into 1D, 2D, or 3D
descriptors, depending on the dimensionality of the molecular representation
from which they can be calculated [20]. Specifically, 1D descriptors are based
exclusively on the type of atoms which make up the molecule. In addition to
the types of atoms, 2D descriptors also incorporate the bonding pattern of
the molecule. 3D descriptors consider the spatial arrangement of the atoms
in the molecule. Figure 1.2 shows examples of 1D, 2D, and 3D descriptors
of Acetone (PubChem CID:180 ). The QSAR models [75], are focused on
estimating the biological activity of a molecule. QSAR modeling generates
predictive models derived from the application of statistical/machine learning
techniques correlating biological activity (including desirable therapeutic effect
and undesirable side effects) or physio-chemical properties with descriptors
representatives of molecular structure or properties. A good quality QSAR
model depends on many factors, such as the quality of input data, the choice
of descriptors and statistical methods for modeling and for validation. The
Figure 1.3 shows the main steps involved in a QSAR process. Any QSAR
modeling [196] should ultimately lead to statistically robust and predictive
models, capable of making accurate and reliable predictions about the activity
of new compounds.
Clinical Data Analysis
Clinical decision support systems are essential to improve the cost-effectiveness
of overall health care systems, especially since the cost of health care for age-
related diseases such as cancer is significantly increased due to aging populations
[12]. In medical applications, clinical decision support system helps clinicians
to improve their clinical decision making. Clinicians are also overwhelmed
by a tsunami of data for each single patient. Clinical data based on patient
history, tumor characteristics, laboratory analysis, ultrasound parameters, or
environmental factors are more easily accessible [63]. Information obtained from
genome, proteome, transcriptome, contributes to personalize medicine equally
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Figure 1.2: Examples of 1D, 2D, and 3D descriptors: Acetone
well. This enables clinicians to make decisions regarding diagnosis, prognosis
and response to therapy based on real biological insights on why tumors behave
differently from patient to patient.
1.2 Motivation and Problem Statement
Genomics, proteomics, and clinical data being generated from clinical
tumors have the potential to transform cancer management. The rapid
developments of high-throughput technologies of molecular profiling at the
genome, transcriptome, epigenome, protein, and pharmacological levels demand
efficient computational approaches for combining or analyzing the results of
those technologies.
Recently, data-driven computational cancer modeling has become an active field
of cancer research [47]. In particular, the development of cancer models that
encompass different biological scales in time and space (i.e. multiscale cancer
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Figure 1.3: QSAR Process
models), has gained attention in view of the potential to integrate disparate
kinds of patient data and to enable patient-specific prediction and assist in
treatment planning [89]. Several computational tools that assist biologists
and human geneticists have been developed, including tools to organize and
query scientific literature (such as e.g. Pubmed, GOPubmed [49]) or tools to
analyze and interpret high-throughput data such as expression data (GeneSpring,
Bioconductor [61]).
Recent technological advances in high-throughput biology have generated vast
amounts of disparate biological data describing different aspects of cellular
functioning also known as omics layers[66]. It has largely been accepted that
a comprehensive understanding of a biological system (cell) can come only
from a joint analysis of all omics layers [69, 91]. One of the main aims is to
define efficient algorithms that combine existing knowledge with raw data in
order to create novel hypotheses to be experimentally assayed and eventually
enrich our knowledge. The main goal of any data integration methodology is to
extract additional biological information from multiple data sets that cannot be
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gained from any single data set alone[66]. To reach this goal, data integration
methodologies have to meet many computational challenges. These challenges
arise owing to different sizes, formats, and dimensionalities of the data being
integrated, also due to their complexity, noisiness, information content etc [66].
Alter et al. [3] proposed a comparative mathematical framework, based
on generalized singular value decomposition (GSVD), for two genome-scale
expression data sets. This framework formulates expression as the superposition
of the effects of regulatory programs, biological processes, and experimental
artifacts common to both data sets, as well as those that are exclusive to one
data set or the other, by using GSVD. This framework enables comparative
reconstruction and classification of the genes and arrays of both data sets. This
GSVD framework can be used for comparison of two genomic data sets from
the same repeated experiments or two different types of genomic information
such as DNA copy number, mRNA expression, or protein abundance, collected
from the same set of samples to explain the molecular composition of the
overall biological signal in these samples, to illustrate the relation between
chromosomes of the same organism [3]. GSVD has been successfully used in
many bioinformatics applications. As the performance of the model completely
depends on choosing parameter estimation criterion, it is necessary to obtain
the best estimate of the parameters associated with the GSVD (in terms of
generalized eigenvectors). In GSVD, the generalized eigenvectors are generally
obtained using matrix decomposition techniques [68]. Of course, there are a
variety of optimization criteria to be considered when evaluating parameter
estimation methods (e.g. robustness, bias and variance of the estimators) and
none is universally the best [36]. One widely used approach is to employ a
maximum likelihood criterion. Maximum likelihood estimation, a method of
estimating the parameters of a statistical model, help us to obtain the most
appropriate estimators of the generalized eigenvectors.
In this part, we focus on the following three research questions:
Q1 Develop a mathematical framework for the maximum likelihood estimation
via generalized eigenvectors?
Q2 Does the generalized eigenvectors obtained by maximum likelihood
estimation techniques, perform better than generalized eigenvectors obtained
by matrix decomposition techniques?.
Q3 Does the data integration using GEVD framework improve the classifica-
tion/clustering performance in decision-making?
Machine learning techniques have been commonly applied to many scientific
domains such as engineering, finance, biology, remote sensing, and economics.
The dimensionality of this data could be more than thousands, such as digital
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images and videos, gene expressions and DNA copy numbers, documents, and
financial time series. The data analysis of such data sets always suffers from
the curse of dimensionality. To solve this problem, the dimensionality reduction
algorithms have been proposed to project the original high-dimensional feature
space to a low-dimensional space, keeping as much information as possible from
the original space. The unsupervised dimensionality reduction methods are
more useful in the practical applications, especially if we do not have any prior
knowledge to new scientific problems, for example, the labeled data are not
available.
In microarray analysis, it has been observed that although there are thousands
of genes for each observation, a few underlying gene components may account
for much of the data variability. Principal component analysis (PCA) provides
an efficient way to find these underlying gene components and reduce the
input dimensions [15]. This linear transformation has been widely used in gene
expression data analysis and compression [200]. If the data are concentrated
in a linear subspace, PCA provides a way to compress data and simplify the
representation without losing much information. However, if the data are
concentrated in a nonlinear subspace, PCA will fail to work well. In this
case, one may need to consider kernel principal component analysis (KPCA).
KPCA is a nonlinear version of PCA. It has been studied intensively in the
last several years in the field of machine learning and has claimed success in
many applications [126]. As a kernel method, KPCA suffers from the problem
of choosing hyperparameters for kernel functions. No well-founded methods,
however, have been established for this based on unsupervised learning. Most of
the existing approaches for parameter estimation of KPCA were coupled with
the final classifier. In this case, the performance of KPCA obviously depends
on the choice of the classifier. This shows the importance of a mathematical
technique which selecting the hyperparameters of kernel function based on
unsupervised learning.
In this part, we focus on the following three research questions:
Q4 Does the kernel PCA perform better than PCA as a pre-processing step in
classification/clustering tasks?
Q5 Design a parameter optimization criterion for RBF-KPCA based on an
unsupervised learning?
Q6 What are the advantages and disadvantages of using feature selection and
feature transformation techniques?
Principal components analysis (PCA) is a very popular dimension reduction
technique which is widely used as a first step in the analysis of high-dimensional
microarray data. However, the classical approach which is based on the mean
10 INTRODUCTION
and the sample covariance matrix of the data is very sensitive to outliers [85].
Also, classification methods based on this covariance matrix give bad results
in the presence of outliers in the data. In real-world applications, the data
outliers often largely appear in the datasets, thus PCA may not get the optimal
performance. Moreover, PCA and KPCA transform the data into a new space,
losing the original feature space and hence, further feature selections are made
impossible.
In this part, we focus on the following research question:
Q7 What are the alternative analysis for PCA and KPCA, if the data are highly
corrupted with noise/outliers?
With the recent rapid developments in high-throughput technologies, such
as next-generation sequencing, array comparative hybridization, and mass
spectrometry, databases are increasing in both the amount and the complexity
of the data they contain. In bioinformatics, it is a challenge to integrate
these data to improve the available biological information. Some of the most
powerful methods for integrating heterogeneous data types are kernel-based
methods [37, 103]. The heterogeneous genomics data, such as expression data,
amino acid sequence information, protein-protein interaction data, have been
integrated to solve single classification problem: classification of transmembrane
and non-transmembrane proteins [103]. Each data was transformed into a kernel
matrix and integration occurred on this kernel level without referring back to
the data. However, it was important to generate a framework to understand
the importance of each data by assigning weights to the kernel matrix. In
[37], Daemen and colleagues investigated whether clinical and microarray data
can be efficiently combined using a kernel-based approach. They opted for
intermediate integration in which the data sets are treated as separate entities
and then combined at the kernel level–possibly weighted as before, building one
final model. A kernel based network prediction method with automatic data
selection for gene expression, phylogenetic profiles and amino acid sequences was
proposed in [94]. The heterogeneous data, such as protein characteristics and
sequence alignment features, were integrated into a kernel framework for fold
recognition [42]. A hierarchical multi-label prediction of gene function was done
by combining predictions of multiple SVM classifiers in a Bayesian framework
[11]. In all these cases, high accuracy was obtained than when based on any of
the data sets individually. However, the final performance of the model depends
on the hyperparameters associated with kernel functions, the chosen weights of
kernel matrix in the data integration framework and the classifier applied on
the integrated data sets. This requires a simple and efficient algorithm to solve
both data fusion and non-linear classification problems in a single mathematical
framework.
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In this part, we focus on the following three research questions:
Q8 Do the non-linear data integration techniques perform better than linear
data integration?
Q9 Develop a simple mathematical framework for non-linear data integration?
Q10 What are the benefits of using this framework in data integration tasks?
The chemoinformatics generally intends simply to produce useful computational
models that can predict chemical and biological properties of compounds given
the chemical structure of a molecule [122]. Traditionally the identification of
active molecules is usually performed by screening a libraries of molecules in
a wet lab experiment. These procedures remain costly and time-consuming
as the number of molecules increases in this library. Virtual screening [140]
is based on a computational model which identify the activity of molecules in
a specific biological condition of their structure. In this case, an initial set of
molecules with known activity information is used to build a model that relates
the structure of molecules to its activity. This model development usually
involves statistical and machine learning procedures. To build the models first,
we need to convert the structural description of the compounds into a numerical
representation. The way of representing structural information of molecules
into numerical form usually referred to as descriptors in chemoinformatics [71].
More specifically, they are quantitative representations of physical, chemical or
topological characteristics of molecules that summarize the molecular structure
and activity from different aspects. Deriving a chemical descriptor which
completely describes the chemical structure of the compound is one of the most
challenging tasks in chemoinformatics. Examples of few chemical descriptors
are given below:
• Extended Connectivity Fingerprints are generated by first assigning
some initial label to each atom and then applying a Morgan type algorithm
[123] to generate the fingerprints. Morgan’s algorithm consists of l
iterations. In each iteration, a new label is generated and assigned to
each atom by combining the current labels of the neighboring atoms (i.e,
connected via a bond) [105]. The union of the labels assigned to all the
atoms over all the l iterations is used as the descriptors to represent each
compound.
• Maccs Keys [10] are the sets of descriptors based on structural fragments,
that have been identified a priori by a domain expert [51]. Each such
structural fragment becomes a key and occupies a fixed position in the
descriptor space.
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• BCUT descriptor [21] are based on an earlier descriptor developed by
Burden [21] that is calculated from a matrix representation of a molecule’s
connection table [105]. These descriptors were designed to encode atomic
properties relevant to atomic molecular interactions.
Several research scientists have already designed and developed various chemical
descriptor and fingerprints for chemical compound representation. Besides their
extensive usage in QSAR modeling, based on machine learning techniques [26,
124, 113, 98], these descriptors have a significant potential for the identification
of bimolecular targets and network analysis of protein-ligand interactions. By
combining the chemical similarity and side-effect similarity, certain potential
targets has been identified in [23]. The relationships between proteins function
similarity and the ligand structure similarity has been investigated in [95] to
predict new high-potential drug targets. Furthermore, several studies used
chemical descriptors to predict the drug target interaction [77, 184, 167, 41, 130]
and to characterize the structural information of amino acids for developing
more effective proteins [25, 70, 48].
The most common representation of the structure of chemical compounds is a
connection-table, i.e., a table enumerating the atoms and another enumerating
the bonds. Studies already used connection table partially to represent the
chemical compounds based on the subdivision and classification of the molecular
surface area according to atomic properties [102]. As the connection-table
completely represents the chemical structure of chemical compounds, it is
important to define a chemical descriptor based on this table, which completely
representing the structural properties of chemical compounds.
In this part, we focus on the following three research questions:
Q11 Do the 3D chemical descriptors perform better than 2D descriptors in
QSAR process?
Q12 What are the advantages of using chemical descriptors based on connection
table of compounds?
Q13 What are the applications of QSAR modelling in biological sciences?
1.3 Thesis overview
This thesis starts with a general introduction to data integration and
dimensionality reduction techniques, then continue with motivation and problem
statement, and finally the outline of the thesis. The general methodology
introduction is given in Chapter 2. Subsequently, Chapter 3 introduces the
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maximum likelihood interpretation of the generalized eigenvalue decomposition
(GEVD) in which one of the data set acts as prior information in the model
development. In real data examples, we show how to incorporate external
knowledge extracted from microarray data/literature information into medical
diagnosis. In Chapter 4, we use a robust PCA (RPCA) approach as a framework
for identifying differentially expressed genes from microarray and literature
information. Chapter 5 introduces a new data-driven bandwidth selection
criterion for kernel PCA (KPCA) which is related to least squares cross-
validation for kernel density estimation. In Chapter 6 we propose a machine
learning approach, a weighted LS-SVM classifier to integrate two data sources:
microarray and clinical parameters. The proposed model has been shown
to be a promising mathematical framework in both data fusion and non-
linear classification problems. Chapter 7 proposes a new chemical descriptor
for chemical compounds and shows how to predict the activity of chemical
compounds in a biological condition. Finally, Chapter 8 presents the conclusion
of our work. By summarizing the proposed computational techniques for
biological data analysis, this Chapter also elaborates on the opportunities and
directions for future research.
Unless stated otherwise, the chemical data analyzed in this thesis (Chapter 7)
have been prepared and kindly made available by our collaborative partners:
• Chemical synthesis of the compounds and contribution of compounds: Prof.
Marc de Maeyer and Xiaoyu Qing: Laboratory for Organic Microwave-
Assisted Chemistry (LOMAC), Department of Chemistry, KU Leuven,
Celestijnenlaan 200F, B-3001 Leuven, Belgium.
• Anti-biofilm testing: Prof. Jos Vanderleyden and Dr. Hans P. Steenackers:
Centre of Microbial and Plant Genetics (CMPG), Department of Microbial
and Molecular Systems, KU Leuven, Kasteelpark Arenberg 20, box 2460,
B-3001 Leuven, Belgium.
The main results of this thesis overall are the following:
• The main aim of the work is to show the equivalence between
maximum likelihood estimation via a generalized eigenvalue decomposition
(MLGEVD) and generalized ridge regression. This relationship reveals
an important mathematical property of the generalized eigenvalue
decomposition (GEVD), in which the second data matrix acts as prior
information in the model. We illustrate the importance of prior knowledge
in clinical decision making/identifying differentially expressed genes
with case studies for which microarray data sets with corresponding
clinical/literature information are available. In our analysis, we have
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shown that MLGEVD can be used as an alternative of GEVD for better
classification/prediction.
This work was published in the following journal:
Thomas M., Daemen, A., De Moor B. Maximum Likelihood Estimation
of GEVD: Applications in Bioinformatics. Computational Biology and
Bioinformatics, IEEE/ACM Transactions on. Volume: 11, Issue: 4, 673
- 680: 2014
• In our work a data integration approach is used, in which microarray
expressions values are weighted with literature information. Initially, we
present the GEVD in terms of the ordinary eigenvalue decomposition
(EVD) for the integration of microarray and literature information. Then
robust PCA (RPCA) is used for the identification of differentially expressed
genes in colon cancer. Initially, we apply RPCA on colon cancer data
and then on weighted colon cancer data with literature information.
The results suggest that the incorporation of external knowledge into
microarray analysis improves the identification of disease-specific genes.
Further to identify the co-expressed genes of the obtained disease-specific
genes, we make the network analysis of the selected genes using the
GeneMania tool. We obtained sets of co-expressed genes which are parts
of colon cancer data, but not identified by our approach. Thus, searching
for co-expressed genes helped us to identify disease related genes which
are really missing in our analysis.
• The ultimate goal of our work is to design a powerful preprocessing step,
decoupled from the classification method, for large dimensional data sets.
By following the idea of least squares cross-validation in kernel density
estimation, we propose a new data-driven bandwidth selection criterion
to tune the LS-SVM formulation of RBF-KPCA. The tuned LS-SVM
formulation to KPCA is applied to several data sets and serves as a
dimensionality reduction technique for a final classification task.
This work was published in the following journal:
Thomas M., De Brabanter K., De Moor B.: New bandwidth selection
criterion for Kernel PCA: Approach to Dimensionality Reduction and
Classification Problems. BMC Bioinformatics 2014, 15:137 (2014)
• In this work, while bringing up the benefits of LS-SVM classifiers
and generalized eigenvalue/singular value decompositions, we propose
a machine learning approach, a single mathematical framework for data
integration and classification: weighted LS-SVM classifier. The advantages
of this new classifier will be demonstrated in five breast cancer case studies,
for which expression data and an extensive collection of clinical data are
publicly available.
This work was published in the following journal:
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Thomas M., De Brabanter K., Suykens J.A.K., De Moor B.: Predicting
breast cancer using an expression values weighted clinical classifier. BMC
Bioinformatics 2014, 15:6603 (2014).
• Finally, we intend to derive a new chemical descriptor from the connection-
table of chemical compounds, allowing a better distinction between
biologically active and inactive compounds. Our method is applied to
the identification of inhibitors of Salmonella and Pseudomonas biofilm
formation. Development of this type of anti-microbial is urgently needed
as biofilms, surface-associated bacterial communities embedded in a self-
produced polymeric matrix, provide strong protection against the activity
of antibiotics, disinfectants, and the immune system. The results of the
validation set illustrate the ability of the proposed descriptor to identify
compounds with very high activity against the biofilms. To the best of
our knowledge, this is the first time in chemoinformatics that a prediction
model is developed on a connection-table of chemical descriptors and a
weighted LS-SVM classifier.
Minta Thomas, Hans P Steenackers, Marc De Maeyer, Johan AK Suykens,
Inge Thijs, Xiaoyu Qing, Tran Thi Thu Tran, Erik Van der Eycken,
Jos Vanderleyden and Bart De Moor : Chemoinformatics approach to
identify new compounds which inhibit bio films formed by either Salmonella
or Pseudomonas. Internal Report 16-169, ESAT, KU Leuven (Leuven,
Belgium), 2016
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Figure 1.4: The structure of the thesis and dependence between Chapters
Chapter 2
Methodology Overview
High-dimensional datasets present many mathematical challenges, and are
bound to give rise to new theoretical developments [50]. One of the problems
with high-dimensional datasets is that, in many cases, not all the measured
variables are important for understanding the underlying phenomena of interest.
While certain computationally expensive novel methods can construct predictive
models with a high accuracy of high-dimensional data [8], it is still of interest
in many applications to reduce the dimension of the original data prior to any
modeling of the data.
Computational techniques for analyzing high-throughput data in genomics,
proteomics, and visualization have been extensively studied and have played
vital roles in understanding biological mechanisms. Machine learning [99]
and related techniques such as support vector machines [185], decision trees
[137], and neural networks [191] have been increasingly used to solve problems
in genomics and systems biology. Machine learning is a branch of artificial
intelligence that induces pattern from past experience or large, complex data by
optimizing a performance criterion. It has been shown that machine learning
methods substantially improve performances compared to traditional statistical
techniques [35]. We have chosen machine learning approaches such as the
LS-SVM classifier [170] in connection with dimensionality reduction and data
integration for the analysis of biological data sets.
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2.1 Dimensionality Reduction Techniques
Dimensionality reduction [133] can also be seen as the process of deriving a set
of degrees of freedom which can be used to reproduce most of the variability
of a data set. Due to the increase in large data sets, the use of dimensionality
reduction techniques has become a necessity in many biological data sets. Many
algorithms for dimensionality reduction have been developed to accomplish
these tasks. While all of these methods have a similar goal, approaches to
the problem are different. Dimensionality reduction can be accomplished in
two ways: feature selection [72] and feature transformation [129]. With the
feature transformation techniques, the information contained in the original
data set to transform into a reduced set of new variables. Principal component
analysis (PCA)[128] is a linear-transformation that project data into a lower
dimensional space. Although these transformed features may provide a better
discriminative ability, they lack a clear physical interpretation. Feature selection
techniques, on the other hand, select important features from the given data set,
without changing the original representation of the variables. Since both of these
techniques are well known pre-processing steps in the field of bioinformatics, we
have considered both of them in this dissertation.
2.1.1 Principal Component Analysis (PCA)
Principal Component Analysis (PCA) [128] is mathematically defined as an
orthogonal transformation that converts the data into a new coordinate system,
such that the largest variance by any projection of the data lies on the first
coordinate (first principal component), the second largest variance in the second
coordinate, and so on. The full principal components decomposition of m× n
matrix A can therefore, be given as follows:
Score = A ∗ Coef
where each column of the n× n matrix Coef are the eigenvectors of ATA and
Score, m × n matrix, is the representation of A in the principal component
space.
The basics of PCA can be explained with simple geometrical interpretations of
the data as shown in Figure 2.1. To allow for such interpretations, imagine that
the microarray in our example, measured the expression levels of only two genes,
gene 1 and gene 2. This simplifies plotting the cancer samples according to
their expression profiles, which in this case consist of two numbers (Fig. 2.1a).
Patient samples are classified as being either positive (class 1) or negative (class
2).
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Figure 2.1: PCA: (a) Each dot represents a cancer sample plotted against its
expression levels for two genes. (In a–c, samples are colored according to type of
classes: class 1, red; class 2, black). (b) PCA identifies the two directions (PC1
and PC2) along which the data have the largest spread. (c) Samples plotted in
one dimension using their projections onto the first principal component (PC1)
for class 1, class 2 and all samples separately.
2.1.2 Singular Value Decomposition(SVD)
Any real m× n matrix can be factored as [68]
A = UΣV T
where U is anm×m orthogonal matrix whose columns are the eigenvectors of
AAT , V is an n× n orthogonal matrix whose columns are the eigenvectors of
ATA, and Σ is an m× n diagonal matrix. There are several facts about SVD
Figure 2.2: SVD form of a matrix A
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[88]:
(a) rank(A) = rank(Σ) = r
(b) The column space of A is spanned by the first r columns of U .
(c) The null space of A is spanned by the last n - r columns of V .
(d) The row space of A is spanned by the first r columns of V .
(e) The null space of AT is spanned by the last m - r columns of U .
In gene expression analysis generally, we want to classify samples in a diagnostic
study, or classify genes in system biology. Projection of data into SVD subspaces
and visualization with scatter plots can reveal structures in the data that may
be used for classification. If we have a m× n gene expression data A, the SVD
decomposes it into A = UΣV T . The projection of data into the direction of V ,
i.e, AV is used to classify genes and the projection of data into the direction
of U , i.e, UTA is used to classify samples. For projection, instead of using
all columns of orthogonal matrices U and V , we will choose only the first r
columns as shown in Figure 2.2, which capturing the majority of the variance
in the data sets. The Figure 2.3 illustrates how the SVD can be useful for
Figure 2.3: SVD scatter plots on artificial data sets
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classification/clustering tasks. Assume that the gene expression data A contains
three different classes of genes. Initially data is projected onto the subspace of
SVD (i.e, the first two columns of the matrix V in Figure 2.3 ) and then simple
scatter plot is used for grouping the genes into different clusters.
2.1.3 Eigenvalue Decomposition(EVD)
The eigenvalue decomposition of matrix ATA and AAT [68] is given as follows:
ATA = V DV T ,
AAT = UD′UT ,
where V is an n× n orthogonal matrix consisting of the eigenvectors of ATA,
D is an n × n diagonal matrix with the eigenvalues of ATA on the diagonal,
U an m×m orthogonal matrix consisting of the eigenvectors of AAT , and D’
is an m×m diagonal matrix with the eigenvalues of AAT on the diagonal. It
turns out that D and D’ have the same non-zero diagonal entries except that
the order might be different.
The SVD of a matrix A gives the complete eigensystems of AAT and ATA
without forming these products explicitly. From the standpoint of accuracy, this
is the right way to compute these eigensystems, since information about the
smaller eigenvalues are lost when AAT and ATA are computed in floating-point
arithmetic [192]. Hence we worked with SVD, instead of EVD for which explicit
commands are provided in Matlab. The numerically optimal way to calculate
GEVD is via 3 SVDs.
2.1.4 Generalized Singular Value Decomposition(GSVD)
The generalized singular value decomposition (GSVD) of m× n matrix A and
p× n matrix B is [68] is obtained from the singular value decomposition (SVD)
of matrix [A;B] as follows:
A = UΣAXT (2.1)
B = V ΣBXT (2.2)
where U , V are orthogonal matrices and columns of X are generalized singular
vectors.
Figure 2.4 illustrates how GSVD perform simultaneous linear transformation
of the two expression data sets from the two m-genes × n-arrays and p-genes
× n-arrays spaces to the two reduced n-genelets × n-arraylets spaces [3]. The
genelets and arraylets are data-driven decoupled superpositions of genes and
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Figure 2.4: GSVD decomposition of two expression data sets collected from two
experimental conditions.
arrays. The arraylets are orthogonal projections of the datasets onto the space
spanned by the non-orthogonal genelets, that are shared by both datasets
[3]. In the GSVD expression A = UΣAXT , the values in the ith row of U
express this projection for the ith gene. In that row, the column with the
largest absolute value corresponds to the genelet which explains the greatest
proportion of variance. The mth row vector in XT lists the expression signal
of the mth genelet across the different arrays in both data sets simultaneously.
The GSVD framework provides a technique to combine two gene expression
datasets with only partial overlap of both gene sets and experimental conditions.
The framework help us to identify the genes which present in only one dataset
co-expressed with a target gene present exclusively in the other dataset, even
when experimental conditions for the two datasets are not identical [148].
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2.1.5 Generalized EVD(GEVD)
If BTB is invertible, then the GEVD [68] of ATA and BTB can be obtained
from Equations 2.1 and 2.2 as follows:
ATA(XT )−1 = BTB(XT )−1Λ. (2.3)
where (XT )−1 is generalized eigenvectors, Λ is a diagonal matrix with diagonal
entries Λii = (
ΣAii
ΣBii
)2, i = 1, . . . , N . A(XT )−1 indicates projection of data A
into the direction of generalized eigenvectors. Similar to EVD problem, these
projected data can be used further for classification of samples or clustering of
features.
2.1.6 Robust Principal Component Analysis (RPCA)
Finding a low-rank decomposition of a matrix is an essential tool in data mining
and information retrieval [7]. Prominent applications include in summarizing
adjacency matrices for social network analysis or term-document matrices for
text classification [78]. In addition to missing values, microarray data are often
corrupted with extreme values (outliers). Since the ordinary SVD is not robust
enough to outliers, RPCA is an alternate decomposition technique to obtain
the low-rank approximation of the matrix.
RPCA, a new method for matrix recovery has been introduced recently in the
field of signal processing [24]. The problem of matrix recovery can be described
as follows, assume that all the data points are stacked as column vectors of a
matrix A, and the matrix (approximately) have low rank:
A = R+ Z
where R has low-rank and Z is a perturbation matrix. The robust PCA proposed
by Candes et al. can recover a low-rank matrix R from highly corrupted
measurements A [24]. Here, the entries in Z can have an arbitrarily large
magnitude, and their support is assumed to be sparse but unknown. Figure
2.5 demonstrates how the RPCA decomposing the given observation into a
low-rank matrix and an error matrix.
RPCA was proposed by Candes and colleagues in [24]. Let ‖A‖∗ = Σiσi(A)
denote the nuclear norm of the matrix A, that is, the sum of its singular values,
and ‖R‖1 = Σij |Rij | denote the l1-norm of R, which is efficient and robust to
outliers. For a given data matrix A, RPCA solves the following optimization
problem:
min
R,Z
‖R‖∗ + λ‖Z‖1, (2.4)
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Figure 2.5: Robust PCA decomposes the given observation (A) into low rank
matrix (R) and sparse matrix (Z), a graphical representation of the equation
A=R+Z.
subject to A = R+Z, where λ is a positive regulation parameter. According to
[110], the Augmented Lagrange multiplier method on the Lagrangian function
can be applied: Thus the two components R and Z can be exactly recovered
through solving the following convex problem,
L(A,R,Z, µ) = ‖A‖∗ + λ‖R‖1+ < Y,A−R− Z > +(µ/2)‖A−R− Z‖2F
where Y can now be interpreted as an estimate of a dual variable, µ is a
positive scalar and ‖.‖2F denotes the Frobenius norm. Several mathematical
techniques are available to solve the optimization problem in Equation 2.4. Here
we have chosen the inexact ALM (IALM) algorithm proposed in [110] to solve
the RPCA problem due to its accuracy, stability, and fast convergence. The
IALM algorithm for solving the RPCA problem can be designed by adapting the
algorithm of Augmented Lagrange Multipliers. The exact convergence rate of
the IALM is difficult to obtain in theory, that is why it is known as inexact, but
extensive numerical experiments have shown that it still converges Q-linearly
[154]. An Augmented Lagrangian algorithm [13] consists of a sequence of
outer iterations. At each outer iteration, a minimization problem with simple
constraints is approximately solved whereas Lagrange multipliers Y and penalty
parameter µ are updated in the master routine.
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2.2 Kernel Methods
Kernel methods are a class of algorithms for pattern analysis, to find and
study general types of relations in general types of data such as sequences,
text documents, images, etc [147]. These methods work by mapping data x
into a high dimensional feature space with a nonlinear feature map φ(x). This
kernel function forms an inner product k(xi, xj) = φ(xi)Tφ(xj) between all
pairs of data items xi and xj in the feature space. Any symmetric, positive
semidefinite function is a valid kernel function, resulting in many possible kernels
[82]. The functions that are most frequently employed in classification problems
are the linear kernel xiTxj , the polynomial kernel(xiTxj + b)d with - as kernel
parameters - the intercept constant b ∈ R+ and degree d ∈ N, the radial basis
function (RBF) exp(−||xi − xj ||22/σ2) with σ ∈ R+ representing the bandwidth
[147].
2.2.1 Support Vector Machines
Support vector machines (SVM) [185] are supervised learning models with
associated learning algorithms that analyze data and recognize patterns, used
for classification and regression analysis. The basic SVM takes a set of input
data and predicts, for each given input, which of two possible classes forms
the output, making it a non-probabilistic binary linear classifier. Given a set
of training examples, each marked as belonging to one of two categories, an
SVM training algorithm builds a model that assigns new examples into one
category or the other. In addition to performing linear classification, SVMs
can efficiently perform non-linear classification using the so-called kernel trick,
implicitly mapping their inputs into high-dimensional feature spaces.
More formally, a support vector machine constructs a hyperplane or set of
hyperplanes in a high - or infinite - dimensional space, which can be used
for classification, regression, or other tasks. Intuitively, a good separation is
achieved by the hyperplane that has the largest distance to the nearest training
data point of any class, since in general the larger the margin the lower the
generalization error of the classifier.
Consider a training set for classification {xi, yi}Ni=1 of N samples with feature
vectors xi ∈ Rp and binary output labels yi ∈ {−1,+1}. The aim is to design a
function f(x) = y that correctly classifies unseen samples {x, y}. Data points
xi with f(xi) ≥ 0, are assigned to the label +1, data points with f(xi) ≤ 0
to the label -1. Vapnik [185] considered a set of hyperplanes {wTx + b = 0},
corresponding to a linear function of the form f(x) = wTx + b. Variable b
represents the bias term and w is the normal vector to hyperplane. Vapnik
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further introduced a principled way to choose the best possible hyperplane
among all hyperplanes that separates two classes of samples. Simply for linear
separable data, the corresponding classifier was defined as y(x) = sign[wTx+ b],
with the closet data points xi satisfying the equality constraint [wTxi + b] = 1
or [wTxi + b] = −1. This optimal discriminant boundary is known as the linear
SVM. The above constraint forces the margin (that is,the distance between
the nearest points of both classes) to be equal to 2‖w‖2 . The SVM classifier is
thus obtained from the solution to a convex optimization problem in which
the margin is maximized or equivalently ‖w‖22 = wTw minimized, subject to
the constraint of correctly classifying the training data points with strong
confidence.
The optimization problem in primal weight space, is defined as [185]:
min
w,b
(12w
Tw)
subject to
yi[wTxi + b] ≥ 1, i = 1, . . . , N
where N is the number of data points.
As the dimension of w is determined by the number of elements in the feature
vector xi, the calculation of w can be avoided for problems with high dimensional
data by solving the problem as a quadratic programming (QP) problem in dual
space. The unknown variables in dual space are the Lagrange multipliers αi,
referred to as support values. Vector α is of size N and thus typically N small
for high-throughput data sets. The resulting classifier equals:
y(x) = sign[ΣNi=1αiyixiTx+ b].
In most binary classification problems, classes are characterized by overlapping
distributions in such a way that a separating hyperplane does not exist. To
obtain an algorithm that can cope with misclassifications and a certain fraction
of outliers, the problem is extended with slack variables η. The non-negative
slack variables, ηi, which measure the degree of misclassification of the data xi,
are introduced as:
yi[wTxi + b] ≥ 1− ηi, i = 1, . . . , N .
For data that are not linearly separable, the decision boundary can directly be
constructed in the input space and the problem formulation in primal space
changes into [185]:
min
w,b
(12w
Tw + CΣNi=1ηi)
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subject to
yi[wTxi + b] ≥ 1− ηi,
ηi ≥ 0, i = 1, . . . , N
The positive hyper parameter C represents the trade-off between the requirement
of large margin and that of few misclassifications (that is, ηi > 1) or
classifications with little confidence (0 < ηi ≤ 1). Increasing C forces the
function f(x) = wTx + b to have a smaller margin, but correctly classifying
more data points with strong confidence. In the case of nonlinearly separable or
Figure 2.6: Support Vector Machine For Non-linearly Separable Data: Initially
the data is nonlinearly separable. Using feature map, data is transformed from
the input space into a high dimensional feature space. After transformation, a
linearly assumed classification problem is solved, resulting in a linear hyperplane
in feature space.
non-separable data, a transformation of the data from the input space into a high
dimensional feature space is required as a φ(x). The constructed hyperplane
corresponds to the nonlinear discriminant boundary y(x) = sign[wTφ(x) + b] in
the original input space. Figure 2.6 illustrates the principle of the SVM for non-
linearly seperable data. The linear SVM is thus easily extendable to the nonlinear
case by replacing xi by φ(xi) in the problem formulation and applying the kernel
trick to avoid explicit knowledge of φ(x), which is often infinite dimensional as
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well as w. The nonlinear SVM therefore needs to be solved in dual space with as
discriminant boundary y(x) = sign[ΣNi=1αiyik(xi, x) + b]. The kernel function
k(xi, x) interprets inner products between all pairs of data items xi and x in the
feature space. Support vector machines are also suited for regression problems.
In case of a linear problem, the functionf(x) = wTx+ b is estimated using the
training data with continuous out variable y ∈ R. Similarly to classification,
this strategy can be extended to nonlinear regression problem by replacing x
by φ(x). The resulting SVM model becomes y(x) = ΣNi=1[αik(xi, x) + b].
2.2.2 Least Squares Support Vector Machines
A modified version of the SVM, the LS-SVM, was developed by Suykens et
al [170, 172]. The main difference between standard SVM and the LS-SVM
is that the difference in loss function and the inequality constraints in the
formulation of SVM are replaced by equality constraints, thereby considering
the value 1 at the right-hand side as a target value rather than a threshold
value. In this way, the interpretation of slack variables ηi slightly changes into
the offset with respect to target 1, and the variables are referred to as error
variable ei. Moreover, the second term in the objective function is replaced
by the squared error contributions. These modifications transform the QP
problem, which requires expensive computations, into a much simpler set of
linear equations. The LS-SVM is therefore much faster on high-dimensional
data sets with low computational cost. The formula for this constrained convex
optimization problem equals:
min
w,b,e
1
2w
Tw + γ 12Σ
N
i=1e
2
i
subject to:
yi[wTφ(xi) + b] = 1− ei, i = 1, . . . , N
with γ the regularization parameter, representing-in analogy to the hyperpa-
rameter C the trade-off between margin maximization and minimization of the
squared error contribution. In dual space the equivalent problem is obtained by
solving the Lagrangian, resulting in a system of linear equations in functions of
the number of data points N :[
0 yT
y Ω + Iγ
] [
b
α
]
=
[
0
1N
]
with α and b are known variables and Ωij = yiyjk(xi, xj), i, j = 1, . . . , N .
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2.2.3 Kernel PCA
KPCA, which is a generalization of PCA, a nonlinear dimensionality reduction
technique that has proven to be a powerful pre-processing step for classification
algorithms. It has been studied intensively in the last several years in the
field of machine learning and has claimed success in many applications [126].
An algorithm for classification using KPCA was developed by Liu et al. [111].
KPCA was proposed by Schölkopf and Smola [146], by considering a mapping
to a high-dimensional feature space (possible infinite) and applying Mercer’s
theorem. Figure 2.7 illustrates how does KPCA find a projection of the data
which makes data linearly separable.
Figure 2.7: PCA and KPCA: If the data is not linearly separable, linear
projections of the data does not make the data linearly separable, while non-
linear projection does. The inverse transform of non-linear projections of the
data brings it back to the original space.
Suykens et al. [170, 171] proposed a simple and straightforward primal-dual
support vector machine formulation to the PCA problem as follows: The PCA
analysis problem is interpreted as a one-class modeling problem with a target
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value equal to zero around which the variance is maximized. This results into a
sum of squared error cost function with regularization. The score variables are
taken as additional error variables. We now follow the usual SVM methodology
of mapping the data from the input space to a high-dimensional feature space
φ : Rd → Rnh , where nh can be infinite, and apply Mercer’s theorem [118].
Our objective is the following
max
v
N∑
k=1
[0− vT (φ(xk)− µˆφ))]2
with µˆφ = (1/N)
∑N
k=1 φ(xk) and v is the eigenvector in the primal space with
maximum variance. This formulation states that one considers the difference
between vT (φ(xk) − µˆφ) (the projected data points to the target space) and
the value 0 as error variables. The projected variables correspond to what is
called score variables. These error variables are maximized for the given N data
points. Next, by adding a regularization term we also want to keep the norm of
v small. The following optimization problem is formulated now in the primal
weight space
max
v,e
JP (v, e) = γ
1
2
N∑
k=1
e2k −
1
2v
T v
such that
ek = vT (φ(xk)− µφ), k = 1, ..., N.
The Lagrangian yields
L(w, e;α) = γ 12
N∑
k=1
e2k −
1
2v
T v −
N∑
k=1
αk(ek − vT (φ(xk)− µˆφ))
with conditions for optimality
∂L
∂v
= 0→ v =
N∑
k=1
αk(φ(xk)− µˆφ)
∂L
∂ek
= 0→ αk = γek
∂L
∂αk
= 0→ ek − vT (φ(xk)− µˆφ) = 0
By elimination of variables e and w, one obtains
1
γ
αk −
N∑
l=1
αl(φ(xl)− µˆφ)T (φ(xk)− µˆφ) = 0 k = 1, . . . , N.
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Defining λ = 1γ , one obtains the following dual problem
Ωcα = λα
where Ωc denotes the centered kernel matrix with ijth entry: Ωc,i,j = K(xi, xj)
- 1N
∑N
r=1K(xi, xr) - 1N
∑N
r=1K(xj , xr) + 1N2
∑N
r=1
∑N
s=1K(xr, xs).
2.3 Performance Measures
In machine learning and statistics, two classes of samples that need to be
distinguished are often referred to as the positive and negative class. Throughout
this dissertation, the positive class is often annotated with disease samples,
while the negative class contains the normal samples.
For the evaluation of a binary classifier, the predicted labels are compared with
the given output labels, for all samples. The measures are given by, true positives
(TP) - the number of correctly classified positive samples, false positives (FP)
- the number of incorrectly classified negative samples, true negatives (TN) -
the number of correctly classified negative samples and false negatives (FN) -
the number of incorrectly classified positive samples. The accuracy represents
the proportions of N samples that are correctly classified. The sensitivity or
true positive rate equals the proportion of positive samples that are correctly
classified as such, while specificity, also known as true negative rate, measures
the proportion of negative samples identified as negative.
• Accuracy = (TP+TN)N
• Sensitivity = TP(TP+FN)
• Specificity = TN(TN+FP )
• Precision = TPTP+FP
• Recall = TPTP+FN
• F − Score = 2. Precision∗RecallPrecision+Recall
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For all of the above performance criteria, samples are assigned to the positive
or negative class by a binary classifier. The receiver operating characteristics
(ROC) curve [14, 119] summarizes the performance of a classifier by showing the
true positive rate (sensitivity) versus the false positive rate (1-specificity) as the
discrimination threshold is varied. Each threshold corresponding to a particular
operating point on the ROC curve. Increasing the threshold simultaneously
enlarges the number of true positives and false alarms, whilst reducing the
number of false positives automatically reduces the number of hits. The area
under the ROC curve (AUC) is an evaluation measure that is independent of
the operating point. An AUC of 0.5 corresponds to a random classifier lacking
discriminative power, while a perfect classifier is characterized by an AUC of 1.
Thus, the larger the AUC, the better the classifier, with a high sensitivity at a
small positive rate (high specificity). The F-Score are indicative of precision
and recall, with scores ranging from 0 to 1.
Chapter 3
A mathematical framework
for the incorporation of prior
information in medical data
analysis
The work was published as Thomas, M., Daemen, A., De Moor, B., Maximum
Likelihood Estimation of GEVD: Applications in Bioinformatics, IEEE/ACM
Transactions on Computational Biology and Bioinformatics, Volume: 11, Issue:
4, 673 - 680: 2014
Abstract: We propose a method, maximum likelihood estimation via a
generalized eigenvalue decomposition (MLGEVD), that employs a well known
technique relying on a generalization of singular value decomposition (SVD).
The main aim of the work is to show the equivalence between MLGEVD
and generalized ridge regression. This relationship reveals an important
mathematical property of the generalized eigenvalue decomposition (GEVD), in
which the second argument acts as prior information in the model. Thus we show
that MLGEVD allows the incorporation of external knowledge on the quantities
of interest into the estimation problem. We illustrate the importance of prior
knowledge in clinical decision making/in identifying differentially expressed
genes with case studies for which microarray data sets with corresponding
clinical/literature information are available. MLGEVD results in significantly
improved diagnosis, prognosis and prediction of therapy response.
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3.1 Introduction
Microarray technology is a significant tool in gene expression analysis and cancer
diagnosis. These technologies are typically used for class discovery [136, 144]
and prediction [33, 157]. For most diseases and examinations, clinical data such
as age, gender and medical history guide clinicians in diagnosis. The effective
management of these data always leads to better clinical prognosis. Microarray
data is in general much more difficult and expensive to collect while clinical
parameters are routinely measured by clinicians. A vital study on the prediction
of breast cancer outcome has suggested that despite the emergence of these
high-throughput technologies, clinical markers and profiles have similar power
for prognosis [52]. Studies show that clinical and microarray data sets improve
the prediction accuracy [39] in clinical decision making.
Biomarker discovery and prognosis prediction are essential for improved
personalized treatment of cancer. Principal component analysis (PCA) and PCA-
based approaches for example, were used for the identification of differentially
expressed genes (DEG) in pulmonary adenocarcinoma [76] and E. coli [90].
Troyanskaya and colleagues developed nonparametric methods to identify DEG
in microarray data [180]. Besides well-known statistical tests such as the chi-
square test [155], Chun and colleagues proposed a new test, the ’half Student’s
t-test’, specifically for detecting DEG in heterogeneous diseases [83]. The
singular value decomposition (SVD) and the generalized SVD (GSVD) have
been shown to have great potential within bioinformatics for extracting common
information from data sets such as genomics and proteomics data [152, 3].
Maximum likelihood principal component analysis (MLPCA) is an error-in-
variables modeling method in that it accounts for measurement errors in the
estimation of model parameters. Wentzell et al. [194] generalized the PCA
method to MLPCA [193, 195]. The tight equivalence between MLPCA and total
least squares (TLS) is explored in [149]. Finally, several studies have developed
methods for integrating literature and microarray data sets for identifying
disease related genes [56, 64].
In this Chapter we propose a method which incorporates external knowledge
of interest in the analysis of microarray and clinical data sets. The main aim
of the work is to show the equivalence of maximum likelihood estimation via
the generalized eigenvalue decomposition (MLGEVD) with generalized ridge
regression. This reveals an important mathematical property of GEVD in which
the second matrix acts as the prior information in the model. We incorporate
microarray/literature information as prior information in the model to improve
the accuracy in clinical decision making.
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3.2 Classification Problem
Breast cancer is one of the most extensively studied cancer types for which many
microarray data sets are publicly available. Among them, we selected three cases
for which also clinical information was available [31, 79, 158]. All the three data
sets are available in the Integrated Tumor Transcriptome Array and Clinical
data Analysis database (ITTACA): http://bioinfo-out.curie.fr/ittaca/.
Overview of all the data sets are given in Table 3.1.
Table 3.1: Summary of the 3 breast cancer data sets.
Case Study #Samples #Genes #Clinical variables
Class 1 Class2
Case I 85 25 4997 Age, Ethnicity, ER status, PR status, Radiation treatment,
Chemotherapy, Hormonal therapy, Nodal status, Metastasis,
Tumor stage, Tumor size, Tumor grade.
Case II 33 96 5997 Age, Ethnicity, pretreatment tumor stage, nodal status,
nuclear grade, ER status, PR status, HER2 status.
Case III 112 65 12633 Age, Tumor size, Nodal status, ER status, Tamoxifen treatment.
3.2.1 Microarray Data
The microarray data were obtained with the Affymetrix technology and
preprocessed with MAS5.0, the GeneChip Microarray Analysis Suite 5.0 software
(Affymetrix)[112]. However, as probe selection for the Affymetrix gene chips
relied on earlier genome and transcriptome annotation that are significantly
different from current knowledge, an updated array annotation was used
for the conversion of probes to Entrez Gene IDs, lowering the number of
false positives [40]. Finally, the low signal-to-noise [121] ratio of microarray
data was taken into account by unsupervised exclusion of genes with low
variation (variance less than the 20th percentile), retaining the 4997, 5997
and 12633 most varying genes for the first, second and third microarray data
respectively [31, 79, 158]. All the data set that we have used are available in
the Integrated Tumor Transcriptome Array and Clinical data Analysis database
(ITTACA):http://bioinfo-out.curie.fr/ittaca/. This resulted in a p× n
matrix B with p =number of genes and n =number of samples.
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3.2.2 Clinical Data
The first case study of 129 patients contained information on 17 available clinical
variables. Five variables were excluded [31]: two redundant variables that were
least informative based on univariate analysis in those variable pairs with a
correlation coefficient exceeding 0.7, and three variables with too many missing
values. After exclusion of patients with missing clinical information, this data
set consisted of 110 patients, of which 85 were disease free whilst in 25 patients
the disease occurred [38].
The second case study, in which response to treatment was studied, entailed
12 variables for 133 patients [79]. Patient and variable exclusion performed as
described above, resulted in 129 patients and 8 variables. Of the 129 remaining
patients, 33 showed complete response to treatment while, 96 patients were
characterized by residual disease.
In the last case study, relapse was studied in 187 patients [158]. After
preprocessing, this data set retained information on 5 variables for 177 patients.
In 112 patients, no relapse occurred while 65 patients had a relapse.
The clinical data contain three different types of variables: continuous (C),
ordinal (O) and nominal (N). Normalization is required to make these variables
comparable to each other. Rank order, min-max and square root transformations
were applied to the ordinal, continuous and nominal variables, respectively.
This resulted in a m× n matrix A with m =number of clinical parameters and
n =number of samples.
3.3 Feature Selection Problem
Colon cancer is a common malignancy affecting both women and men. Including
the literature information in the analysis of gene expression data offers an
opportunity to incorporate functional information about the genes when
identifying disease associated genes [139]. In this study, we use gene expression
data and the corresponding literature information of colon cancer to identify
differentially expressed genes.
3.3.1 Microarray Data
The colon cancer data set investigated here was taken from the Bioinformatics
Research Group Repository: http://www.upo.es/eps/bigs/datasets.html.
It contains 62 samples, among them 40 colon tumor samples and 22 normal
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colon samples, with 1,988 genes and 12 controls. Data were standardized to a
mean of 0 and standard deviation of 1. This resulted in a m× n matrix A with
m = 62 and n = 2000.
3.3.2 Literature Information
We used a well defined cancer vocabulary with 2406 terms from the NCI
Dictionary of Cancer Terms: http://www.cancer.gov/dictionary. Pubmed
abstracts with the terms in the vocabulary were extracted using Perl, version
5.10.1 for windows. We defined literature information as a matrix with row
corresponding to cancer related terms and the columns with the same genes as in
Section 3.3.1. Each entry in the matrix corresponding to the number of Pubmed
abstracts in which the gene and term co-occur. We chose to retrieve entries
containing the official gene name, abbreviations or aliases in the corresponding
field, following the same strategy as used by Gevaert et al [64]. Finally, the
cosine similarity measure was used to obtain gene-to-gene distances between 0
and 1, derived from the literature information. This resulted in a p× n matrix
B with p = 2406 and n = 2000.
3.4 Methods
In this section, we formulate a mathematical framework, the maximum likelihood
estimation via a generalized eigenvalue decomposition (MLGEVD) and show
the similarity between MLGEVD and generalized ridge regression.
3.4.1 Maximum Likelihood Estimation of Generalized Eigen-
value Decomposition:
The GEVD in Equation 2.3 can now be rewritten as EVD problem:
(BTB)−1/2ATA(BTB)−1/2[(BTB)1/2(XT )−1] = [(BTB)1/2(XT )−1]Λ. (3.1)
If we call (BTB)1/2(XT )−1 = W , then Equation 3.1 can be rewritten as:
(BTB)−1/2ATA(BTB)−1/2W = WΛ.
where (BTB)−1/2ATA(BTB)−1/2, is a symmetric matrix.
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Let SVD of A(BTB)−1/2 be
A(BTB)−1/2 = PSQT (3.2)
Then
(BTB)−1/2ATA(BTB)−1/2Q = QSTS
where STS = Λ and W = Q with QTQ = In.
Let define,
D = A(BTB)−1/2Q = A(XT )−1 (3.3)
with (X)−1(BTB)(XT )−1 = In and columns of (XT )−1 are GEVs.
Equation 3.3 shows that projection of weighted matrix A(BTB)−1/2 onto
eigenvectors Q are equivalent to the projection of matrix A onto GEVs (XT )−1.
MLGEVD is an analog to GEVD that incorporates information about projection
errors to develop GEVD models. The theoretical foundations of MLGEVD
are initially established using GEVD and extended to the framework of ridge
regression. An efficient iterative algorithm based on the ridge regression method
is described.
MLGEVD problem which estimates the optimal GEVs are formulated as follows:
minimize ||D −A(XT )−1||2 subject to [(X)−1(BTB)(XT )−1] = In.
Maximum Likelihood Estimation of GEVD can be formulated with the
assumptions that BTB is invertible, let SVD of A(BTB)−1/2 = PSQT and
D = A(BTB)−1/2Q are known. D(0) = A˜(BTB)−1/2Q , where A˜ is the rank
k truncated SVD approximation of A. Di and D(0)i are the ith columns of
the matrices D and D(0) respectively. Each column of the matrix D can be
considered to represent a point in the m-dimensional row space, with the true
measurements corrupted by normally distributed errors. Here Di is a column
vector of D, D(0)i represents the error-free column vector and ηi = Di −D(0)i
is the vector of measurement errors, which has an error covariance matrix
Fi = cov(ηi) and e˜i = Ar˜i where ri is unknown (ith column of (XT )−1).
One defines the Lagrangian of MLGEVD problem as follows:
L = Σni=1(Di − e˜i)TF−1i (Di − e˜i)− Σni=1(1− rTi BTBri)− Σni=1αi(Ar˜i − e˜i) .
with the optimality conditions,
∂L
∂e˜i
= −2F−1i (Di − e˜i) + αTi = 0.
∂L
∂ri
= −ATαT + 2(BTB)ri = 0.
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∂L
∂αi
= e˜i −Ar˜i = 0, i = 1 . . . , n.
Eliminations of e˜i and αi yields an equation in the form of
r˜i = (ATF−1i A+BTB)−1ATF−1i Di, i = 1 . . . , n.
Thus, the Maximum Likelihood estimation of GEVD is
r˜iMLGEVD = (ATF−1i A+BTB)−1ATF−1i Di, i = 1 . . . , n. (3.4)
which is in the form of generalized ridge regression. Thus BTB is interpreted
as the prior information to obtain the optimal GEVs.
To obtain MLGEVD via GEVD, an iterative algorithm based on generalized
regression has been proposed as follows:
An Algorithm for MLGEVD
1. Input data matrices A ∈ Rm×n, B ∈ Rp×n.
2. Initial approximation: A(BTB)−1/2 = PSQT , D = A(BTB)−1/2Q,
D(0) = A˜(BTB)−1/2Q where A˜ is the rank k truncated SVD approx-
imation of A, Di and D(0)i are the ith column of matrices D and D(0)
respectively. Fi is the error covariance of (Di −D(0)i ).
3. j=0;
4. repeat
5. Compute the solution of ML GEVD: ri = (A˜TF−1i A˜+BTB)−1A˜TF−1i Di,
i = 1 . . . ,n, are the GEVs (columns of R(j)).
6. Compute D(j+1) = A˜R(j) using Equation 3.3.
7. j=j+1
8. Until||D(j) − D(j−1)||F /||D(j)||F ≤ ε, where ε is the convergence
parameter.
9. Output: D˜ = D(j), R˜ = R(j)
The MLGEVD algorithm, an iterative algorithm monotonically decreases the
cost function value and the convergence of the algorithm is quite reliable. The
convergence rate, however, is linear and depends on the distribution of the
singular values of A(BTB)−1/2.
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3.5 Results
The proposed MLGEVD algorithm obtains an optimal GEVs for the GEVD.
GEVD and MLGEVD capture common information from two data sets in
terms of GEVs by matrix decomposition [68] and ML estimation framework
described in Section 3.4.1, respectively. In the model development, initially
we used matrix BTB as the prior information to obtain the GEVs. Then we
applied these technique as a pre-processing step which projected the matrix A
onto the directions of GEVs, i.e, A(XT )−1. We illustrated the applications of
MLGEVD/GEVD in bioinformatics with two problems: one for the classification
of breast cancer patients and the second for the identification of differentially
expressed genes in colon cancer.
3.5.1 Classification of Breast Cancer Patients
The summary of the data sets are given in Table 3.1. In all the three case
studies, clinical data A contain measurements on m clinical parameters, for
n samples and microarray data B contain expression level of p genes over
these n samples. For all case studies, 2/3rd of clinical and microarray data
were randomly assigned to the training set and the remaining to the test set.
The split was performed with the relative proportion of outcomes sampled
in both training and test set was similar to the original proportion in the
full data set, which resulted in four matrices: Atrain, Atest, Btrain and Btest.
In the first step, GEVs were obtained from both clinical and microarray -
training data sets by MLGEVD and GEVD, respectively. Projected variables
corresponding to clinical training data set was obtained by projecting these
data onto the direction of GEVs, Atrain(XT )−1. Next, the LS-SVM classifier
[170] was trained using ATtrainAtrain(XT )−1, followed by classification of the
ATtestAtrain(XT )−1. Classification performance was given in terms of test set
Area Under the ROC Curve (AUC) and F-score [156]. In this section all the
steps were implemented using Matlab R2012b and LS-SVMlab v1.8 toolbox
[46] with the default parameter settings.
Table 3.2 summarizes the average test AUC of LS-SVM classifier on 30 random
iterations of trained and test data sets. For the sake of comparison, LS-SVM
classifiers with the linear, RBF and polynomial kernel function were applied.
The LS-SVM classifier with the linear kernel function resulted in the best test
AUC for both GEVD and MLGEVD. Probably the data distribution is linearly
separable in the projected space hence, with the kernel function we obtained
a good prediction performances in all cases. The F-scores for these classifiers
shown in Table 3.2 are indicative of precision and recall, with scores ranging
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Table 3.2: MLGEVD and GEVD were used as a pre-processing step which
transforms the clinical data onto the direction of generalized eigenvectors. LS-
SVM classifier with linear, RBF and polynomial kernel functions applied on
these projected clinical data for the patient classification. The performance are
measured in terms of average test AUC (std) and average F-score (std) over 30
iterations
kernel function linear RBF polynomial
Case I
test AUC MLGEVD 0.80(0.09) 0.79(0.01) 0.77(0.07)
GEVD 0.77(0.08) 0.74(0.09) 0.63(0.02)
p-value 0.03 0.01 2.72E-10
test F-score MLGEVD 0.64(0.01) 0.57(0.02) 0.51 (0.13)
GEVD 0.55(0.01) 0.49 (0.01) 0.26(0.03 )
p-value 0.17 0.23 0.03
Case II
test AUC MLGEVD 0.80(0.05) 0.75(0.09) 0.70(0.10)
GEVD 0.79(0.06) 0.78(0.08) 0.61(0.06)
p-value 0.01 0.04 0.01
test F-score MLGEVD 0.60(0.03) 0.46 (0.06) 0.47(0.01)
GEVD 0.56(0.02) 0.51(0.07) 0.50(0.05)
p-value 0.02 0.06 0.11
Case III
test AUC MLGEVD 0.67(0.07) 0.60(0.08) 0.60(0.04)
GEVD 0.66(0.08) 0.57(0.05) 0.54(0.06)
p-value 0.02 0.26 0.86
test F-score MLGEVD 0.44(0.04) 0.29(0.46 ) 0.28(0.03)
GEVD 0.32(0.08) 0.23 (0.12) 0.24 (0.08)
p-value 0.06 0.18 0.04
p-value: two-sided sign test ; RBF: radial basis function
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from 0 to 1. While comparing the case III with other cases in Table 3.2, it is
observed that case III perform much worse than other case studies. As the
number of genes increase, the linear projections based on GEVD cannot capture
the non-linear pattern in the data well and in addition, there is a high chance
of overfitting. The solution for this problem, especially for the large data set, is
the projection based on kernel GEVD.
High-throughput data, such as microarray data are in general much more difficult
and expensive to collect while clinical parameters are routinely measured by
clinicians. We have used the MLGEVD/GEVD framework as a pre-processing
step in which BTB were used as a prior information to obtain the GEVs. Later
the matrix A is projected onto the directions of GEVs to transform the data
onto the common space. The final classification is performed on clinical data in
the transformed space, that is, ATtestAtrain(XT )−1.
3.5.2 Identification of differentially expressed genes in colon
cancer
The summary of the Data Sets are given in Table 3.3. In this problem,
Table 3.3: Summary of the Data Sets - Identification of differentially expressed
genes in colon cancer.
Matrix Rows Columns
A 62 Patients 2000 Genes
B 2406 Terms 2000 Genes
matrix A was microarray data (62 samples × 2000 genes) and matrix B was
literature information (2406 terms × 2000 genes). The GEVs were obtained
from microarray data and literature information using MLGEVD and GEVD
framework. Finally microarray data was divided into two groups: normal and
cancerous samples. Each set of these samples were projected onto the direction
of GEVs, resulted in two sets of scores Z1 and Z2. Let gi = Z1i − Z2i be the
difference in score for gene i between normal and cancerous samples.
Each gene was represented graphically as a point in the n-dimensional space
(with n the number of GEVs selected for projection). The gene i with similar
expression levels has approximately the same scores Z1i ≈ Z2i and form a cloud
of points around the origin. Differentially expressed genes have significantly
different scores and are located away from the origin. To identify the outliers
in this n-dimensional space, the Mahalanobis distance is calculated for each
gene MD2i = (gi− c)Σ−1(gi− c)T , with c the multivariate arithmetic mean and
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Table 3.4: The 50 top ranked genes for relevance in colon cancer diagnosis
identified by MLGEVD and GEVD, with the literature references.
MLGEVD GEVD
Gene Symbol Ref Gene Symbol Ref
IGLC1 [84] EIF4A1 [87]
RPLP1 [87] N2b5HR [87]
TMSB4X [87] ITIH1 [87]
FTL [87] IGHG3 [59]
IGKC [186] IGLC1 [84]
TCTP [87] RPLP2 [87]
EIF4A1 [87] MYL6 [87]
S100A6 [87] TCTP [87]
RPS [87] RPL41 [87]
SELENBP1 – ACTB [87]
RPS29 [87] RPS9 [87]
RPSA [87] HSP90B1 [87]
RPL30 [87] RPL37A [87]
RPL37A [87] BBC1 [87]
RPL32 [87] RPLP1 [87]
IGHG3 [59] YBX1 [87]
YBX1 [87] UBB [87]
CPSF1 – RPSA [87]
RPL37A – GAPDH [87]
LGALS3 – SRF [87]
RPS18 [87] IGF2 –
UBB [87] RPL37A –
PFN1 [87] RPL1 –
RPS6 [87] HSPB1 –
GAPDH [87] RPS29 [87]
HSP90B1 [87] RPS18 [87]
RPS24 [87] FTL [87]
BBC1 [87] IGKC [186]
RPS28 [87] RPL30 [87]
RPL38 [2] RPS [87]
MUC2 [84] RPS28 [87]
IGHG3 [58] HLA-B [87]
ITIH1 [87] S100A6 [87]
RPLP2 [87] EEF1A2 [87]
RPL41 [87] IFI27 –
ALDOA [87] EEF1B2 –
ACTB [87] JUND –
RPS9 [87] MT1G –
OAZ [87] SELENBP1 –
HSP90AB1 [55] RPS8 –
RPS24 [2] ARNT –
B2M [87] TSPAN8 –
MAMDC2 [87] OAZ [87]
SRF [87] RPS11 [87]
DESMIN [202] RPS24 [87]
LYZ [198] MUC2 [84]
N2b5HR [87] TPM2 [202]
MYL6 [87] RPS19 [2]
FCGRT – RPL32 [87]
RPL37 – LYZ [198]
Σ−1 the inverse of the covariance matrix of the differences in scores [90]. Genes
with the largest Mahalanobis distances are defined as the most differentially
expressed genes.
Table 3.4 shows the top 50 differentially expressed genes obtained with MLGEVD
and GEVD. Among these genes, relevance for colon cancer has been shown
for 44 and 38 genes respectively with MLGEVD and GEVD. An LS-SVM
model with RBF kernel was built for the prediction of tumor vs. non-tumor
samples. The microarray data was split into training and test data which
followed the same strategy of breast cancer case studies. In Table 3.5, we
compared the prediction performances (test AUC) of LS-SVM classifier on full
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Table 3.5: LS-SVM model for prediction of tumor and non-tumor samples of
colon cancer on whole sets of genes and subsets of genes selected by MLGEVD
and GEVD. Average classification performances test AUC (std) are given in
terms of test AUC.
Genes selected by kernel function test AUC p-valuea
full data set RBF 0.821(0.147) 0.019
GEVD RBF 0.841(0.087) 0.072
MLGEVD RBF 0.895(0.060)
a two-sided sign test for the comparison of full data sets
and GEVD with MLGEVD.
sets of genes, genes obtained from GEVD and MLGEVD. LS-SVM classifier
offered the best prediction performances (see Table 3.5) on the 50 genes obtained
from MLGEVD. Results shows that MLGEVD based gene selection obtained
the disease specific genes better than GEVD, which significantly improved the
classification performance.
Several genes selected by this approach are known to be involved in, and
important for, colon cancer. The ribosome, the essential cellular organelle for
protein synthesis in all cells, consists of ribosomal RNAs (rRNAs) and ribosomal
proteins (RPs). Ribosomal protein L41 (RPL41) is a microtubule-associated
protein essential for functional spindles and for the integrity of centrosome.
Abnormal mitosis and a disrupted centrosome associated with RPL41 down-
regulation may be related to malignant transformation [188]. In our analysis,
RPL41 ranked as one of the differentially expressed gene. Studies in [87] and
[109] already reported on the importance of RPL41 in colon cancer.
Ectopic expression of tumor rejection antigen 1 (Tra1) was detected in the
ulcerative colitis (UC) affected colonic mucosa [101]. Tra1 is reported as a
differentially expressed gene in colon cancer [87]. Calcyclin binding protein
(CacyBP) was a promising candidate biomarker for colorectal cancer (CRC)
metastasis and also sheds light on the underlying molecular mechanism by which
CacyBP promotes CRC metastasis [65]. 60S acidic ribosomal protein P1 was
reported as a top-ranked gene in colon cancer [87, 190].
Translationally controlled tumor protein (TCTP) is a highly conserved and
ubiquitously expressed protein in all eukaryotes highlighting its important
functions in the cell. Previous studies revealed that TCTP is implicated in
many biological processes, including cell growth, tumor reversion, and induction
of pluripotent stem cells. In human colon cancer, the level of TCTP mRNA
was detected in three human colon carcinoma cell lines (SNU-C2A, SNU-C4,
and SNU-C5) [27]. Ornithine decarboxylase (OAZ1) catalyzes the conversion
of ornithine to putrescine in the first and apparently rate-limiting step in
DISCUSSION 45
polyamine biosynthesis. The ornithine decarboxylase antizymes play a role in
the regulation of polyamine synthesis by binding to and inhibiting ornithine
decarboxylase. OAZ was reported as a top ranked gene in colon cancer [87, 2].
Alterations in the distribution and/or adhesiveness of laminin receptors in colon
cancer cell lines were suggested to be associated with increased tumorigenicity
[96]. A study of cultured colon cancer cells suggests that laminin may play
an important role in hematogeneous metastasis by mediating, tethering and
spreading of colon cancer cells under blood flow [97]. In general, the markers
are involved in cell signaling, adhesion and communication, immune response,
heat shock, and DNA repair [87].
In short, out of 50 genes identified as differentially expressed by MLGEVD,
majority of these genes is reported as top ranked genes in colon cancer in various
studies. In addition, LS-SVM classifier on selected genes by MLGEVD offered
the best prediction performances than LS-SVM classifier on whole gene sets
and subsets of genes selected by the GEVD framework.
3.6 Discussion
Several studies have already used GSVD as a comparative mathematical
framework for two data sets [3, 107]. In this study, we showed that one of the
data matrix in GSVD/GEVD framework acts as a prior information in the model
development to obtain the GEVs. In addition, we showed tight equivalence
between MLGEVD and regularized regression. MLGEVD was applied to four
case studies for which gene expression with corresponding clinical/literature
information were available. Microarray and clinical parameters were gathered
from patients with breast cancer. Literature information from Pubmed were
collected for colon cancer. The main aim of the work was to interpret the
GEVD problem in the framework of maximum likelihood estimation. To
validate the merit of MLGEVD over GEVD/GSVD, models were built for
classifying patients. In this study we performed MLGEVD, on clinical data sets
with microarray as prior information and on microarray data with literature
as prior information. In both cases, initially GEVs obtained from MLGEVD
and GEVD respectively. Subsequently, clinical parameters/microarray were
projected onto the generalized eigenvectors, referred to as the projected clinical
space/gene space.
In the breast cancer case study, MLGEVD performed better than GEVD in
classification while in colon cancer the incorporation of external knowledge into
the analysis of microarray improves the identification of disease related genes.
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The proposed model is very cost effective. In breast cancer case studies, the high
throughput technologies which are difficult and expensive to collect are used
only for the model development. The clinical parameters which are routinely
measured by clinicians are used for prediction. In real data examples, we
have shown how to incorporate external knowledge, extracted from microarray
data/literature information into medical diagnosis. The proposed method
provides a general way to incorporate such ever-increasing amounts of prior
knowledge in the analysis and further improve the predictive performance.
3.7 Conclusion
In this work, we developed a mathematical framework MLGEVD which relied
on a generalization of SVD and then compared its performance with GEVD. We
showed that the proposed approach could be used as an alternative of GEVD
which significantly improved diagnosis, prognosis and prediction of therapy
response. Both GEVD and MLGEVD used high-throughput data, which were
difficult and expensive to collect only for model development. In the near future,
we will investigate the applicability of MLGEVD to more than two matrices
and interpret these matrix results in a Bayesian context.
Chapter 4
Robust PCA improves
biomarker discovery in colon
cancer with incorporation of
literature information
Microarray technology handles thousands of genes of several hundreds of patients
at a time. It is hard, however, to extract relevant information about genes and
diseases from these data. Bioinformatics and statistical methods collect the
appropriate information from these data sets in light of the specific application.
To date, many research groups identified differentially expressed genes based on
microarray data and literature information. Still, the lack of efficient methods
for assessing the biological implications of gene expression data remains an
important difficulty in exploiting this information.
In this study a data integration approach is used, in which microarray
expressions values are weighted with literature information. First, we present
the generalized eigenvalue decomposition (GEVD) in terms of the ordinary
eigenvalue decomposition (EVD) for the integration of microarray and literature
information. Then robust PCA (RPCA) is used for the identification of
differentially expressed genes of colon cancer. Initially, we apply RPCA on colon
cancer data only and then on both colon cancer and literature information.
Finally, we search for, the co-expressed genes of differentially expressed ones,
which are part of the colon cancer data.
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To evaluate the obtained genes which are really associated with colon cancer,
we perform classification of patients using an LS-SVM classifier on this subset
of genes. Then we compare the prediction performances on the whole set of
genes, subsets of differentially expressed genes and subsets of both differentially
expressed and co-expressed genes. In colon cancer, the highest leave-one-out
(LOO) areas under the receiver operating characteristic curves (AUC) are
obtained ranging from 0.868 to 0.989 on the subsets of differentially expressed
and co-expressed genes.
The results suggest that the incorporation of external knowledge into microarray
analysis improves the identification of disease specific genes. This emphasizes
the importance of data integration in gene expression analysis.
4.1 Introduction
Biomarker discovery and prognosis prediction are essential for improved,
personalized treatment of cancer. Microarray technology is a significant tool
in gene expression analysis and cancer diagnosis. It can simultaneously handle
thousands of genes. Microarray data are typically used for class discovery
[136, 144] and prediction [33, 157]. The challenge in dealing with microarray
data lies in the fact that there is a difference in orders of magnitude between
the number of samples (typically less than hundred) and the number of genes
(typically tens of thousands). The measurements also contain both measurement
and systematic noise with an impact on classification accuracy.
An ever increasing number of techniques has been available for the discovery
of clusters of samples with similar gene expressions in microarray data.
Troyanskaya and colleagues developed nonparametric methods to identify
differentially expressed genes (DEG) in microarray data [180]. Principal
component analysis (PCA) and PCA-based approaches were used as well for
the identification of DEG in pulmonary adenocarcinoma [76] and E coli [168].
Besides well-known statistical tests such as the chi-square test [155], Chun
and colleagues proposed a new test, the ’half Student’s t-test’, specifically
for detecting DEG in heterogeneous diseases [83]. Generalized Eigen Value
Decomposition has been shown to have great potential within bioinformatics for
extracting common information from datasets such as genomics and proteomics
data [3, 152]. Recently the robust PCA (RPCA) based method for discovering
differentially expressed genes was proposed in [111]. Several studies used
microarray and literature information together to obtain differentially expressed
genes with elements for biological understanding, generating and validating new
biological hypotheses [56, 30, 28].
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In this Chapter, we propose a data integration strategy in which gene expression
values are weighted with literature information. We represent the generalized
eigenvalue decomposition (GEVD) in terms of the eigenvalue decomposition
(EVD) for the integration of two data sets. Then we apply robust PCA (RPCA)
to discover the differentially expressed genes in colon cancer. Finally we assume
that there are disease-specific genes that are not identified by the analysis. Thus
we search GeneMANIA tool: www.genemania.org for finding co-expressed genes
related to the obtained disease specific genes of colon cancer data.
4.2 Method
The methods used for this study can be subdivided into two categories:
representation of GEVD in terms of EVD which offers a framework in which
the microarray data set is weighted with literature information and then the
robust PCA approach is applied on these data sets to recover a low rank and a
sparse matrix.
4.2.1 Generalized Eigenvalue Decomposition
The GEVD in Equation 2.3 can now be rewritten as EVD problem:
(BTB)−1/2ATA(BTB)−1/2W = WΛ.
where W = (BTB)1/2(XT )−1, and (BTB)1/2 is a symmetric square root the
matrix BTB. Thus, if BTB is invertible, the GEVD can be represented as a
PCA estimation of weighted matrix (BTB)−1/2ATA(BTB)−1/2.
Let D = (BTB)−1/2AT , and its SVD be
D = PSQT . (4.1)
The matrix (BTB)−1/2 is defined [80] as follows: Let the EVD of BTB = TΣTT ,
where the columns of T are the eigenvectors and Σ is a diagonal matrix.
(BTB)1/2 = TΣ1/2TT and (BTB)−1/2 = TΣ−1/2TT .
We can estimate the low rank decomposition of matrix D by SVD as shown in
Equation 4.1. But standard SVD is highly susceptible to outliers. This problem
can be addressed by using a robust analysis.
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4.2.2 The RPCA Model of Gene Expression Data
We followed the same RPCA model for gene expression data, which is proposed
in [111], but here we considered both gene expression data and literature
information. In this section, we used the same data sets which we described
in Sections 3.3.1 and 3.3.2. We used Equation 4.1 in which a m × n matrix
A is microarray (m = 62 samples and n = 2000 genes) and p× n matrix B is
literature information (p = 2406 terms and n = 2000 genes). We obtain a n×m
matrix D = (BTB)−1/2AT , a gene expression data weighted with literature
information. Each row of D represents the transcriptional responses of a gene
weighted with literature information in all the m samples, and each column of
D represents the weighted expression levels of all the n genes in one sample.
Our goal of using RPCA model on weighted microarray data is to identify disease
associated genes. Assume that the matrix decomposition D = R+ Z has been
done by using RPCA. By choosing the appropriate parameter λ, the positive
regularization parameter in Equation 2.4, the sparsity of the perturbation matrix
Z can be influenced, i.e. most of the entries in Z are zero. Studies show that
in RPCA estimation, the low-rank component R corresponds to the stationary
patterns and the sparse component Z captures the differentially expressed
pattern [24]. Hence the differentially expressed genes can be treated as sparse
perturbation signals Z.
The sparse matrix Z, in which most of the entries are zero, can be denoted as:
Z =

z11 z12 .. z1m
z21 z22 .. z2m
... ... ... ...
zn1 zn2 .. znm

In RPCA estimation, the low-rank component R corresponding to the stationary
pattern and the sparse component Z containing the differentially expressed
patterns. In microarray analysis, the normal genes obtain similar profiles over
all samples and differentially expressed ones behave differently on diseased
and normal samples. Thus we assume that the non-zero entries in the matrix
Z corresponds to differentially expressed patterns. The matrix Z contains
both positive and negative values. Hence to obtain the differentially expressed
features, the absolute value of the entries in the each row of the matrix Z need
to be considered. For that the following two steps are executed: firstly, the
absolute values of the entries in the sparse matrix Z are found out; secondly,
to get the evaluating vector Z˜, the matrix is summed by row. This resulted
into an n × 1 vector in which each row corresponding to the gene and each
entry in the vector represents the sum of the absolute values of entries in the
corresponding row of the sparse matrix Z.
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Z˜ = [Σmi=1‖s1i‖ . . .Σmi=1‖sni‖]T .
Consequently, the evaluating vector, the sum of the different expression profile
Zˆ is sorted in descending order, to arrange genes from most differentially
expressed ones. Without loss of generality, suppose that the first c1 entries in
Zˆ are non-zero, that is,
Zˆ = [zˆ1, . . . , zˆc1, 0, . . . , 0]T .
Thus, the larger the element in Zˆ, is the more different gene in weighted
expression data. The indices of Zˆ correspond to differentially expressed genes.
Thus we identified differentially expressed genes of colon cancer data set.
To evaluate the relevance of identified genes in colon cancer, we applied LS-
SVM classifier on these subsets of genes to classify cancerous and non-cancerous
samples. In addition literature references helped us to understand the biological
importance of these genes in colon cancer.
4.3 Results
In our analysis, we collected a publicly available binary class colon data set
(disease vs. normal) of 1,988 genes and 62 samples (See Section 3.3.1). Then
we generated a gene-term matrix as described in Section 3.3.2 resulting in
a matrix with 1,988 genes and 2,406 terms. In order to integrate these two
data sets, we have applied the Equation 4.1, on an 62×1,988 matrix A and a
2,406×1988 matrix B. Thus the colon cancer data set is weighted with the
literature information resulting in a single matrix D = (BTB)−1/2AT .
Then we applied RPCA on the integrated data set by solving the Equation 2.4
using the inexact ALM (IALM) algorithm proposed in [110]. In RPCA model,
the matrix has been decomposed as D = R+ Z. By choosing the appropriate
parameter λ, the positive regularization parameter in Equation 2.4, the sparse
perturbation matrix S can be obtained, i.e., most of entries in S are zero or
near-zero. We adjusted the λ to obtain approximately 20 non-zero entries in the
matrix S. The IALM algorithm is simple to implement, each iteration involves
computing a partial SVD of a matrix D, and converges to the true solution in
a small number of iterations.
Liu et al [111] already has used RPCA to identify the differentially expressed
genes from colon cancer data. Our main objective is to compare the performance
of the RPCA model to identify disease related genes from gene expression data
with both gene expression and literature information. To validate the relevance
of obtaining genes in colon cancer, we performed LS-SVM classifier [172] on the
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subsets of genes selected by RPCA. Classification of patients was performed on
subsets of genes using an LS-SVM classifier, in which 2/3rd samples are split into
training and the remaining as test sets. In all cases, a linear kernel function was
used with the LS-SVM classifier. To further identify the co-expressed genes of
the obtained disease specific genes, we make the network analysis of the selected
genes using the GeneMania tool www.genemania.org. Table 4.1 shows the
averaged classification performance of colon cancer data set on whole data sets,
subsets of genes identified by RPCA in [111] and proposed approach, over 30
iterations. The results show that better prediction performance in terms of test
areas under curve (AUC) is obtained with the proposed approach. We obtained
sets of co-expressed genes which are parts of colon cancer data, but not identified
by our approach. Thus searching for co-expressed genes helped us to identify
disease related genes which are really missing in our analysis. Then we estimated
prediction performance to classify patients on sets of genes, including both
co-expressed and differentially expressed ones. The predictive performance has
improved while considering both co-expressed genes and differentially expressed
ones. Thus the incorporation of literature information into microarray analysis
improves the identification of disease associated genes and hence offer better
diagnosis, progonosis, and patient therapy.
Table 4.1: Averaged LS-SVM classifier performance, for classification of colon
cancer patients, on whole genes, subset of differentially expressed genes, and
subset of both differentially expressed and co-expressed genes, over 30 iterations.
Data Sources No. of genes Methods test AUC
Microarray and literature information 23 proposed approach 0.834(0.087)
Microarray 30 RPCA in [111] 0.834(0.085)
Microarray and literature information 33 proposed approach and GeneMania 0.870(0.078)
Microarray 46 RPCA in [111]and GeneMania 0.795(0.095)
Microarray 2000 whole data set 0.834(0.097)
The colon cancer related genes were selected by the proposed approach are shown
in Table 4.2. Several genes selected by this approach are known to be involved in,
and important for, colon cancer. Ribosome, the essential cellular organelle for
protein synthesis in all cells, consists of ribosomal RNAs (rRNAs) and ribosomal
proteins (RPs). Ribosomal protein L41 (RPL41) is a microtubule-associated
protein essential for functional spindles and for the integrity of centrosome
and that the abnormal mitosis and disrupted centrosome associated with the
RPL41 down-regulation may be related to malignant transformation [188]. In
our analysis, RPL41 (H55933) ranked as the most differentially expressed gene.
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Table 4.2: 23 Differentially expressed genes of colon cancer identified by the
proposed method
Gene Id Gene Annotation
Hsa.3004 H55933 Homo sapiens mRNA for homologue to yeast ribosomal protein L41
Hsa.2357 T52342 Human tra1 mRNA for human homologue of murine tumor rejection antigen gp96
Hsa.474 L28809 Homo sapiens dbpB-like protein mRNA
Hsa.6080 J02763 Human calcyclin gene
Hsa.20836 R02593 60S acidic ribosomal protein P1
Hsa.45293 H86060 Negative factor (Simian immunodeficiency virus)
Hsa.20836 R02593 60S acidic ribosomal protein P1 (Polyorchis penicillatus)
Hsa.13491 R39465 Eukaryotic Initiation factor 4A (Oryctolagus cuniculus)
Hsa.3835 H79852 60S acidic ribosomal protein P2 (Babesia bovis)
Hsa.37254 R85482 Serum response factor (Homo sapiens)
Hsa.909 M11799 Human MHC class I HLA-Bw58 gene
Hsa.749 T63508 Ferritin in heavy chain (HUMAN)
Hsa.2597 T49423 Breast basic conserved protein 1 (HUMAN)
Hsa.750 T72863 Ferritin light chain (HUMAN)
Hsa.2800 X55715 Human Hums3 mRNA for 40S ribosomal protein s3
Hsa.8068 T57619 40S ribosomal protein S6 (Nicotiana tabacum)
Hsa.467 H20709 MYOSIN LIGHT CHAIN ALKALI, SMOOTH-MUSCLE ISOFORM (HUMAN)
Hsa.3087 T65938 Translationally controlled tumor protein (HUMAN)
Hsa.5710 T63484 Human ornithine decarboxylase antizyme (Oaz) mRNA
Hsa.3061 X63469 Transcription initiation factor iie-beta chain (HUMAN)
Hsa.878 T61609 Laminin receptor (HUMAN)
Hsa.9994 T51539 Hepatocyte growth factor-like protein precursor (Homo sapiens)
Hsa.4689 T95018 40s ribosomal protein s18 (Homo sapiens)
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Studies in [87] and [109] already reported that RPL41 (H55933) gene has high
rank in colon cancer.
Ectopic expression of tumor rejection antigen 1 (Tra1) were detected in the
UC affected colonic mucosa [101]. Tra1 is reported as a differentially expressed
gene in colon cancer [87]. Calcyclin binding protein (CacyBP) as a promising
candidate biomarker for colorectal cancer (CRC) metastasis and also sheds
light on the underlying molecular mechanism by which CacyBP promotes CRC
metastasis [65]. 60S acidic ribosomal protein P1 (R02593) were reported as a
top-ranked gene in colon cancer [87, 190].
Eukaryotic initiation factor (elF) functions as a subunit of the initiation factor
complex elF4F, which mediates the binding of mRNA to the ribosome. Serum
response factor (SRF)regulates transcription of many serum-inducible and
muscle-specific genes. It binds to the serum response element, a DNA sequence
required for the transcription of a number of genes in response to growth
factor or mitogen stimulation. These genes might provide an indication of the
migratory capacity of the cells in the specimens and hence their propensity for
metastasis [87, 159].
Human Leukocyte Antigen (HLA) class I molecules are of major importance
for cell-mediated anti-tumor immune responses. Expression of HLA class I/2-
microglobulin (2-m) complexes carrying tumor-specific peptides is a prerequisite
for adaptively matured cytotoxic T cells (CTLs) to be able to recognize tumor
cells [179]. Loss of expression of HLA class I molecules has been frequently
reported for colorectal tumors [92, 22].
Low serum ferritin levels are associated with patients having serious gastroin-
testinal pathologies such as neoplasia and acid peptic disease [182]. Previous
work has shown that the majority of colorectal adenocarcinomas exhibit ferritin
expression [34], but the clinical significance remains unknown. Myosin light
chain alkali, smooth-muscle isoform (H20709) also reported as top ranked genes
in colon cancer on several studies [87].
Translationally controlled tumor protein (TCTP) is a highly conserved and
ubiquitously expressed protein in all eukaryotes—highlighting its important
functions in the cell. Previous studies revealed that TCTP is implicated in
many biological processes, including cell growth, tumor reversion, and induction
of pluripotent stem cell. In human colon cancer, the level of TCTP mRNA
was detected in three human colon carcinoma cell lines (SNU-C2A, SNU-C4,
and SNU-C5) [27]. Ornithine decarboxylase (OAZ1) catalyzes the conversion
of ornithine to putrescine in the first and apparently rate-limiting step in
polyamine biosynthesis. The ornithine decarboxylase antizymes play a role in
the regulation of polyamine synthesis by binding to and inhibiting ornithine
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decarboxylase. OAZ(T63484) were reported [87, 2] as a top ranked gene in
colon cancer.
Alterations in the distribution and/or adhesiveness of laminin receptors in colon
cancer cell lines may be associated with increased tumorigenicity [96]. A study
of cultured colon cancer cells suggests that laminin may play an important role
in hematogeneous metastasis by mediating tethering and spreading of colon
cancer cells under blood flow [97]. In general, the markers are involved in cell
signaling, adhesion and communication, immune response, heat shock, and DNA
repair [87]. Hepatocyte growth factor (HGF) signaling has been implicated in
a broad spectrum of human cancers. Studies show that HGF-induced colon
tumor cell proliferation, invasion as well as tumor growth and metastasis in
xenograft models [165].
In short, out of 23 genes identified as differentially expressed genes of colon
cancer, majority of these genes are reported on several studies as top ranked genes
in colon cancer. In addition, the selected genes clearly distinguish cancerous
and non-cancerous samples indicating that these genes are part of colon cancer.
4.4 Discussion
The proposed method has been applied to colon cancer data of which the
corresponding literature information is available. Literature information was
gathered from Pubmed by searching gene and term co-occurrence, in which
columns corresponded to genes, and rows to cancer related terms. We chose
to retrieve column entries containing the official gene name, abbreviations or
aliases and row entries corresponding to cancer related terms such as colon
cancer, crohn’s disease, abdominal pain etc. To verify the merit of our approach
over the use of RPCA on the single expression data source, models were built
for classifying colon cancer patients. In many studies, single data sources
are explored for the identification of differentially expressed genes. In our
opinion, a single data source is inadequate to explain complex networks of genes
underlying a disease. In this study, microarray data are weighted with literature
information. These types of external knowledge in the analysis of microarray
improves the identification of cancer related genes accurately.
In RPCA, firstly, the matrix microarray data weighted with literature
information D is decomposed into a low rank matrix R and perturbation
matrix Z by using Equation 2.4; secondly, the differentially expressed genes
were discovered as explained in Section 4.2.2. The proposed approach offer
an efficient approach to incorporate prior information into microarray analysis
for gene selection. In addition, compared to other statistical approaches for
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gene selection, it does not widely vary on the number of genes selected on each
iterations. Finally the biological relevance and the prediction performance of
selected genes emphasize the relevance of our approach for the identification of
differentially expressed genes.
4.5 Conclusion
The results suggest that the proposed approach to colon cancer data, improve
the identification of differentially expressed genes and performance of decision
support in cancer. With real data examples, we have shown how to incorporate
external knowledge, extracted from literature information on medical diagnosis.
The proposed method provides a general way to incorporate such ever-increasing
amounts of prior knowledge into the analysis and to further improve the
predictive performance. These results emphasize the need for comprehensive
prior knowledge gathered with microarray data, but it is unknown which type
and levels of external knowledge are most relevant for the biomarker discovery
and prognostic prediction.
Chapter 5
Bandwidth selection criterion
of KPCA: Applications in
Bioinformatics
This paper was published in BMC Bioinformatics: Thomas M., De Brabanter
K., De Moor B.: New bandwidth selection criterion for Kernel PCA: Approach
to Dimensionality Reduction and Classification Problems. BMC Bioinformatics
2014, 15:137 (2014).
Background: DNA microarrays are potentially powerful technology for
improving diagnostic classification, treatment selection, and prognostic
assessment. The use of this technology to predict cancer outcome already
has a history of almost a decade. Disease class predictors can be designed for
known disease cases and provide diagnostic confirmation or clarify abnormal
cases. The main input of these class predictors is high dimensional data with
many variables and only a few observations. Reducing the dimensionality of the
feature set significantly speeds up the prediction task. Feature selection (t-test)
and feature transformation (Principal Component Analysis (PCA)) methods are
well known preprocessing steps in the field of bioinformatics. Several prediction
tools are available based on these techniques.
Results: Studies show that a well tuned Kernel PCA (KPCA) is a valuable
preprocessing step for dimensionality reduction, but the available bandwidth
selection method for KPCA was computationally expensive. In this paper, we
propose a new data-driven bandwidth selection criterion for radial basis function
(RBF) KPCA which is related to least squares cross-validation for kernel density
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estimation. We propose a new prediction model with a well tuned KPCA and
Least Squares Support Vector Machine (LS-SVM). We estimate the accuracy of
the newly proposed model on 9 case studies. Then, we compare its performance
(in terms of test set Area Under the ROC Curve (AUC) and computation time)
with other well known techniques such as LS-SVM on the whole data set, PCA
+ LS-SVM, t-test + LS-SVM, Prediction Analysis of Microarrays (PAM) and
Least Absolute Shrinkage and Selection Operator (Lasso). Finally, we assess
the performance of the proposed strategy with an existing KPCA parameter
tuning algorithm by means of two extra case studies.
Conclusion: We propose, evaluate, and compare several mathematical/sta-
tistical techniques that apply feature transformation/selection for subsequent
classification, and consider their application to medical diagnostics. Both feature
selection and feature transformation perform well on classification tasks. Due to
the dynamic selection property of feature selection, it is hard to define significant
features for the classifier which predicts classes of future samples. Moreover,
the proposed strategy enjoys a distinctive advantage with its relatively low time
complexity.
5.1 Introduction
Biomarker discovery and prognosis prediction are essential for improved,
personalized treatment of cancer. Microarray technology is a significant tool
in gene expression analysis and cancer diagnosis. It can simultaneously handle
thousands of genes. Microarray data are typically used for class discovery
[144, 136] and prediction [157, 33]. The high dimensionality of the input
feature space in comparison with the relatively small number of subjects (curse
of dimensionality) is a widespread concern, so some form of dimensionality
reduction is often applied. Feature selection and feature transformation are
two commonly used dimensionality reduction techniques. The key difference
between feature selection and feature transformation is that in the former only a
subset of original features is selected while the latter is based on the generation
of completely new features.
In this genomic era, several classification and dimensionality reduction methods
are available for analyzing and classifying microarray data. Prediction Analysis
of Microarrays (PAM) [177] is a statistical technique for class prediction from
gene expression data using Nearest Shrunken Centroids (NSC). PAM identifies
subsets of genes that best characterize each class. LS-SVM [170, 172] is a
promising method for classification because of its solid mathematical foundations
which convey several salient properties that other methods hardly provide. A
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commonly used technique for feature selection, the t-test, assumes that the
feature values from two different classes follow normal distributions. Several
studies, especially microarray analysis, have used t-test and LS-SVM together
to improve the prediction performance by selecting important features [32, 83].
The Least Absolute Shrinkage and Selection Operator (Lasso) [176] is often used
for gene selection and parameter estimation in high-dimensional microarray
data [93]. The Lasso shrinks some of the coefficients to zero, and the amount of
shrinkage is determined by the tuning parameter, often determined by cross
validation.
Inductive learning systems were successfully applied in a number of medical
domains, e.g. in localization of a primary tumor, prognostic of recurrence of
breast cancer, diagnosis of thyroid diseases, and rheumatology [57]. An induction
algorithm is used to learn a classifier, which maps the space of feature values to
the set of class values. The classifier is later used to classify new instances with
unknown classifications (class labels). Researchers and practitioners realize that
the effective use of these inductive learning systems requires data preprocessing
before a learning algorithm can be applied [129]. Due to the large variability of
feature selection techniques, it may be difficult or even impossible to remove
irrelevant and/or redundant features from a data set. Feature transformation
techniques, such as KPCA, discover a new feature space having fewer dimensions
through a functional mapping while keeping as much information in the data
as possible.
KPCA, which is a generalization of PCA, is a nonlinear dimensionality reduction
technique that has proven to be a powerful pre-processing step for classification
algorithms. It has been studied intensively in the last several years in the
field of machine learning and has claimed success in many applications [126].
An algorithm for classification using KPCA was developed by Liu et al. [111].
KPCA was proposed by Schölkopf and Smola [146], by considering a mapping
to a high-dimensional feature space (possible infinite) and applying Mercer’s
theorem. Suykens et al. [170, 171] proposed a simple and straightforward
primal-dual support vector machine formulation to the PCA problem.
Pochet et al.[134] proposed an optimization algorithm for KPCA with
RBF kernel followed by Fisher Discriminant Analysis (FDA) is to find the
parameters of KPCA. In the latter case, parameter selection is coupled with the
corresponding classifier. This means that the performance of the final procedure
depends on the chosen classifier. Such a procedure could produce very bad
results in case of weak classifiers. In addition, this appears to be time consuming
when tuning the parameters of KPCA.
Most classification methods have problem with high dimensionality of microarray
data and require dimensionality reduction first. The ultimate goal of our work is
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to design a powerful preprocessing step, decoupled from the classification method,
for large dimensional data sets. In this Chapter, we explain an LS-SVM approach
to KPCA. Next, by following the idea of least squares cross-validation in kernel
density estimation, we propose a new data-driven bandwidth selection criterion
to tune the LS-SVM formulation of KPCA. The tuned LS-SVM formulation to
KPCA is applied to several data sets and serves as a dimensionality reduction
technique for a final classification task. In addition, we compared the proposed
strategy with an existing optimization algorithm for KPCA as well as with other
preprocessing steps. Finally, for the sake of comparison, we applied LS-SVM
without dimensionality reduction, PCA+LS-SVM, t-test + LS-SVM, PAM and
Lasso. Randomization on all data sets are carried out in order to get a more
reliable idea of the expected performance.
5.2 Data sets
In our analysis, we collected 11 publically available binary class data sets
(disease vs. normal). The data sets are: colon cancer data [2], breast cancer
data [79], pancreatic cancer premalignant data [81], cervical cancer data
[197], acute myeloid leukemia data[166], ovarian cancer data[http://home.ccr.
cancer.gov/ncifdaproteomics/ppatterns.asp], head & neck squamous cell
carcinoma data [100], early-early stage duchenne muscular dystrophy(EDMD)
data [131], HIV encephalitis data [115], high grade glioma data [127], and breast
cancer data [181]. Missing values of these data sets have been imputed based on
the nearest neighbor method. An overview of the characteristics of all the data
sets can be found in Table 5.1. In breast cancer II and high grade glioma data
sets, all data samples have already been assigned to a training set or test set. In
all other cases, 2/3rd of the data samples of each class are assigned randomly to
the training and the rest to the test set. These randomization are the same for
all numerical experiments on all data sets. This split was performed stratified
to ensure that the relative proportion of outcomes sampled in both training
and test set was similar to the original proportion in the full data set. In all
these cases, the data were standardized to zero mean and unit variance.
5.3 Methods
Link with an LS-SVM approach to KPCA in Section 2.2.3 and the idea of
least squares cross-validation in kernel density estimation, we propose a new
data-driven bandwidth selection criterion to tune the LS-SVM formulation of
KPCA.
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Table 5.1: Summary of the 11 binary disease data sets.
Data set #Samples #Genes
Class 1 Class2
1: Colon 40 22 2000
2: Breast cancer I 34 99 5970
3: Pancreatic 50 50 15154
4: Cervical 8 24 10692
5: Leukemia 26 38 22283
6: Ovarian 91 162 15154
7: Head & neck squamous
cell carcinoma 22 22 12625
8: Duchenne muscular dystrophy 23 14 22283
9: HIV encephalitis 16 12 12625
10: High grade glioma 28 22 12625
11: Breast cancer II 46 51 24188
5.3.1 Data-Driven Bandwidth Selection for KPCA
Model selection is a central issue in all learning tasks, especially in KPCA. Since
KPCA is an unsupervised technique, formulating a data-driven bandwidth
selection criterion is not trivial. Analogue to least squares cross validation
[19, 145] in kernel density estimation, we propose a new data driven selection
criterion for KPCA. Let
zn(x) = ΣNi=1α
(n)
i K(xi, x)
where K(xi, xj) = exp(− ||xi−xj ||
2
2h2 ) (RBF kernel with bandwidth h) and set
the target equal to 0 and denote by zn(x) the score variable of sample x on
nth eigenvector α(n). Here, the score variables are expressed in terms of kernel
expressions in which every training point contributes. These expansions are
typically dense (nonsparse). Therefore we have chosen the L1 loss function to
induce sparsness in kernel PCA. We propose the following tuning criterion for
the bandwidth h:
J(h) =h∈R+0 E
∫
|zn(x)|dx, (5.1)
where E denotes the expectation operator. Maximizing Equation (5.1) would
lead to overfitting since we used all the training data in the criterion. Instead,
we work with Leave One Out (LOO) cross validation estimation of zn(x) to
obtain the optimum bandwidth h of KPCA, which gives projected variables
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Figure 5.1: Bandwidth selection of KPCA for cervical and colon cancer data on
fixed number of components. The plot J(h) vs. h maximizes J(h) at optimal
bandwidth h. (a) 5th principal component for cervical cancer data and (b) 15th
principal component for colon cancer .
with maximal variance. A finite approximation to Equation (5.1) is given by
J(h) =h∈R+0
1
N
N∑
j=1
∫
|z(−j)n (x)|dx (5.2)
where N is the number of samples and z(−j)n denotes the score variable with the
jth observation is left out. In case the leave one out approach is computationally
expensive, one could replace it with a leave v group out strategy (v- fold cross-
validation). Integration can be performed by means of any numerical technique.
The final model with optimum bandwidth is constructed as follows:
Ωc,hˆmaxα = λα,
where hˆmax = maxh∈R+0
1
N
∑N
j=1
∫ |z(−j)n (x)|dx. Figure 5.1 shows the bandwidth
selection for cervical and colon cancer data sets for fixed number of components.
To also retain the optimum number of components k of KPCA, we modify
Equation (5.2) as follows: Figure 5.3 shows the surface plot of Equation (5.3)
for various values of h and k.
J(h, k) =h∈R+0 ,k∈N0
1
N
k∑
n=1
N∑
j=1
∫
|z(−j)n (x)|dx (5.3)
where k = 1, . . . , N . Figure 5.2 illustrate the proposed model. Thus, the
proposed data-driven model can obtain the optimal bandwidth for KPCA, while
retaining minimum number of eigenvectors which capture the majority of the
variance of the data. Figure 5.4 shows a slice of the surface plots. The values of
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Figure 5.2: Data-Driven Bandwidth Selection for KPCA
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Figure 5.3: The surface plot of Equation (5.3) for various values of h and k.
Model selection for KPCA-optimal bandwidth and number of components.(a)
Cervical cancer (b) Colon cancer .
the proposed criterion were rescaled to be maximum 1. The parameters that
maximize Equation (5.3) are h = 70.71 and k = 5 for cervical cancer data and
h = 43.59 and k = 15 for colon cancer data.
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Figure 5.4: Slice plot for the Model selection for KPCA for the optimal
bandwidth.(a) Cervical cancer (b) Colon cancer .
5.4 Results
First we considered nine data sets described in Table 5.1. We have chosen
the RBF kernel K(xi, xj) = exp(− ||xi−xj ||
2
2h2 ) for KPCA. In this section all the
steps are implemented using Matlab R2012b and LS-SVMlab v1.8 toolbox [46].
Next, we compared the performance of the proposed method with classical PCA
and an existing tuning algorithm for RBF-KPCA developed by Pochet et al.
[134]. Later, with the intention to comprehensively compare PCA+LS-SVM
and KPCA+LS-SVM with other classification methods, we applied four widely
used classifiers to the microarray data, being LS-SVM on whole data sets, t-test
+ LS-SVM, PAM and Lasso. To fairly compare kernel functions of the LS-SVM
classifier; linear, RBF and polynomial kernel functions are used (in Table 5.2
referred to as linear/poly/RBF). The average test accuracies and execution time
for all these methods when applied to the 9 case studies are shown in Table
5.2 and Table 5.3 respectively. For all these methods, training on 2/3rd of the
samples and testing on 1/3rd of the samples was repeated 30 times.
5.4.1 Proposed Criterion with PCA
For each data set, the proposed methodology is applied. This methodology
consists of two steps. First, Equation (5.3) is maximized in order to obtain
an optimal bandwidth h and corresponding number of components k. Second,
the reduced data set is used to perform a classification task with LS-SVM. We
retained 5 and 15 components respectively for cervical and colon cancer data sets.
For PCA, the first k components capturing most of the variability of the original
dataset were used. We retained 13 components (83.68% of variance explained)
and 15 components (83.20% of variance explained) for cervical and colon cancer
respectively for PCA. Similarly, we obtained number of components of PCA
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Table 5.2: Comparison of classifiers: Mean AUC(std) of 30 iterations
Data set Kernel preprocessing + LS-SVM PAM Lasso
function classifier
whole data PCA KPCA t-test(p<0.05)
RBF 0.769(0.127) 0.793(0.081) 0.822(0.088) 0.816(0.094)
I lin 0.822(0.068) 0.837(0.088) 0.864(0.078) 0.858(0.077) 0.787(0.097) 0.837(0.116)
poly 0.818(0.071) 0.732(0.072) 0.825(0.125) 0.829(0.071)
RBF 0.637(0.146) 0.749(0.093) 0.780(0.076) 0.760(0.080)
II lin 0.803(0.059) 0.772(0.094) 0.790(0.075) 0.764(0.067) 0.659(0.084) 0.766(0.074)
poly 0.701(086) 0.752(0.063) 0.753(0.072) 0.766(0.064)
RBF 0.832(0.143) 0.762(0.066) 0.879(0.058) 0.913(0.047)
III lin 0.915(0.043) 0.785(0.063) 0.878(0.066) 0.913(0.047) 0.707(0.067) 0.9359( 0.0374)
poly 0.775(0.080) 0.685(0.105) 0.8380(0.068) 0.913(0.047)
RBF 0.615(0.197) 0.853(0.112) 0.867(0.098) 0.853(0.187)
IV lin 0.953(0.070) 0.917(0.083) 0.929(0.077) 0.924(0.070) 0.759(0.152) 0.707(0.194)
poly 0.762(0.118) 0.811(0.140) 0.840(0.131) 0.733(0.253)
RBF 0.807(0.238) 0.790(0.140) 0.976(0.035) 0.950(0.150)
V lin 0.997(0.005) 0.528(0.134) 0.982(0.022) 0.999(0.001) 0.923(0.062) 0.934(0.084)
poly 0.942(0.051) 0.804(0.121) 0.975(0.028) 0.999(0.002)
RBF 0.998(0.001) 0.982(0.002) 0.984(0.012) 0.998(0.004)
VI lin 0.990(0.005) 0.973(0.002) 0.978(0.013) 0.993(0.013) 0.960(0.016) 0.951(0.045)
poly 0.998(0.006) 0.985(0.016) 0.973(0.018) 0.955(0.042)
RBF 0.946(0.098) 0.941(0.057) 0.932(0.071) 0.940(0.098)
VII lin 0.983(0.025) 0.947(0.047) 0.954(0.051) 0.983(0.031) 0.931(0.058) 0.952(0.030)
poly 0.785(0.143) 0.903(0.078) 0.915(0.080) 0.920(0.025)
RBF 0.823(0.159) 0.923(0.096) 0.858(0.113) 0.950(0.150)
VIII lin 0.840(0.164) 0.969(0.044) 0.800(0.019) 0.999(0.005) 0.982(0.050) 0.890(0.081)
poly 0.781(0.186) 0.870(0.117) 0.785(0.121) 0.998(0.007)
RBF 0.638(0.210) 0.823(0.159) 0.852(0.180) 0.873(0.166)
IX lin 0.931(0.126) 0.840(0.164) 0.846(0.143) 0.875(0.136) 0.703(0.175) 0.705(0.174)
poly 0.841(0.176) 0.781(0.186) 0.798(0.193) 0.798(0.193)
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Table 5.3: Summary of averaged execution time of each classifiers over 30
iterations in seconds.
Dataset whole PCA KPCA t-test PAM Lasso
data (p < 0.05)
1: Colon 17 10 18 13 8 72
2: Breast 56 38 54 42 12 258
3: Pancreatic 17 12 26 19 20 453
4: Cervical 43 28 29 33 43 106
5: Leukemia 225 185 184 195 28 680
6: Ovarian 51 25 39 44 19 865
7: Head & neck squamous
cell carcinoma 59 39 45 47 30 238
8: Duchenne muscular dystrophy 146 115 113 110 80 20100
9: HIV encephalitis 45 27 27 28 88 118
and the number of components with corresponding bandwidth for KPCA for
the remaining data sets.
The score variables (the new coordinate of samples projected onto the KPCA
or PCA components having maximum variance) are used to develop an LS-
SVM classification model. The test AUC values averaged over the 30 random
repetitions are reported.
While comparing the performance (test AUC and execution time) KPCA
outperformed PCA on a majority of the cases in terms of test AUC with
only very small difference in execution time.
5.4.2 Proposed Criterion with Existing Optimization Algo-
rithm for RBF-KPCA
We selected two experiments from Pochet et al. [134] (last two data sets in
Table 5.1), being high-grade glioma and breast cancer II data sets. We repeated
the same experiments as reported in Pochet et al. [134] and compared with the
proposed strategy. The results are shown in Table 5.4. The three dimensional
surface plot of LOO-CV performance of Pochet et al. method [134] for the
high-grade glioma data set is shown in Figure 5.5, with the optimal h = 114.018
and k = 12. The optimum parameters are h = 94.868 and k = 10 obtained
by the proposed strategy (see Equation (5.3)) for the same data set. When
looking at test AUC in Table 5.4, both case studies applying the proposed
strategy, perform better than the method proposed by Pochet et al.[134] with
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Figure 5.5: The three dimensional surface plot of LOO-CV performance of
optimization algorithm [134] on high-grade glioma data set
Table 5.4: KPCA + LS-SVM Classifier: Comparison of performance of proposed
bandwidth selection criterion for KPCA with the method proposed by Pochet
et al. [134]: Averaged test AUC(std) over 30 iterations and execution time in
minutes
Data set proposed strategy Pochet et al. [134]
Test AUC time Test AUC time
high-grade glioma data 0.746(0.071) 2 0.704(0.104) 38
breast cancer II 0.6747(0.1057) 4 0.603(0.157) 459
less variability. In addition, the tuning method Pochet et al. [134] appears
to be quite time consuming, whereas the proposed model enjoys a distinctive
advantage with its low time complexity to carry out the same process.
5.4.3 Proposed Criterion with Other Classifiers
When looking specifically at all these methods in term of test AUC, we note
that LS-SVM performance was slightly low on PCA. On breast cancer I, cervical
cancer and HIV encephalitis data sets LS-SVM with linear kernel performs
significantly better in terms of test AUC. The t-test + LS-SVM classifier shows
the best test AUC for Leukemia and EDMD data sets. LS-SVM with linear
kernel and t-test + LS-SVM classifiers have approximately the same test AUC
on ovarian cancer and head & neck squamous cell carcinoma data sets. The
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proposed strategy with LS-SVM (RBF) classifiers offer better test AUC for
colon cancer, breast cancer I, cervical cancer and head & neck squamous cell
carcinoma data sets. Only on pancreatic data set, Lasso outperformed all other
case studies. The test AUC of PAM was significantly worse on all data sets
except DMD data set.
5.5 Discussions
While analyzing the test AUC of different classifiers on nine data sets does
not direct to a common conclusion that one method outperforms the other.
Instead, it shows that each of these methods has their own advantage
in classification tasks. When considering classification problems without
dimensionality reduction, the regularized LS-SVM classifier on half of data
sets shows a good performance. Up till now, most microarray data sets are
quite small, but it can be expected that these data sets will become larger
or perhaps represent more complex classification problems in the future. In
this case, dimensionality reduction processes (feature selection and feature
transformation) become important.
The selected features on feature selection methods such as t-test, PAM and Lasso
widely vary for each random iteration. Further, the classification performance
of these methods on each iteration depends on the number of features selected.
Table 5.5 shows the range, i.e. minimum and maximum number of features
selected on 30 iterations. PAM and Lasso only outperformed in two case studies.
However, PAM is a user friendly toolbox for gene selection and classification
tasks, its performance depends really on the selected features. In addition,
it is interesting that the Lasso selected only very small subsets of the actual
data sets. But, in the lasso, the amount of shrinkage varies, depending on the
value of the tuning parameter, which is often determined by cross validation
[187]. The number of genes selected as the outcome-predictive genes generally
decrease as the value of the tuning parameter increases. The optimal value of
the tuning parameter that maximizes the prediction accuracy is determined;
however, the set of genes identified using the optimal value contains the non-
outcome-predictive genes (ie, false positive genes) in many cases [93].
The test AUC on all nine case studies show that KPCA performs better than
classical PCA. But the parameters of KPCA need to be optimized. We note
that an already existing optimization algorithm for KPCA proposed by Pochet
et al. [134] is completely coupled with the subsequent classifier. In addition, it
appears to be very time-consuming. By the data-driven parameter selection of
KPCA, the proposed strategy enhances KPCA as a real preprocessing step.
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Table 5.5: Summary of the range (minimum to maximum) of features selected
by t-test over 30 iterations.
Dataset t-test (p < 0.05) PAM Lasso
1: Colon 173-522 15-373 8-36
2: Breast 746-1124 13-4718 7-87
3: Pancreatic 2564-4855 3-1514 12-112
4: Cervical 954-2108 2-10692 5-67
5: Leukemia 742-3468 137-11453 2-69
6: Ovarian 321-950 34-278 62-132
7: Head and neck squamous
cell carcinoma 1761-2828 1-12625 3-35
8: Duchenne muscular dystrophy 3066-4536 129-22283 8-24
9: HIV encephalitis 620-2013 1-12625 1-20
In combination with classification methods, microarray data analysis can be
useful to guide clinical management in cancer studies. In this study, several
mathematical and statistical techniques evaluated and compared in order to
optimize the performance of clinical predictions based on microarray data.
Considering the possibility of increasing size and complexity of microarray data
sets in the future, dimensionality reduction and nonlinear techniques have its
own significance. In many cases, in a specific application context the best feature
set is still important (e.g. drug discovery). While considering the stability and
performance (both accuracy and execution time) of classifiers, the proposed
methodology has its own importance to predict classes of future samples of
known disease cases.
5.6 Conclusion
The objective in class prediction with microarray data is an accurate classification
of cancerous samples, allowing for directed and more successful therapies. In this
paper, we proposed a new data-driven bandwidth selection criterion for KPCA
(which is a well defined preprocessing technique). In particular, we optimize the
bandwidth and the number of components to maximize the projected variance
of KPCA. In addition, we compared several data preprocessing techniques prior
to classification. In all case studies, most of these data preprocessing steps
performed well on classification with approximately similar performance. We
observed that feature selection based methods selected features widely vary on
each iteration. Hence it is difficult, even impossible to design a stable class
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predictor for future samples with these methods. Experiments on nine data
sets show that the proposed strategy provides a stable preprocessing algorithm
for classification of high dimensional data with good performance on test data.
The advantages of the proposed KPCA+LS-SVM classifier were presented in
four aspects. First, we propose a data-driven bandwidth selection criterion
for KPCA by tuning the optimum bandwidth and the number of principal
components. Second, we illustrate that the performance of the proposed strategy
is significantly better than an existing optimization algorithm for KPCA. Third,
its classification performance is not sensitive to any number of selected genes, so
the proposed method is more stable than others proposed in literature. Fourth,
it reduces the dimensionality of the data while keeping as much information as
possible of the original data. This leads to computationally less expensive and
more stable results for massive microarray classification.
Chapter 6
Predicting breast cancer
using an expression values
weighted clinical classifier
This paper was published in BMC Bioinformatics: Thomas M., De Brabanter
K., Suykens J.A.K., De Moor B.: Predicting breast cancer using an expression
values weighted clinical classifier. BMC Bioinformatics 2014, 15:411 (2014).
Background: Clinical data, such as patient history, laboratory analysis,
ultrasound parameters-which are the basis of day-to-day clinical decision support-
are often used to guide the clinical management of cancer in the presence of
microarray data. Several data fusion techniques are available to integrate
genomics or proteomics data, but only a few studies have created a single
prediction model using both gene expression and clinical data. These studies
often remain inconclusive regarding an obtained improvement in prediction
performance. To improve clinical management, these data should be fully
exploited. This requires efficient algorithms to integrate these data sets and
design a final classifier.
LS-SVM classifiers and generalized eigenvalue/singular value decompositions
are successfully used in many bioinformatics applications for prediction tasks.
While bringing up the benefits of these two techniques, we propose a machine
learning approach, a weighted LS-SVM classifier to integrate two data sources:
microarray and clinical parameters.
Results: We compared and evaluated the proposed methods on five breast
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cancer case studies. Compared to LS-SVM classifier on individual data sets,
the generalized eigenvalue decomposition (GEVD) and the kernel GEVD, the
proposed weighted LS-SVM classifier offers good prediction performance, in
terms of test area under the ROC Curve (AUC), on all breast cancer case
studies.
Conclusions: A clinical classifier weighted with microarray data set results in
significantly improved diagnosis, prognosis and prediction responses to therapy.
The proposed model has been shown to be a promising mathematical framework
in both data fusion and non-linear classification problems.
6.1 Background
Microarray technology, which can handle thousands of genes of several hundreds
of patients at a time, makes it hard for scientists to manually extract relevant
information about genes and diseases, especially cancer. Moreover this technique
suffers from a low signal-to-noise ratio. Despite the rise of high-throughput
technologies, clinical data such as age, gender and medical history, guide clinical
management of most diseases and examinations. A recent study [183] shows
that the importance of the integration of microarray and clinical data have a
synergetic effect on predicting breast cancer outcome. Gevaert et al. [64] have
used a Bayesian framework to combine expression and clinical data. They found
that decision integration, and partial integration leads to a better performance,
whereas full data integration showed no improvement. These results were
obtained by using a cross validation approach on the 78 samples in the van’t
Veer et al.[181] data set. On the same data set, Boulesteix et al. [18] employed
random forests and partial least squares approaches to combine expression and
clinical data. In contrast, they reported that microarray data do not noticeably
improve the prediction accuracy yielded by clinical parameters alone.
The representation of any data set with a real-valued kernel matrix, independent
of the nature or complexity of data to be analyzed, makes kernel methods ideally
positioned for heterogeneous data integrations. Integration of data using kernel
fusion is featured by several advantages. Biological data has diverse structures,
for example, high dimensional expression data, the sequence data, the annotation
data, the text mining data and heterogeneous nature of clinical data and so
on. The main advantage is that the data heterogeneity is rescued by the use of
kernel trick, where data which has diverse data structures are all transformed
into kernel matrices of the same size. To integrate them, one could follow
the classical additive expansion strategy of machine learning to combine them
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linearly. These nonlinear integration methods of kernels have attracted great
interests in recent machine learning research.
Daemen et al.[39] proposed kernel functions for clinical parameters and pursued
an integration approach based on combining kernels (kernel inner product
matrices derived from the separate data types) for application in a Least
Squares Support Vector Machine (LS-SVM)[170]. They explained that the
newly proposed kernel functions for clinical parameter do not suffer from the
ambiguity of data preprocessing by equally considering all variables. That means,
a distinction is made between continuous variables, ordinal variables with an
intrinsic ordering, but often lacking equal distance between two consecutive
categories and nominal variables without any ordering. They concluded that the
clinical kernel functions represent similarities between patients more accurately
than linear or polynomial kernel function for modeling clinical data. Pittman
et al. [132] combined clinical and expression data for predicting breast cancer
outcome by means of a tree classifier. This tree classifier was trained using
meta-genes and/or clinical data as inputs. They explained that key metagenes
can up to a degree, replace traditional risk factors in terms of individual
association with recurrences. But the combination of metagenes and clinical
factors currently defines models most relevant in terms of statistical fit and
also, more practically, in terms of cross-validation predictive accuracy. The
resulting tree models provide an integrated clinico-genomic analysis that generate
substantially accurate and cross-validated predictions at the individual patient
level.
Singular Value Decomposition (SVD) and generalized SVD (GSVD) have been
shown to have great potential within bioinformatics for extracting common
information from data sets such as genomics and proteomics data [152, 3].
Several studies have used LS-SVM as a prediction tool, especially in microarray
analysis [32, 83].
In this Chapter, we propose a machine learning approach for data integration:
a weighted LS-SVM classifier. Initially we will explain generalized eigenvalue
decomposition (GEVD) and kernel GEVD. Later we will explore the
relationships of kernel GEVD with weighted LS-SVM classifier. Finally, the
advantages of this new classifier will be demonstrated on five breast cancer case
studies, for which expression data and an extensive collection of clinical data
are publicly available.
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6.2 Data sets
Breast cancer is one of the most extensively studied cancer types for which
many microarray data sets are publicly available. Among them, we selected
five cases for which a sufficient number of clinical parameters were available
[31, 79, 158, 181, 120]. All the data sets that we have used are available in the
Integrated Tumor Transcriptome Array and Clinical data Analysis database
(ITTACA): http://bioinfo-out.curie.fr/ittaca/. Overview of all the data
sets are given in Table 6.1.
Table 6.1: Summary of the 5 breast cancer data sets.
Case Study #Samples #Genes #Clinical variables
Class 1 Class2
Case I 85 25 5000 Age, Ethnicity, ER status, PR status, Radiation treatment,
Chemotherapy, Hormonal therapy, Nodal status, Metastasis,
Tumor stage, Tumor size, Tumor grade.
Case II 33 96 6000 Age, Ethnicity, pretreatment tumor stage, nodal status,
nuclear grade, ER status, PR status, HER2 status.
Case III 112 65 5000 Age, Tumor size, Nodal status, ER status, Tamoxifen treatment.
Case IV 46 51 12192 Age, Tumor size, Grade, Erp, Angioinvasion, Lymphocytic Infiltrate, PRp.
Lymphocytic Infiltrate, PRp.
Case V 58 193 20055 Age, Tumor size, Grade, ER, Prp, Lymph node.
6.2.1 Microarray Data
For the first three data sets, the microarray data were obtained with the
Affymetrix technology and preprocessed with MAS5.0, the GeneChip Microarray
Analysis Suite 5.0 software (Affymetrix). However, as probe selection for the
Affymetrix gene chips relied on earlier genome and transcriptome annotation that
are significantly different from current knowledge, an updated array annotation
was used for the conversion of probes to Entrez Gene IDs, lowering the number
of false positives [40].
A fourth data set consists of two groups of patients[181]. The first group of
patients, the training set, consists of 78 patients of, which 34 patients belonged
to the poor prognosis group and 44 patients belonged to the good prognosis
group. The second group of patients, the test set, consists of 19 patients, of
which 12 patients belonged to the poor prognosis group and 7 patients belonged
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to the good prognosis group. The microarray data was already background
corrected, normalized and log-transformed. Preprocessing step removes genes
with small profile variance, less than the 10th percentile.
The last data set consists of transcript profiles of 251 primary breast tumors
were assessed by using Affymetrix U133 oligonucleotide microarrays. cDNA
sequence analysis revealed that 58 of these tumors had p53 mutations resulting
in protein-level changes, whereas the remaining 193 tumors were p53 wt [120].
6.2.2 Clinical Data
The first data of 129 patients contained information on 17 available clinical
variables, 5 were excluded [31]: two redundant variables that were least
informative based on univariate analysis in those variable pairs with a correlation
coefficient exceeding 0.7, and three variables with too many missing values. After
exclusion of patients with missing clinical information, this data set consisted of
110 patients remained in 85 of whom disease did not recur whilst in 25 patients
disease recurred.
The second data in which response to treatment was studied, consisted of 12
variables for 133 patients [79]. Patient and variable exclusion as described above
resulted in this data set. Of the 129 remaining patients, 33 showed complete
response to treatment, while 96 patients were characterized as having residual
disease.
In the third data, relapse was studied in 187 patients [158]. After preprocessing,
this data set retained information on 5 variables for 177 patients. In 112 patients,
no relapse occurred while 65 patients were characterized as having a relapse.
The fourth data set [181] consisted of predefined training and test sets same
as that of corresponding microarray data. The last data set consisted of 251
patients with 6 available clinical variables [120]. After exclusion of patients with
missing clinical information, this data set consisted of 237 patients, of which 55
patients with p53 mutant breast tumor and the remaining patients without p53
mutant breast tumor.
6.3 Methods
In the first section, we will discuss the GEVD and represent it in terms of
an ordinary EVD. Next, we formulate an optimization problem for kernel
GEVD in primal space and solution in dual space. Finally, by generalizing
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this optimization problem in terms of LS-SVM classifier, we propose a new
machine learning approach for data fusion and classifications, a weighted LS-
SVM classifier.
6.3.1 kernel GEVD
The GEVD in Equation 2.3 can now be rewritten as EVD problem :
(BTB)−1/2ATA(BTB)−1/2W = WΛ.
where W = (BTB)1/2(XT )−1. The SVD of matrix A(BTB)−1/2 is given below:
D = A(BTB)−1/2 = PSQT . (6.1)
The matrix (BTB)−1/2 is defined [80] as follows: Let EVD of BTB = TΣTT ,
where the columns of T are eigenvectors and Σ is a diagonal matrix. (BTB)1/2 =
TΣ1/2TT and (BTB)−1/2 = TΣ−1/2TT .
In this section we discuss LS-SVM formulations to kernel GEVD, which is a
non-linear GEVD of m × n matrix A, and p × n matrix B, and a weighted
LS-SVM classifier. LS-SVM formulations to different problems were discussed
in [170]. This class of kernel machines emphasizes primal-dual interpretations
in the context of constrained optimization problems.
Given a training data set of n points D = {x(1)i , x(2)i , yi}ni=1 with output data
yi ∈ R and input data sets x(1)i ∈ Rm, x(2)i ∈ Rp (x(1)i and x(2)i are the ith
column of matrices A and B respectively).
Consider the feature maps ϕ(1)(.) :Rm → Rn1 and ϕ(2)(.) :Rp → Rn2 to a
high dimensional feature space F , which is possibly infinite dimensional. The
centered feature matrices Φ(1)c ∈ Rn1×N , Φ(2)c ∈ Rn2×N become
Φ(1)c = [ϕ(1)(x
(1)
1 )T − µˆT(ϕ1); . . . ;ϕ(1)(x
(1)
N )T − µˆT(ϕ1)]T
Φ(2)c = [ϕ(2)(x
(2)
1 )T − µˆT(ϕ2); . . . ;ϕ(2)(x
(2)
N )T − µˆT(ϕ2)]T ,
where µˆϕl = 1NΣNi=1ϕ(l)(x
(l)
i ), l = 1, 2
LS-SVM approach to Kernel GEVD
Kernel GEVD is a nonlinear extension of GEVD, in which the data are first
embedded into a high dimensional feature space introduced by the kernel and
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then linear GEVD is applied. While considering the matrix A(BTB)−1/2
in Equation 6.1 and the feature maps ϕ(1)(.) :Rm → Rn1 and ϕ(2)(.) :Rp
→ Rn2 described in the previous section, the approximation of covariance
matrix for A(BTB)−1/2 by explicit feature map in the feature space becomes
C ≈ Φ(1)c (Φ(2)
T
c Φ(2)c )−1Φ(1)
T
c with eigendecomposition Cv = λv.
While considering the kernel PCA formulation based on the LS-SVM framework
in [4] and EVD of Cv = λv in primal space, our objective is to find the directions
in which projected variables have maximal variance.
The LS-SVM approach to kernel GEVD is formulated as follows:
minv,e J(v, e) = γ 12eT (Φ
(2)T
c Φ(2)c )−1e− 12vT v
such that e = Φ(1)
T
c v ,
(6.2)
where v is the eigenvector in the primal space, γ ∈ R+ is a regularization
constant and e are the projected data points to the target space.
Defining the Lagrangian
L(v, e;α) = γ2 e
T (Φ(2)
T
c Φ(2)c )−1e− 12v
T
v − αT {(e− Φ(1)Tc v)},
with optimality conditions,
∂L
∂v = 0→ v = Φ(1)c α,
∂L
∂e = 0→ α = γ(Φ(2)
T
c Φ(2)c )−1e,
∂L
∂α = 0→ e = Φ(1)
T
c v,
elimination of v and e will yield an equation in the form of a GEVD:
Ω(1)c α = λΩ(2)c α,
where λ = 1γ eigenvalue, Ω
(1)
c , Ω(2)c are centered kernel matrices and α are
generalized eigenvectors. The symmetric kernel matrices Ω(1)c and Ω(2)c resolves
the heterogeneities of clinical and microarray data by the use of kernel trick,
where data which have diverse data structures are transformed into kernel
matrices with same size.
In a special case of GEVD, if one of the data matrix is the identity matrix, it will
be equivalent to an ordinary EVD. If (Φ(2)
T
c Φ(2)c )−1 = I, then the optimization
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problem proposed for kernel GEVD (See Equation 6.2)) will be equivalent to
optimization problem in [171] for the LS-SVM approach to kernel PCA.
6.3.2 Weighted LS-SVM classifier
Our objective is to represent kernel GEVD in the form of weighted LS-SVM
classifier. Given the link between LS-SVM approach to kernel GEVD in Equation
6.2 and the weighted LS-SVM classifier (see [169] in a different type of weighting
to achieve robustness), one considers the following optimization problem in
primal weight space:
minv,e,b J(v, e) = γ 12eT (Φ
(2)T
c Φ(2)c )−1e+ 12vT v
such that y = Φ(1)
T
c v + b1N + e,
with e = [e1, . . . , eN ]T a vector of variables to tolerate misclassifications, weight
vector v in primal weight space, bias term b and regularization parameter
γ ∈ R+. Compared to the constrained optimization problem for least squares
support vector machine (LS-SVM) [170, 172], in this case, the error variables
are weighted with a matrix (Φ(2)
T
c Φ(2)c )−1/2.
The weight vector v can be infinite dimensional, which makes the calculation of
v impossible in general. One defines the Lagrangian
L(v, e, b;α) = 12vT v + γ2 eT (Φ(2)
T
c Φ(2)c )−1e− αT {((Φ(1)
T
c v) + b1N ) + e− y},
with Lagrange multipliers α ∈ RN .
∂L
∂v = 0→ v = Φ(1)c α
∂L
∂b = 0→ 1TNα = 0
∂L
∂e = 0→ α = γ(Φ(2)
T
c Φ(2)c )−1e
∂L
∂αi
= 0→ e + Φ(1)Tc v + b = y
Elimination of v and e yields a linear system[ 0 1TN
1N Ω(1)c + γ−1Ω(2)c
] [
b
α
]
=
[
0
y
]
(6.3)
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with y = [y1, ..., yN ]T , 1N = [1, ..., 1]T , α = [α1, ..., αN ]T , Ω(1)c = Φ(1)
T
c Φ(1)c and
Ω(2)c = Φ(2)
T
c Φ(2)c .
The resulting classifier in the dual space is given by
y(x) =
N∑
i=1
αi([K(1)(x, xi) +
1
γ
K(2)(x, xi)] + b) (6.4)
with αi are the Lagrange multipliers, γ is a regularization parameter chosen
by the user, K(1)(x, z) = ϕ(1)(x)Tϕ(1)(z), K(2)(x, z) = ϕ(2)(x)Tϕ(2)(z) and
y(x) is the output corresponding to validation point x. The LS-SVM for
nonlinear function estimation in [169] is similar to the proposed weighted
LS-SVM classifier.
The symmetric, kernel matrices K(1) and K(2) resolve the heterogeneities of
clinical and microarray data sources such that they can be merged additively as
a single kernel. The optimization algorithm for the weighted LS-SVM classifier
is given below:
Algorithm: Optimization algorithm for the weighted LS-SVM
classifier
1. Given a training data set of N points D = {x(1)i , x(2)i , yi}Ni=1 with output
data yi ∈ R and input data sets x(1)i ∈ Rm, x(2)i ∈ Rp.
2. Calculate Leave-One-Out cross validation (LOO-CV) performances of
the training set with different combinations of γ and σ1, σ2 (bandwidths
of kernel functions K(1), K(2)) by solving linear system Equation 6.3
and Equation 6.4. In case the Leave-One-Out (LOO) approach is
computationally expensive, one could replace it with a leave p group
out strategy (p-fold cross-validation)
3. Obtain the optimal parameters combinations (γ, σ1, σ2) which have the
highest LOO-CV performance.
The proposed optimization problem is similar to the the weighted LS-SVM
formulation in [4] which replaced (Φ(2)
T
c Φ(2)c )−1 with a diagonal matrix to
achieve sparseness and robustness.
The proposed method is a new machine learning approach in data fusion and
subsequent classifications. In this study, the advantages of a weighted LS-SVM
classifier were explored, by designing a clinical classifier. This clinical classifier
combined kernels by weighting kernel inner product from one data set with that
from the other data set. Here we considered microarray kernels as weighting
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Figure 6.1: Overview of the algorithm. The data sets represented as matrices,
with rows corresponding to patients and columns corresponding to genes and
clinical parameters respectively for first and second data sets. LOO-CV is
applied to select the optimal parameters.
matrix for clinical kernels. In each of these case studies, we compared the
prediction performance of individual data sets with GEVD, kernel GEVD and
weighted LS-SVM classifier. In kernel GEVD, σ1 and σ2 are the bandwidth of
RBF-kernel function K(x, z) = exp(− ||x−z||22σ2 ) of clinical and microarray data
sets respectively. The parameters σ1, σ2 were chosen as to obtain the highest
LOO-CV performance. The parameter selection (see Algorithm) for the weighted
LS-SVM classifier is illustrated in Figure 6.1. For several possible values (10−2
to 102, with grid size 10 ) of the kernel parameters σ1 and σ2, the LOO cross
validation performance is computed for each possible combination (10−2 to 102,
with grid size 10) of γ. The optimal parameters are the combinations (σ1, σ2, γ)
with best LOO-CV performance. Remark the complexity of this optimization
procedure because both the kernel parameters (σ1 and σ2) and γ need to be
optimized in the sense of the LOO-CV performance.
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6.4 Results
The summary of data sets for the five case studies is given in Table 6.1. In all
the case studies, clinical data A contain measurements of m clinical parameters,
for n samples and microarray data B contain expression levels of p genes over
these n samples of breast cancer data. In all cases except the fourth, 2/3rd of
the data samples of each class are assigned randomly to the training and the rest
to the test set. This randomization is the same for all numerical experiments
on all data sets. This split was performed to ensure that the relative proportion
of outcomes sampled in both training and test set was similar to the original
proportion in the full data set. In all these cases, the microarray data were
standardized to zero mean and unit variance. Normalization of training sets
as well as test sets is done by using the mean and standard deviation of each
gene expression profile of the training sets. In the fourth data set [181], all data
samples have already been assigned to a training set or test set.
Initially, LS-SVM classifier applied to RBF kernel functions of clinical and
microarray data, individually for cancer patient classification. Then GEVD and
kernel GEVD have used as a pre-processing step and LS-SVM classifier applied
on the reduced data sets. Thus we compared the classification performances on
single data source (microarray or clinical data) with two data sources (microarray
and clinical data). In addition, we compared the performance of pre-processing
with GEVD and kernel GEVD on classification task. Finally, we integrated
the two data sets, microarray and clinical, and perform further classification
using the weighted LS-SVM classifier. In addition, we compared the proposed
weighted LS-SVM classifiers with other existing data fusion techniques.
6.4.1 Kernel GEVD
In kernel GEVD, initially we formulated two symmetric kernel matrices Φ(1)c
and Φ(2)c for clinical and microarray data respectively. The optimal parameters
of these kernel matrices (σ1 and σ2, the bandwidths of clinical and microarray
kernels) in GEVD framework were selected using LOO-CV performance. N − 1
samples were used to create microarray and clinical kernels. Kernel GEVs α
were obtained by applying GEVD on these matrices. Then the clinical kernel
matrix projected on to the direction of kernel GEV α resulting in the training
scores. Then the validation score on left-out sample obtained by projecting
the validation clinical kernel onto the direction of kernel GEV α. Similar to
GEVD, LS-SVM model was trained and tested on the training and test scores
respectively. This procedure repeated for each sample in the given data sets
with different combinations of σ1 and σ2. The combinations of σ1 and σ2 values
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which offered the best CV-result will be chosen as the optimum ones. Then
LS-SVM classifier is applied on the training and test clinical data projected
onto the direction of kernel GEV α, to train the model and prediction. High-
throughput data such as microarray have used only for the model development,
that is, for obtaining generalized eigenvector α. Further the classifications are
performed only on clinical kernels. Initially we applied LS-SVM classifier on
microarray and clinical kernels individually. Then we used the GEVD and
kernel GEVD as pre-processing steps and the LS-SVM classifier applied on the
transformed clinical data. The results show that considerations of two data sets
in a single framework improve the prediction performance than individual data
sets. In addition, pre-processing with the kernel GEVD significantly improved
the prediction performance than GEVD. The results of the five case studies are
shown in Table 6.2 and Figure 6.2. We represented expression and clinical data
with kernel matrix, based on RBF kernel function. The RBF kernel functions
makes each of the these data which had diverse structures, transformed into
kernel matrices with same size.
6.4.2 Weighted LS-SVM classifier
We proposed a weighted LS-SVM classifier, a useful technique in data fusion
as well as in supervised learning. The parameters (γ in Equation 6.3 and σ1,
σ2 the bandwidths of microarray and clinical kernel functions) associated with
this method are selected by Algorithm. For several possible values (10−2 to 102
with grid size 10) of the kernel parameters σ1 and σ2, the LOO cross validation
performance is computed for each possible combination (10−2 to 102 with grid
size 10 ) of γ. In each LOO-CV, 1 samples is left out and models are built
for all possible combinations of parameters on the remaining N − 1 samples.
The optimization problem is not sensitive to small changes of bandwidths of
microarray and clinical kernel functions. Careful tuning of γ allows tackling
the problem of overfitting and tolerating misclassifications. Model parameters
are chosen corresponding to the model with highest LOO AUC. The LOO-CV
approach takes less than a minute for a single iteration of the first three case
studies and 1-2 minutes for the rest of case studies on Windows 7, Intel core i3
processor. Statistical significance test are performed in order to allow a correct
interpretations of the results. A non-parametric paired test, the Wilcoxon signed
rank test (signrank in Matlab) [45], has been used in order to make general
conclusions. A threshold of 0.05 is chosen, which means that the two results are
significantly different if the value of the Wilcoxon signed rank test applied to
both of them is lower than 0.05. On all case studies, weighted LS-SVM classifier
outperformed all other discussed methods (LS-SVM on RBF clinical kernel and
microarray kernel individually, GEVD and kernel GEVD as pre-processing step,
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Table 6.2: The summary of the classification performances (averaged test AUC
(std) on ROC curve in 100 repetitions) of 5 breast cancer cases. CL+LS-
SVM and MA + LS-SVM indicates that LS-SVM classifier applied on clinical
and microarray kernels. Then we have used GEVD and kernel GEVD as
preprocessing step and then applied LS-SVM classifier on the transformed
data set. Finally the weighted LS-SVM classifier used for data integration and
classification on clinical and microarray kernels. The AUC values obtained with
different techniques were compared using a paired test, Wilcoxon signed rank
test.
Case I Case II Case III Case IV Case V
Classifiers
CL +LS-SVM
test AUC 0.7795(0.0687) 0.7772(0.0554) 0.6152(0.0565) 0.6622(0.0628) 0.7740(0.0833)
p-value 0.0039 1.48E-04 0.0086 5.21E-06 0.1602
MA+LS-SVM
test AUC 0.7001(0.0559) 0.8065(0.0730) 0.6217(0.0349) 0.7357(0.0085) 0.6166(0.0508)
p-value 0.0059 0.0140 0.0254 2.41E-04 0.0020
GEVD+LS-SVM
test AUC 0.7801(0.0717) 0.7673(0.0548) 0.6196(0.0829) 0.7730(0.1011) 0.8001(0.0648)
p-value 0.0137 3.41E-05 0.0040 0.1558 0.0840
KGEVD+LS-SVM
test AUC 0.7982(0.0927) 0.8210(0.0670) 0.6437(0.0313) 0.7901(0.0917) 0.8031(0.0624)
p-value 0.0195 0.1144 0.0020 0.6162 0.0720
weighted LS-SVM
test AUC 0.8177(0.0666) 0.8465(0.0480) 0.6985(0.0443) 0.8119(0.0893) 0.8210(0.0477)
p-value: a paired test, Wilcoxon signed rank test.
CL and MA are the clinical and microarray kernels of RBF kernel functions.
followed by LS- SVM on reduced data), in terms of test AUC, as shown in Table
6.2 and Figure 6.2. The weighted LS-SVM performance is slightly better on
the second and fourth cases, but not significantly, than the kernel GEVD.
Then we compare the proposed weighted LS-SVM classifiers with other data
fusion techniques which integrate microarray and clinical data sets. Daemen et
al [39] investigated the effect of data integration on performance with three case
studies [31, 79, 158]. They reported that a better performance was obtained
when considering both clinical and microarray data with the weights (µ) assigned
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Table 6.3: Comparisons of RBF with clinical kernel functions: On weighted
LS-SVM framework, we evaluated the LOO-CV performances of, clinical kernel
function in [39] and RBF microarray kernels, with RBF clinical and microarray
kernels. In the weighted LS-SVM classifier framework, RBF kernel functions of
clinical parameters performs better than clinical kernel functions on three case
studies.
Kernel functions Case I Case II Case III Case IV Case V
Clinical kernel 0.8108(0.0351) 0.8315 (0.0351) 0.7479(0.0111) 0.7385(0.1100) 0.7673(0.0213)
RBF 0.8243(0.0210) 0.8202(0.0100) 0.7143(0.0217) 0.7846(0.0699) 0.7862(0.0221)
to them optimized (µClinical+(1-µMicroarray)). In addition, they concluded
from their 10-fold AUC measurements that the clinical kernel variant, led to a
significant increase in performance, in the kernel based integration approach
of clinical and microarray. The first three case studies, we have taken from
the work of Daemen et al [39]. They have considered the 200 most differential
genes selected from the training data with the Wilcoxon rank sum test, for
the kernel matrix obtained from microarray. The fourth case study, we have
taken from the paper of Gevaert et al [64] in which they investigated different
types of integration strategies, with Bayesian network classifier. They concluded
that partial integration performs better in terms of test AUC. Our results also
confirm that consideration of microarray and clinical data sets together, improves
prediction performances than individual data sets. In addition, non-linear
projections of data using kernel GEVD significantly improved the prediction
performance than the linear GEVD because these projections captured the
non-linear relationship in the data. In case III, feature selection of microarray
has reduced the overfitting in the trained model, but the number of features of
clinical data are not sufficient to generate a good model, hence the model did
not perform well during the validation/testing step.
In our analysis, microarray-based kernel matrix are calculated on full data set
without preselecting genes and thus avoiding potential selection bias [5]. In
addition, we compared RBF kernel with the clinical kernel function [39] in
terms of LOO-CV performance. Results are given in Table 6.3. We followed
the same strategy which was explained for weighted LS-SVM classifier, except
the clinical kernel function have been used for the clinical parameters. On three
out of five case studies, RBF kernel functions performed better than clinical
kernel function. Clinical kernel function outperformed RBF kernel function in
cases II and III. But further study is required to make a conclusion that why
did the clinical kernel function perform well in few cases, in which the RBF
kernel function failed to perform, especially on case III.
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6.5 Discussion
Integrative analysis has been primarily used to prioritize disease genes or
chromosomal regions for experimental testing, to discover disease subtypes or
to predict patient survival or other clinical variables. The ultimate goal of this
work is to propose a machine learning approach which is functional in both
data fusion and supervised learning. We further analyzed the potential benefits
of merging microarray and clinical data set for prognostic application in breast
cancer diagnosis.
We integrate microarray and clinical data into one mathematical model, for the
development of highly homogeneous classifiers in clinical decision support. For
this purpose, we present a kernel based integration framework in which each
data set is transformed into a kernel matrix. Integration occurs on this kernel
level without referring back to the data. Some studies [39, 183] already reported
that intermediate integration of clinical and microarray data set, improves
prediction performance on breast cancer outcome. In primal space, the clinical
classifier is weighted with expression values. The solution in dual space is given
on Equations 6.3 and 6.4 which provides a way to integrate two kernel functions
explicitly and perform further classifications.
To verify the merit of the proposed approach over the single data sources such as
clinical and microarray data, the LS-SVM were built on all data sets individually
for classifying cancer patients. Next, GEVD and kernel GEVD were used as pre-
processing step. Then the data in the projected space (scores) have used to build
the LS-SVM classifier. Results show that these types of integration information
helped us to achieve better prediction performances than considering single data
sets. Integration of different data sources is relevant in cancer studies for better
diagnosis, prognosis and personal therapy. In addition, the results suggest that
kernel based data integration increases the predictive performance of clinical
decision support models. This indicates that there might be non-linear pattern
in the data that effectively modelled with kernel based techniques. Finally
weighted LS-SVM approach was used for the integration of both microarray
and clinical kernel functions and performed subsequent classifications. The
weighted LS-SVM classifier proposes a new optimization framework to solve the
problem of classification using features of different types such as clinical and
microarray data. In this framework, kernel functions were applied to each data
sets separately and a decision boundary was made in high dimensional feature
space. Due to its unique property, that is, data fusion and classification in a
single framework with kernel methods, it became a competitive non-linear data
fusion and classification technique.
We should note that the models proposed in this paper are expensive, but
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less than the other kernel-based data fusion techniques. Since the proposed
weighted LS-SVM classifier simplified both data fusion and classification in a
single framework, it does not have an additional cost for tuning parameters
for kernel-based classifiers. And it is given that, the weighting matrix should
be invertible in the optimization problem of kernel GEVD and the weighted
LS-SVM classifier.
In life science research, there is an increasing need for heterogeneous data
integration such as proteomics, genomics, mass spectral imaging and so on.
Such studies are required to determine, which data sets are most significant to
be considered as weighting matrix. The proposed weighted LS-SVM classifier
integrates heterogeneous data sets to achieve best performing and affordable
classifiers.
6.6 Conclusion
The results suggest that the use of our data integration approach on gene
expression and clinical data can improve the performance of decision making
in cancer. We proposed a weighted LS-SVM classifier for the integration of
two data sources and further prediction task. Each data set is represented
by a kernel matrix, based on the RBF kernel function. The proposed clinical
classifier gives a step towards improving predictions for individual patients
about prognosis, metastatic phenotype and therapy responses.
Because the parameters (bandwidth for kernel matrices and regularization
term γ of weighted LS-SVM) had to be optimized, all possible combinations
of these parameter were investigated with a LOO-CV. Since these parameters
optimization strategy is time consuming, one can further investigate a parameter
optimization criterion for kernel GEVD and weighted LS-SVM.
The applications of the proposed method are not limited to, clinical and
expression data sets. Possible additional applications of weighted LS-SVM
include integration of genomic information collected from different sources
and biological processes. In short, the proposed machine learning approach
is a promising mathematical framework in both data fusion and non-linear
classification problems.
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Figure 6.2: Boxplots depict the summary of the classification performances
(averaged test AUC on ROC curve in 100 repetitions) of 5 breast cancer cases.
CL and MA are the clinical and microarray kernels of RBF kernel functions.
CL+LS-SVM and MA + LS-SVM indicates that LS-SVM classifier applied
on clinical and microarray kernels. We have used GEVD and kernel GEVD
as preprocessing step and then LS-SVM classifier applied on the transformed
data set. Finally weighted LS-SVM classifier used as a single mathematical
framework for the integration of clinical and microarray kernels and further
classification (a) Case I (b) Case II (c) Case III (d) Case IV (e) Case V.
Chapter 7
A novel chemoinformatics
method for identification of
biofilm inhibitors
Background: The most common representation of compounds in chemoinfor-
matics is a connection-table, i.e., a table enumerating the atoms and another
enumerating the bonds. In this study, we intend to derive a new chemical
descriptor from this table, allowing a better distinction between biologically
active and inactive compounds. Our method was applied to the identification
of inhibitors of Salmonella, Pseudomonas biofilm formation and inhibitors of
thrombin, trypsin, and factor Xa. Development of this type of anti-microbial is
urgently needed as biofilms, surface-associated bacterial communities embedded
in a self-produced polymeric matrix, provide strong protection against the
activity of antibiotics, disinfectants and the immune system.
Method: We propose a new machine learning approach for the identification of
biologically active compounds. Principal Component Analysis (PCA) converts
the connection-table of each compound into a structural descriptor of two
vectors: one corresponding to atoms and the other to bonds. As a supervised
classification algorithm, a weighted least squares support vector machine (LS-
SVM) is used in which the table enumerating the atoms is weighted against the
table enumerating the bonds. We apply this framework to, a given experimental
data set of preventive activity of 308 2-aminoimidazole-based compounds
against Salmonella and Pseudomonas biofilms and its 10 newly synthesized
validation compounds, and 72 inhibitors of the benzamidine type with respect
88
INTRODUCTION 89
to their binding affinities toward thrombin, trypsin, and factor Xa. Prediction
performances are evaluated and compared with the LS-SVM classifier on other
well-known chemical descriptors such as Extended-Connectivity Fingerprints,
Path-Length Fingerprints, MACCS Keys and Burden Eigenvalues descriptors.
Result: To evaluate the performance of the proposed machine learning
approach, initially we randomly split the given compounds into two groups:
training (2/3rd of compounds) and test data sets. This split was performed
with the relative proportion of active and inactive compounds in both training
and test sets. The classification model was built on the training data and the
prediction performance of the method was evaluated on the test data. In the
trained model, the averaged performance measurements on 30 iterations of the
test data were calculated. The proposed machine learning approach obtained
the best averaged test accuracy with F-score compared to the LS-SVM classifier
on the other discussed chemical descriptors. In addition, it is experimentally
observed that the proposed approach is able to discriminate the few compounds
with the highest activity of the 10 validation compounds of Salmonella and
Pseudomonas.
Conclusion: The results suggest that the newly proposed approach, the
weighted chemical descriptors of molecular structure, identified accurately the
inhibitors on Salmonella and Pseudomonas biofilms formation, than other
discussed descriptors. The proposed machine learning approach could be
applicable to any problem in which the property or activity of interest is
dependent upon the molecular structure.
7.1 Introduction
Computational methods involving machine learning techniques are among the
most popular tools used in chemoinformatics tasks [62, 117, 150]. Most of
these techniques in chemoinformatics are used for the classification of chemical
compounds based on a descriptor representation of the compounds. Historically,
the most widely used descriptors have been based on fingerprints, such as the
Extended-Connectivity Descriptor in which an iterative process assigns numeric
identifiers to each atom, independent of the original numbering of the atoms
[142]. Path-Length Fingerprints are generated with respect to path lengths of
chemical compounds [178]. MACCS Keys [10] are the sets of descriptors based
on structural fragments, that have been identified a priori by domain experts
[51]. Burden eigenvalue descriptors (BCUT) rely on an eigenvalue factorization
of molecular connection table [21].
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Biofilms have been found to be involved in a wide variety of microbial infections
in the body and it was observed that 80% of all human bacterial infections
are biofilm-associated [44, 73]. Biofilms of Pseudomonas aeruginosa can cause
chronic infections, which are a serious problem for medical care in industrialized
societies, especially for immunocompromised patients and the elderly [143]. They
often cannot be treated effectively with traditional antibiotic therapy. Biofilm
formation is also an important survival strategy of Salmonella Typhimurium,
both within and outside the host [163]. Given the extent of problems caused
by biofilms, there has been a significant effort to develop new anti-biofilm
strategies [16, 104]. Traditionally biologists identify biofilm inhibitors by
wet-laboratory screening of thousands of compounds. This strategy is time
consuming and expensive. Chemoinformatics approaches employ a range of
methods which are primarily used for the rapid evaluation and prioritization
of compounds prior to wet-laboratory testing. Although molecular docking, a
well established computational technique, was applied for the identification of
potential histidine kinase inhibitors to combat Staphylococcus epidermidis [135]
and for the selection of potential biofilm inhibitors of Pseudomonas aeruginosa
[201], chemoinformatics approaches have not been fully exploited yet in the
area of bacterial biofilm inhibition.
The main purpose of this work is to introduce a machine learning approach,
a weighted chemical descriptor based on the connection-table of compounds,
for designing a prediction model for identification of the activity of chemical
compounds in a specific biological condition. This method was applied for the
identification of inhibitors of Salmonella and Pseudomonas biofilm formation and
inhibitors of Thrombin, Trypsin and Factor Xa. Initially, molecular structures
were converted into structural descriptors in terms of two vector spaces: atoms
and bonds by Principal Component Analysis (PCA), which transforms the two
dimensional connection-table into a single dimensional space. Next, a weighted
least squares support vector machine (weighted LS-SVM) classifier [175] was
applied on these two vector spaces to integrate them into a single vector,
named as a weighted chemical descriptor (which is completely representing the
connection-table) and further predict the biological activity of the chemical
compounds. Finally, we compared the prediction performance of the weighted
LS-SVM classifier on the newly proposed descriptor with the LS-SVM classifier
on other well known descriptors such as Extended-Connectivity Fingerprints,
Path-Length Fingerprints, MACCS Keys and BCUT descriptors.
DATA SETS 91
7.2 Data Sets
In our analysis, we have a connection-table of 308 2-aminoimidazole-based
compounds [162, 164, 54, 161, 160] that have the capability to prevent biofilm
formation of S. Typhimurium or P. aeruginosa, for model development and an
independent set of 10 novel compounds for validation. In addition, we have
IC50 values of these 308 compounds. All compounds were synthesized according
to the previously reported protocols in [162, 164, 54, 161, 160]. The IC50
value is defined as the concentration at which biofilm formation is inhibited
by 50% and thus predicts the effectiveness of these compounds against biofilm
formation. The lower the IC50, the more effective a compound is against the
biofilm formation. Later we used Bohm Serin Protease Inhibitor Data Set to
identify the inhibitors of Thrombin, Trypsin and Factor Xa [17]. As an example,
connection-table of chemical compound Melatonin is given in Figure 7.1.
7.3 Methods
The methods used for this study can be subdivided into two categories:
feature selection from the connection-table (table enumerating atoms and table
enumerating bonds) using PCA and prediction with either weighted LS-SVM
classifier or LS-SVM classifier.
7.3.1 Principal Component Analysis (PCA)
PCA was applied to convert the connection-table of each compound in the data
sets, i.e. inhibitors of S. Typhimurium and P. aeruginosa biofilm formation,
into a novel chemical descriptor of two vectors: one corresponding to atoms and
the other to bonds.
PCA [128] is mathematically defined as an orthogonal transformation that
converts the data into a new coordinate system, such that the largest variance by
any projection of the data lies on the first coordinate (first principal component),
the second largest variance on the second coordinate, and so on. The full
principal components decomposition of m× n matrix A can therefore be given
as follows:
Score = A ∗ Coef
where each column of the n× n matrix Coef are the eigenvectors of ATA and
Score, m × n matrix, is the representation of A in the principal component
space.
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PubChem Compound ID896 ----- Melatonin 
  -OEChem-09211506513D 
 33 34  0     0  0  0  0  0  0999 V2000                                                      Header   
   -1.3636    3.0246    0.2970 O   0  0  0  0  0  0  0  0  0  0  0  0 
    3.7267    0.6738    0.6109 O   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.0703   -2.3711   -0.3715 N   0  0  0  0  0  0  0  0  0  0  0  0 
    2.3445   -0.6100   -0.7547 N   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.1101   -1.7944    0.4955 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.8590   -0.6075    0.2605 C   0  0  0  0  0  0  0  0  0  0  0  0 
    1.2503   -1.8778    1.0635 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.0848   -0.9972   -0.2836 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.8813   -2.8618    0.0970 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.3739   -1.8247    0.0151 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.6110    0.7654    0.4590 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.0788   -0.0792   -0.6406 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -1.5962    1.6950    0.1067 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.8103    1.2770   -0.4346 C   0  0  0  0  0  0  0  0  0  0  0  0 
    3.0269    0.5423   -0.3899 C   0  0  0  0  0  0  0  0  0  0  0  0 
    2.8456    1.6577   -1.3843 C   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.1024    3.3879    0.8542 C   0  0  0  0  0  0  0  0  0  0  0  0 
    1.3526   -2.8116    1.6311 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.3966   -1.0685    1.7903 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.6921   -3.9263    0.1033 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.3454   -1.9117    0.5137 H   0  0  0  0  0  0  0  0  0  0  0  0 
    2.2780   -2.6566   -0.6913 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -2.8284   -2.9350   -0.7304 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.3442    1.0364    0.8902 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -4.0243   -0.4036   -1.0620 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -3.5659    2.0117   -0.7032 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.7948   -0.6075   -1.6092 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.0749    2.6144   -0.9071 H   0  0  0  0  0  0  0  0  0  0  0  0 
    3.5238    1.5023   -2.2277 H   0  0  0  0  0  0  0  0  0  0  0  0 
    1.8151    1.6892   -1.7492 H   0  0  0  0  0  0  0  0  0  0  0  0 
   -0.0896    4.4796    0.9383 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.7249    3.1112    0.1938 H   0  0  0  0  0  0  0  0  0  0  0  0 
    0.0217    2.9900    1.8672 H   0  0  0  0  0  0  0  0  0  0  0  0 
   
  1 13  1  0  0  0  0 
  1 17  1  0  0  0  0 
  2 15  2  0  0  0  0 
  3  8  1  0  0  0  0 
  3  9  1  0  0  0  0 
  3 23  1  0  0  0  0 
  4 10  1  0  0  0  0 
  4 15  1  0  0  0  0 
  4 27  1  0  0  0  0 
  5  6  1  0  0  0  0 
  5  7  1  0  0  0  0 
  5  9  2  0  0  0  0 
  6  8  2  0  0  0  0 
  6 11  1  0  0  0  0 
  7 10  1  0  0  0  0 
  7 18  1  0  0  0  0 
  7 19  1  0  0  0  0 
  8 12  1  0  0  0  0 
  9 20  1  0  0  0  0 
 10 21  1  0  0  0  0 
 10 22  1  0  0  0  0 
 11 13  2  0  0  0  0 
 11 24  1  0  0  0  0 
 12 14  2  0  0  0  0 
 12 25  1  0  0  0  0 
 13 14  1  0  0  0  0 
 14 26  1  0  0  0  0 
 15 16  1  0  0  0  0 
 16 28  1  0  0  0  0 
 16 29  1  0  0  0  0 
 16 30  1  0  0  0  0 
 17 31  1  0  0  0  0 
 17 32  1  0  0  0  0 
 17 33  1  0  0  0  0 
M  END 
Table Enumerating  Atoms 
Table Enumerating  Bonds 
Figure 7.1: Connection Table of Chemical Compound Melatonin with pubChem
ID: 896.
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7.3.2 Weighted Least Squares-Support Vector Machine (Weighted
LS-SVM) Classifier
Initially PCA transforms the atom and bond table of each compound into two
descriptor vectors, one in atom space and the other in bond space. These
two vectors should be considered together for the complete representation of
a chemical compound. These descriptors are effectively integrated back into
a single space by using the weighted LS-SVM classifier proposed in [175] and
performs further prediction.
Given a training data set of N points D = {x(1)i , x(2)i , yi}Ni=1 with output data
yi ∈ R and input data sets x(1)i ∈ Rm, x(2)i ∈ Rp. Consider the feature
map ϕ(1)(.) :Rm → Rn1 and ϕ(2)(.) :Rp → Rn2 to high dimensional feature
space, which is possibly infinite dimensional. The centered feature matrices
Φ(1)c ∈ Rn1×N , Φ(2)c ∈ Rn2×N become
Φ(1)c = [ϕ(1)(x
(1)
1 )T − µˆT(ϕ1); . . . ;ϕ(1)(x
(1)
N )T − µˆT(ϕ1)]T
Φ(2)c = [ϕ(2)(x
(2)
1 )T − µˆT(ϕ2); . . . ;ϕ(2)(x
(2)
N )T − µˆT(ϕ2)]T ,
where µˆϕl = 1NΣNi=1ϕ(l)(x
(l)
i ), l = 1, 2.
The weighted LS-SVM classifier proposed in [175] optimizes the following
problem
P : minv,e,b J(v, e) = γ 12eT (Φ
(2)T
c Φ(2)c )−1e+ 12vT v
such that y = Φ(1)
T
c v + b1N + e,
with e = [e1, . . . , eN ]T a vector of variables to tolerate misclassifications, weight
vector v in primal weight space, bias term b and regularization term γ ∈ R+.
Solution to the above problem in dual space,[ 0 1TN
1N Ω(1)c + γ−1Ω(2)c
] [
b
α
]
=
[
0
y
]
(7.1)
with y = [y1, ..., yN ]T , 1N = [1, ..., 1]T , α = [α1, ..., αN ]T , Ω(1)c = Φ(1)
T
c Φ(1)c and
Ω(2)c = Φ(2)
T
c Φ(2)c .
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The resulting classifier in the dual space is given by
y(x) = sign[
N∑
i=1
αi([K(1)(x, xi) +
1
γ
K(2)(x, xi)] + b)]. (7.2)
with αi the Lagrange multipliers, K(1)(x, z) = ϕ(1)(x)
T
ϕ(1)(z), K(2)(x, z) =
ϕ(2)(x)Tϕ(2)(z) and y(x) is the output corresponding to validation point x.
Throughout the Chapter we use radial basis function (RBF) kernel: K(x, xi) =
exp(− ||x−xi||22σ2 ) (RBF kernel with bandwidth σ).
Here the advantages of a weighted LS-SVM classifier are thus explored by
designing two kernel matrices: a measure of similarity between two compounds
based on their atoms and bonds description. In the primal space of the weighted
LS-SVM framework, each atom description is weighted with the bond description
and the solution in dual space, provides a way to integrate these two kernel
matrices efficiently (see Equation 7.2). The resultant chemical descriptors are
completely representing the connection-table of chemical compounds.
The parameter selection for the weighted LS-SVM classifier is illustrated on the
Algorithm box. For several possible values of the kernel parameters σ1 and σ2,
the leave-one-out cross validation (LOO-CV) performance is computed for each
possible combination of γ . The optimal parameters are the combinations (σ1,
σ2, γ) with best LOO-CV performance. Note the complexity of this optimization
procedure because both the kernel parameters (σ1 and σ2) and γ need to be
optimized in the sense of the LOO-CV performance.
Box: Algorithm: weighted LS-SVM classifier for prediction of
chemical compounds
1. Given a training data set of N points D = {x(1)i , x(2)i , yi}Ni=1 with output
data yi ∈ R and input data sets x(1)i ∈ Rm, x(2)i ∈ Rp.
2. Find optimal γ and σ1, σ2 bandwidths of kernel functions K(1), K(2) by
solving linear system Equation 7.1 using leave-one-out cross validation
(LOO-CV).
3. Predict the performance of the model by plugging the optimal parameters
from previous steps into Equation 7.2.
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7.4 Result
The proposed method defines new chemical descriptor of compounds from their
connection-table, a representation of chemical molecules. An example of the
connection-table, a portion of a structure-data file (SDF file) is given in Figure
7.2:
Figure 7.2: An Example of a Connection-Table
The first row of the table is the header line. The remaining rows are actual
part of the connection-table in which the second row indicates: 3 atoms, 2
bonds, ..., V2000 standard. Rows 3-5 represent the atom block (1 line for
each atom) and rows 6-7 represent the bond block (1 line for each bond).
The columns of the atoms block specify the X,Y,Z-coordinates, atom symbol,
isotope, charge, stereo code and the columns of the bond block specify the row
numbers of atoms, and codes for bond type, bond stereochemistry etc. The
table contains non-numerical data, i.e. atom symbol, which is converted to a
numerical representation as follows while the other columns remain the same:
C-0 N-1 H-2 F-3 Br-4 O-5 S-6 CL-7 Si-8 K-9 ...
The molecule in the given example, has three atoms (3 rows with 10 columns) and
two bonds (2 rows with 4 columns). A chemical compound can be denoted with
a variety of different connection tables describing one and the same compound
but with different numbering of atoms. Canonicalization is the task which
taking one of the numberings as the standard one and derive a unique code
from it. It is accomplished by numbering the atoms of a molecule so that it is
represented by only one connection table. Morgan algorithm is used for deriving
a canonical code for the molecule [60, 123].
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Table 7.1: Table enumerating atoms: data source I
5.9800 -0.0000 -0.0000 Br 0 0 0 0 0 0
4.4000 -0.6600 0.8300 C 0 0 0 0 0 0
3.5400 -1.3500 -0.1900 C 0 0 0 0 0 0
Table 7.2: Table enumerating bonds: data source II
1 2 1 0
2 3 1 0
We form two tables (referred to as Table 7.1 and Table 7.2) corresponding to
the atoms and the bonds description of the chemical compounds, respectively.
The size of the atom table will be number of atoms × 10 and bond table be
number of bond × 4. Our aim is to generate two vectors one representing the
atom and other to bond table. These vectors should able to capture as much
information as possible from the original tables. Hence, PCA is applied to
each of these tables individually to define chemical descriptors based on both
atom and bond tables. The first component which captures the majority of
the variance of the data (for each compound, the first component explaining
minimally 70% variance) is selected for each table. After transforming the data
onto direction of the first component, we obtain two vectors, one corresponding
to a table enumerating the atoms and another to a table enumerating bonds for
each compound. Thus, we defined two chemical descriptors for each compound.
Based on this, we construct two tables: compounds vs. atoms and compounds
vs. bonds. The number of atoms and bonds are different for each compound.
The entries in the descriptor vectors are filled with zeros, if the compound
does not have an atom or bond corresponding to an entry. An overview of the
chemical descriptor formation from the connection-table of compounds is given
in Figure 7.3 and Box Algorithm II.
Box: Algorithm II: Chemical descriptor and weighted LS-SVM
classifier for prediction of chemical compounds
1. Split the connection table of each compound into atom and bond table as
shown in Figures 7.1 and 7.3.
2. To generate chemical descriptors based on the atom and bond properties
of chemical compounds, we applied PCA on these two tables individually
and obtain the first eigenvector explaining minimally 70% variance of the
data. Then projecting these tables onto the direction of the corresponding
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MOLCONV
3 2  0  0  1  0              1 V2000
5.9800   -0.0000   -0.0000 Br 0  0  0  0  0  0
4.4000   -0.6600    0.8300  C 0  0  0  0  0  0
3.5400   -1.3500   -0.1900  C 0  0  0  0  0  0
1  2  1  0
2  3  1  0
N compoundsConnection Table of a Compound
C-0
N-1 
H-2  
F-3  
Br-4  
O-5  
S-6  
CL-7  
Si-8  
K-9
...
5.9800   -0.0000   -0.0000 4 0  0  0  0  0  0
4.4000   -0.6600    0.8300  0 0  0  0  0  0  0
3.5400   -1.3500   -0.1900  0 0  0  0  0  0  0
1  2  1  0
2  3  1  0
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Figure 7.3: An overview of chemical descriptor formation from the connection-
table of compounds. PCA is applied to the connection-table of each compounds
to define a new structural descriptor in terms of two vectors. This results into
two matrices: atoms vs. compounds and bonds vs. compounds. The weighted
LS-SVM framework integrates these two vectors into a single vector named
as weighted chemical descriptor and performs further prediction. LOO-CV is
applied to select the optimal parameters.
eigenvector resulting in two descriptor vectors, one corresponding to atom
and other to bond.
3. Repeat the previous steps for each compound. Finally we get two tables,
one corresponding to atom and other to bonds. For 308 compounds, we
generate 308 × atoms matrix for atom and 308 × bonds matrix for bond
properties.
4. Connection table is the structural representation of the compounds. For
the complete representation of chemical compounds, we need to integrate
these two descriptors properly. We used the weighted LS-SVM classifier
for data integration and further classification.
5. Find optimal γ and σ1, σ2 bandwidths of kernel functions K(1), K(2) by
solving linear system Equation 7.1 using leave-one-out cross validation
(LOO-CV) on training data sets.
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6. Predict the performance of the model by plugging the optimal parameters
from previous steps into Equation 7.2 on validation set.
In the weighted LS-SVM classifier, the RBF kernel function provides a measure of
similarity between two compounds based on their atoms and bonds description,
resulting in two kernel matrices. In the primal space of the weighted LS-
SVM framework, each atom description is weighted with the bond description
and the solution in dual space, provides a way to integrate these two kernel
matrices efficiently (see Equation 7.2). The weighting scheme in the weighted
LS-SVM classifier with RBF kernel function provides a way to represent chemical
descriptors and perform further classification. In order to obtain the optimized
values on Equation 7.2 for σ1 and σ2, LOO-CV performance is computed with
each possible combination of γ, with values ranging from 10−3 to 103, with grid
size 10. The combinations of the parameters which offer the highest LOO-CV
performance is selected as the optimal parameters.
To evaluate the performance of the proposed machine learning approach, initially
we randomly split the given compounds into two groups: training (2/3rd
of compounds) and test data sets. This split was performed with relative
proportion of active and inactive compounds in both training and test sets.
The classification model was built on the training data and the prediction
performance of the method was evaluated on the test data. In the case of
Pseudomonas, we have eliminated 78 compounds for which the corresponding
IC50 values were not available. Compounds were categorized into two sets:
active or less (not) active based on the IC50 values. Selecting a cut-off value of
IC50 to classify a compound as active or inactive is arbitrary. In the trained
model of Salmonella and Pseudomonas, the averaged performance measurements
on 30 iterations of the test data were calculated for a range of IC50 values (e.g.
IC50 = 10 µM,..., IC50 = 100 µM). The prediction performance of the model
was represented in terms of test areas under the receiver operating characteristic
curves (AUC), accuracy and F-score. The F-score indicates the balance between
precision and recall. The optimal cut-off value, below which a compound was
considered active, was calculated based on the best prediction performances.
Models with the optimal cut-off value could offer best performance for the
future predictions. We have determined the optimal cut-off value of IC50 as
10 µM for both the Salmonella and Pseudomonas and 5 µM for Thrombin,
Trypsin and Factor Xa case studies. At optimal cut-off value, the Salmonella
data set contains 47 active and 159 inactive compounds as training set, and 23
active and 79 inactive compounds as test set. While the Pseudomonas data set
contains 32 active and 122 inactive compounds as training set and 15 active
and 61 inactive compounds as test set.
Table 7.3 and Figures 7.4, 7.5 compare the prediction performances (with optimal
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Table 7.3: Comparison of averaged classification performances of different
descriptors: proposed descriptor, MACCS keys, ECF, Path keys and BCUT
descriptors to identify the active and inactive compounds in Salmonella
and Pseudomonas biofilm. On both case studies, the proposed descriptor
outperformed other descriptors in terms of averaged accuracy and F-score.
Proposed Method MACCS Keys ECF Path keys BCUT
Salmonella
Accuracy(std) 0.8071(0.0581) 0.7706(0.0500) 0.7686(0.0438) 0.7735(0.0454) 0.766(0.04)
p-value 0.0100 0.0100 0.0005 0.012
Test AUC(std) 0.6453(0.0409) 0.6988(0.0294) 0.6525(0.0263) 0.6425(0.0328) 0.665 (0.077)
p-value 6.73E-05 0.3528 0.2800 0.031
F-score(std) 0.3058(0.0375) 0.0212(0.0333) 0.0315(0.0241) 0.036(0.0142) 0.484(0.0823)
p-value 1.29E-16 5.52E-17 1.00E-17 0.064
Pseudomonas
Accuracy(std) 0.8179(0.0492) 0.7908(0.0441) 0.7829(0.0360) 0.7882(0.0313) 0.65(0.055)
p-value 0.0001 0.0019 0.0004 0.012
Test AUC(std) 0.6549(0.0267) 0.7041(0.0258) 0.6559(0.0397) 0.7118(0.0395)) 0.588(0.066)
p-value 5.06E-06 0.9104 3.30E-05 0.212
F-score(std) 0.3277(0.0346) 0.0211(0.0330) 0.1401(0.0854) 0.0874(0.0469) 0.743(0.059)
p-value 2.34E-17 1.38E-07 8.71E-14 0.024
cut-off) of the proposed weighted LS-SVM descriptor, with LS-SVM on 2D
chemical descriptors; Extended-Connectivity Fingerprints, MACCS keys, Path-
Length Fingerprints and descriptor based on connection table; BCUT. Table
7.4 illustrates the averaged prediction performances of different descriptors on
Thrombin, Trypsin and Factor Xa data sets. Each traditional chemical descriptor
is a complete representation of a compound, thus for final prediction, LS-SVM
classifier is applied directly. While the PCA based descriptor spaces should be
considered together to obtain a complete representation of chemical compounds,
which necessitates the use of the weighted LS-SVM classifier to integrate these
two data sets and further perform predictions. Statistical significance tests
were performed in order to allow a correct interpretation of the results. A
non-parametric paired test, the signed rank test has been used in order to make
general conclusions. Two results are significantly different if the value of the
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Table 7.4: Comparison of averaged prediction performances of different
descriptors - Thrombin, Trypsin and FactorXa.
BCUT ECF MACCS Keys Path keys Proposed Method
Thrombin
Test AUC (std) 0.625(0.101) 0.673(0.012) 0.643(0.013) 0.5(0.0) 0.666(0.133)
Test Accuracy (std) 0.855(0.058) 0.784(0.21) 0.801(0.124) 0.610(0.070) 0.822(0.083)
F-Score(std) NIL NIL NIL NIL 0.600(0.050)
Trypsin
Test AUC (std) 0.53(0.085) 0.625(0.091) 0.695(0.0) 0.500(0.0) 0.653(0.125)
Test Accuracy (std) 0.817(0.027) 0.764(0.042) 0.768(0.0) 0.166(0.125) 0.777(0.058)
F-Score (std) 0.2(0.03) NIL NIL NIL 0.58(0.021)
FactorXa
Test AUC (std) 0.594(0.078) 0.493(0.015) 0.571(0.022) 0.654(0.033) 0.582(0.099)
Test Accuracy(std) 0.727(0.0924) 0.766(0.023) 0.733(0.035) 0.694(0.047) 0.790(0.078)
F-Score (std) 0.835(0.070) NIL NIL NIL 0.802(0.053)
signed rank test (p-value) applied to both of them is lower than 0.05. In both
case studies, the proposed novel machine learning approach performed well with
test accuracy and F-score, while the best test AUC returned by MACCS keys
for Salmonella and Path keys for Pseudomonas. In Tables 7.3 and 7.4, BCUT
descriptor performed better than proposed method in terms of F-score and
test accuracy, respectively. The results show the proposed chemical descriptor
could represent the complete chemical structure of the compounds very well in
a non-linear mathematical framework hence, there is a significant improvement
in the performances for all case studies.
Finally, we used the designed model to predict the activity of 10 novel synthesized
compounds (see Table 7.5) against biofilms. These compounds were synthesized
and in vitro tested for preventive activity against Salmonella and Pseudomonas
biofilm formation according to previously published procedures [162].
First, we trained the model based on 308 compounds for different cut-off values
of the IC50 (e.g. IC50 = 10 µM, IC50 = 20µM, IC50 = 30 µM, IC50 = 50 µM
and IC50 = 100 µM) to define activity and non-activity of the compounds. Then
we used these trained models to predict the activity of the novel compounds
based on different cut-off values. Table 7.8 lists the compounds identified by each
descriptor for different IC50 cut-off values. Finally, with the in vitro measured
IC50 values of the 10 experimentally synthesized compounds, the prediction
performances of all the discussed descriptors were obtained and represented in
Tables 7.7 and 7.8 in terms of test AUC, accuracy and F-score. The results
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Figure 7.4: Salmonella: Error Bar represents the averaged classification
performances in terms of Accuracy, test AUC and F-score over 30 iterations
of different descriptors: proposed descriptor, MACCS keys, ECF and Path
keys to identify the active and inactive compounds in Salmonella biofilm.
Proposed descriptor outperformed in terms of test AUC and F-score and
MACCS keys outperformed in terms of test AUC. In the error bar x-axis
denotes the descriptors and y-axis denotes the test AUC/test accuracy/F-score.
illustrated the ability of the proposed descriptor to identify compounds with
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Figure 7.5: Pseudomonas: Error Bar represents the averaged classification
performances in terms of Accuracy, test AUC and F-score over 30 iterations
of different descriptors: proposed descriptor, MACCS keys, ECF and Path
keys to identify the active and inactive compounds in Pseudomonas biofilm.
Proposed descriptor outperformed in terms of test AUC and F-score and Path
keys outperformed in terms of test AUC. In the error bar x-axis denotes the
descriptors and y-axis denotes the test AUC/test accuracy/F-score.
very high activity against the biofilms.
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Table 7.5: Compound Id, Structure and IC50 for biofilm prevention of 10 novel
compounds used for validation
No Structure Salmonella IC50 in µM Pseudomonas IC50 in µM
1 69.12(50.43 to 94.74 ) 211.90(142.2 to 315.9)
2 42.86(19.02 to 96.56) 60.21(27.25 to 133.0)
3 44.46(22.41 to 88.20) greater than 400
4 115.1(65.28 to 203.0) 358.20(223.5 to 574.1)
5 48.62(36.67 to 64.45) 54.53(24.69 to 120.4)
6 53.79(21.01 to 137.7) greater than 400
7 27.47(18.96 to 39.82) 74.74(43.41 to 128.7)
8 10.78(6.488 to 17.92) 13.92(7.851 to 24.69)
9 25.06(15.38 to 40.83) 28.70(16.04 to 51.37)
10 119.00(80.56 to 175.8) 15.92(2.630 to 96.32)
The values between brackets are the 95% confidence interval
7.5 Discussion
In recent years, the development of computational techniques that build
models to accurately classify chemical compounds, have been an active area
of research. Most of the best performing techniques in this area use chemical
descriptors of compounds. Recently, connection-tables have become the most
complete structural representation of chemical compounds [106]. In this
Chapter we proposed a new chemical descriptor derived from the connection-
table of compounds by PCA analysis, which transforms the two dimensional
connection-table into a single dimensional subspace in terms of two vectors:
one corresponding to atoms and the other to bonds for each compound. The
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Table 7.6: The 10 validation compounds identified as active by each descriptor
(proposed, MACCS, ECF and Path) with different cut-off values (10,20,30,40,50
and 100) for IC50 - Salmonella and Pseudomonas. The numbers in the bold
represent the compound which are correctly identified as active.
SALMONELLA
IC50 cut-off (µM) 10 20 30 40 50 100
Proposed Method NIL 1,2,9,10 4,7,9,10 3,4,6,7,9,10 3,4,6,7,9,10 3,4,5,6,7,8,9
MACCS NIL NIL NIL 3,9 3,9 3,5,7,8,9,10
ECF NIL NIL 3,7,8 3,7,8 7,8 3,5,6,7,8,10
Path NIL 9 9 9 9 1,3,5,7,8,9
PSEUDOMONAS
IC50 cut-off (µM) 10 20 30 40 50 100
Proposed Method 8,10 6,7,8 3,6,7,8 3,6,7,8 3,4,6,7,8,9 1,2,3,4,5,6,7,8,9
MACCS NIL 8,9 8,10 3,8,9,10 3,8,9,10 1,2,3,4,5,7,8,9,10
ECF NIL 9 NIL 3,10 3,7,10 1,2,3,4,5,6,7,8,9,10
Path NIL 9 9 8,9 3,9 1,2,3,4,5,6,7,8,9,10
RBF kernel function provides a measure of similarity between two compounds
based on their atoms and bonds description, resulting in two kernel matrices.
In the primal space of the weighted LS-SVM framework, each atom description
is weighted with the bond description and the solution in dual space provides a
way to integrate these two kernel matrices efficiently.
In order to select the best prediction model, we considered three different
performance measures: accuracy, F-score and test AUC. Generally an AUC
score between 0.6 and 0.7 indicates that the model has sufficient ability to
discriminate positive and negative classes [86]. All discussed descriptors obtained
AUC scores ranging between 0.6 and 0.7, whereas MACCS keys outperformed
in the Salmonella and Path Keys in the Pseudomonas case study. While
considering the prediction performance in terms of accuracy, the proposed
approach significantly outperformed all other descriptors. But for highly class
imbalanced data set with more negative samples, a model can predict the value
of the majority class for all predictions and achieve a high classification accuracy.
In this context, additional measures such as F-score are required to evaluate
a classifier. F-score is often used as an aggregated performance score for the
evaluation of algorithms, which considers both precision and recall. The F-score
will be equal to 1 if the algorithm has perfect precision and recall. F-score with
values between 0 and 1 usually gives a reasonable rank ordering of different
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Table 7.7: Comparison of prediction performances of different descriptors
(proposed, MACCS, ECF and Path) to identify active compounds in Salmonella
biofilm formation. The results are given in terms of test AUC, F-score and
accuracy which illustrating the ability of the proposed descriptor to identify
compounds with very high activity against the biofilms. The other descriptors
missed the ability to identify active compounds at the lower IC50 cut-off values,
but with increasing cut-off values, MACCS on Pseudomonas outperformed all
the other descriptors.
IC50 10 20 30 40 50 100
SALMONELLA
Proposed Approach AUC 0.500 0.722 0.691 0.548 0.548 0.625
F-score NIL 0.286 0.571 0.444 0.546 0.800
accuracy 0.900 0.600 0.700 0.500 0.500 0.700
MACCS AUC 0.500 0.500 0.500 0.700 0.643 0.625
F-score NIL NIL NIL 0.714 0.444 0.714
accuracy 0.900 0.800 0.700 0.700 0.500 0.700
ECF AUC 0.500 0.500 0.762 0.762 0.643 0.562
F-score NIL NIL 0.667 0.667 0.444 0.769
accuracy 0.900 0.800 0.800 0.800 0.500 0.600
Path AUC 0.500 0.750 0.667 0.667 0.571 0.875
F-score NIL 0.200 0.500 0.500 0.250 0.857
accuracy 0.900 0.900 0.800 0.600 0.400 0.800
NIL: If all 10 compounds are identified as inactive by the specific descriptor with corresponding IC50
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Table 7.8: Comparison of prediction performances of different descriptors
(proposed, MACCS, ECF and Path) to identify active compounds in
Pseudomonas biofilm formation. The results are given in terms of test AUC,
F-score and accuracy which illustrating the ability of the proposed descriptor
to identify compounds with very high activity against the biofilms. The other
descriptors missed the ability to identify active compounds at the lower IC50
cut-off values.
IC50 10 20 30 40 50 100
PSEUDOMONAS
Proposed Approach AUC 1.000 0.625 0.4524 0.4524 0.4167 0.4167
F-score 1.000 0.400 0.444 0.444 0.500 0.286
accuracy 1.000 0.700 0.500 0.500 0.400 0.500
MACCS AUC 0.500 0.687 0.833 0.929 0.792 0.625
F-score NIL 0.500 0.800 0.857 0.750 0.800
accuracy 0.800 0.800 0.900 0.900 0.800 0.700
ECF AUC 0.500 0.563 0.500 0.595 0.542 0.500
F-score NIL 0.363 NIL 0.400 0.545 0.750
accuracy 0.800 0.700 0.700 0.700 0.500 0.600
Path AUC 0.500 0.563 0.667 0.833 0.595 0.500
F-score NIL 0.364 0.500 0.800 0.400 0.571
accuracy 0.800 0.700 0.800 0.900 0.600 0.600
NIL: If all 10 compounds are identified as inactive by the specific descriptor with corresponding IC50
algorithms/classifiers. Compared to other descriptors, the proposed weighted
chemical descriptor significantly outperformed in terms of F-score in both case
studies.
The results of the validation set illustrated the ability of the proposed descriptor
to identify compounds with very high activity against the biofilms. It is noted
that the other descriptors have missed the ability to identify active compounds
at the lower IC50 cut-off values. However, with increasing cut-off values,
MACCS on Pseudomonas outperformed all the other descriptors. The proposed
model with validation data obtained the best performance at IC50 = 10 µM,
similar to the test data. It is noted that for the lower IC50 cut-off values, the
number of active compounds in the trained model was very small. Even with
this small number of active compounds in the trained model, the weighted
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chemical descriptor captured enough information to distinguish active and
inactive compounds. This indicates that an increase in the ratio of positive to
negative training instances greatly influences the performance of the classifiers.
To the best of our knowledge, this is the first time in chemoinformatics that a
prediction model is developed on a connection-table based chemical descriptors
and a weighted LS-SVM classifier. We admit that the time needed for building
the predictive model for the weighted LS-SVM classifier was expensive in
terms of parameter optimization. In general, the use of connection-table based
descriptor in combination with the weighted LS-SVM approach could be applied
successfully in the area of of chemoinformatics to identify very active compounds
in a given biological condition.
7.6 Conclusion
It is a challenge for the researcher in chemoinformatics to extract knowledge
from the chemical structure. In our analysis, PCA was used to decompose
the connection-table of each compound effectively to a low dimensional
representation, as such defining a new structural descriptor of chemical
compounds. Then a weighted LS-SVM approach was used to design a weighted
chemical descriptor and to predict the biological activity of chemical compounds.
The results illustrate that the obtained descriptor offers an improved model to
identify very active compounds in a specific biological condition. The proposed
machine learning technique could be applied to any classification/prediction
problem which is based on the molecular structure of compounds.
Chapter 8
Conclusion and Future
Research
High dimensional and heterogeneous biological data sets always raises challenges
in computational biology and chemistry. The aim of this thesis is therefore,
to develop and use mathematical techniques for dimensionality reduction and
data integration. Microarray data analysis offers the improved health care, but
to get there, genomic data must be integrated with clinical information. A
huge amount of important biomedical data is hidden in the bulk of research
articles in the biomedical fields. The integration of information from the
literature, gathered by text mining, with microarray data are essential for
better biological understanding and validation of new biological hypothesis. We
therefore, focused not only on the integration of clinical and microarray data
sets to improve clinical decision support but also including the incorporation
of literature information into microarray data analysis for better prognosis of
diseases. In addition to the applications of these techniques in bioinformatics,
we explained the importance of data integration in chemoinformatics with case
studies, especially for identification of the activity of chemical compounds for a
specific biological condition.
Presently, due to the availability of massive biomedical data on each individual,
both health care and life science is becoming data-driven. The input features
are structured/un-structured data with many challenges, including sparse-
binary features, non-unique distributed structure, and high dimensional data,
which reducing accurate clinical decision in clinical practice [53]. In recent
decades, considerable effort has been made toward overcoming most of these
challenges, but still there is an essential need for significant improvements in
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this field for future personalized medicine. We suggest future work be conducted
to investigate and use big data analytics and large-scale machine learning
frameworks to tackle most of the challenges and provide high-quality health
care with reduced cost.
8.1 Conclusion
Data integration plays an important role in combining clinical, and environ-
mental data with high-throughput genomic data to identify functions of genes,
proteins, and other aspects of the genome [74]. Integrating data from different
sources is, therefore, an important part of current research in genomics and
proteomics. The identification of disease-associated genes and classification of
patients require not only an understanding of the genetic basis of the disease,
but also the correlation of this data with knowledge normally processed in the
clinical setting [6]. Although several research groups have already proposed
GSVD [3] to obtain common information between two data sets, we considered
MLGEVD/GEVD as a pre-processing step in which both clinical and microarray
data were used together to obtain the generalized eigenvectors, a process
common to both methods. We integrated two data sources with a common
process in a maximum likelihood framework [174] to obtain the generalized
eigenvectors in which one data source acts as the prior information. This data
framework will be useful if the availability of one type of biological information is
limited and considered them as the prior information in the model development.
Microarray data, which was difficult and expensive to collect were incorporated
as prior information into clinical decision-making, improving the classification
performance and offering better diagnosis and prognosis. Incorporation of
literature information into microarray analysis improved the possibility for
obtaining stable disease associated genes. In cancer studies, generally combining
these types of heterogeneous data improved the performance of decision support.
In the near future, one can investigate the applicability of MLGEVD to more
than two matrices and interpret these matrix results in a Bayesian context.
If the prior data set is very large with many features, overfitting may occur
in the model development which reducing the performance of the model on
unseen/validation data. The linear projections based on GEVD will not perform
very well in the model development, if the primary data source contains only
limited number of features. To tackle these problems either we have to perform
the projection based on kernel based GEVD or remove irrelevant features from
the prior data using feature selection techniques.
Considering the statistically noisy nature of microarray data (much more
variables than observations) and large collection of existing biological knowledge,
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it is essential to exploit that knowledge for analysis and understanding
of microarray data [125]. Text mining techniques constitute a promising
technology for automating the incorporation of scientific knowledge in the
microarray data mining process [125]. In recent years, there has been a growing
interest in identifying/designing data integration and visualization techniques
which simultaneously discover patterns occurring in multiple data sources.
Incorporation of literature information into gene expression data analysis is
an example of such a scenario, which is concerned with the analysis of the
actual expression data in conjunction with existing textual information on genes,
proteins, diseases, and so on.
The data integration approach in Chapter 3 is built on the SVD framework,
but one major disadvantage of classical SVD is its brittleness with respect to
grossly corrupted or outlying observations. Random errors are unavoidable in
modern applications in imaging and bioinformatics, where some measurements
may be arbitrarily corrupted or simply irrelevant to the structure we are trying
to identify. We, therefore, developed an RPCA approach in Chapter 4 for
integrating data resources and finding and exploiting low-dimensional structure
in high-dimensional data where data sets now routinely lie in thousand- or even
million-dimensional observation spaces. RPCA is a modification of the widely
used statistical procedure PCA, which works well with respect to corrupted
observations. Microarray data are commonly perceived as being extremely noisy
because of many imperfections inherent in the current technology. Hence, we
focused on RPCA to identify differentially expressed genes from highly corrupted
microarray data set. Moreover, our studies show that RPCA on the weighted
microarray data sets with literature information, identify disease-associated
genes much accurately than RPCA on microarray data. The Augmented
Lagrange multiplier based RPCA algorithms are simpler to analyze and easier
to implement [110], compared to accelerated proximal gradient based methods.
Moreover, they are also of much higher accuracy as the iterations are proven
to converge to the exact solution of the problem. Incorporation of biological
literature information into microarray data analysis improved the identification
of stable genes associated with disease and offer better diagnosis and prognosis
in cancer clinical decision making.
In Chapters 3 and 4, we discussed MLGEVD and RPCA, which are linear
dimensionality reduction techniques, which fail to capture the nonlinear
relationship in the data. Kernel methods provide a vectorial representation of
any kind of data by mapping them into high dimensional feature space. Kernel
based machine learning algorithms become an important research area and has
wide applications in image, signal processing, and pattern recognition [108].
To discover the non-linear relationship in the data, kernel methods are widely
used in dimensionality reduction techniques, namely KPCA, kernel discriminant
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analysis (KDA) etc. Studies show that KPCA performs better than PCA in
many applications [1]. But the performance of KPCA completely depends
on the parameter selection of kernel functions. In addition, the unsupervised
dimensionality reduction methods are most useful in the practical applications
in which the labeled data are usually expensive to collect. Chapter 5 provides
a solution to these two problems, that is, it offers a data driven bandwidth
selection criterion for KPCA which is executing in an unsupervised mode.
Although several researchers have already proposed several non-linear data
integration models, they are coupled with the selected classifiers. We proposed
a kernel-based mathematical framework for data integration and classification:
a weighted LS-SVM classifier. Compared with the existing approaches, the
proposed approach will be a simple mathematical framework for kernel based
data integration. This framework can be applied to any two complex data
sources which have a common space and the final goal is to make a prediction
or classification based on this common space. In this framework, the weight
assigned to the second kernel matrix can be obtained from the data, using cross-
validation approaches. In our integration framework, two data sets should not be
completely redundant. This mathematical framework developed based on kernel
GEVD approach have used the second matrix as the weighted matrix for the
model development. The noisy/corrupted data source generally considered as
the second matrix which adding additional information to the primary resource
(first matrix) to perform better classification/prediction. This approach could be
considered as a standard mathematical problem to produce better classification
performance based on heterogeneous data integration.
Machine learning techniques have been widely used in drug discovery and
development especially in the areas of chemoinformatics. In chemoinformatics,
machine learning has been widely used in QSAR studies. In a generalized
machine learning algorithm, modern QSAR is characterized by the use of
chemical descriptors based on the structure of chemical compounds. Molecular
descriptors are generally used for representing structural and physiochemical
properties of compounds, ranging molecular weight to complex 2D and 3D
descriptors. As the descriptors based on molecule’s connection table, represent
the complete representation of the structure of the compounds, usually the
machine learning models based on these descriptors offers good prediction
performances. In Chapter 7, we proposed a new chemical descriptor from the
connection-table of compounds in terms of two vectors: one corresponding
to the atoms and the other to the bonds of each compound. To the best of
our knowledge, this is the first time in chemoinformatics a prediction model
is developed on the connection-table based chemical descriptors and weighted
LS-SVM classifier. This work further can be extended to integrate any two 2D or
3D descriptors and perform further prediction/classification. In addition to their
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application in traditional virtual screening, this framework can be combined
with structural information of chemical compounds in molecular docking to
predict potential off-target properties of any given compound.
8.2 Future Research
Integrating data from different sources creates many challenges in bioinformatics
[74]. In dealing with heterogeneous data, for example, one needs to convert data
from different sources into a single view or common dimension. It is important
to identify the methods which captures as much information as possible from
each individual data sources while integrating them. Data from different sources
might have different quality and informativity depending on their source such
as text, image, sequences and the experimental conditions that generated
the data. Data from different sources might also have different informativity
even if their quality is good and reliable; thus one source of data might give
us more information than the other in answering the biological question of
interest [74]. Extensive research is, therefore, needed for developing quality and
informativity scores for various genomic, genetic, and proteomic data. The data
exploitation aspect of data integration requires more attention in the usage of
prior knowledge, development of statistical methods and visualization tools to
analyze heterogeneous data sets [69].
The term bigdata intuitively describes a situation present in many research fields:
the amount of data generated by instruments is exploding, and in many cases
doubling over short periods of time [69]. Big data analytics is the use of advanced
analytic techniques against very large, diverse data sets that include different
types such as structured/unstructured and streaming/batch, and different sizes
from terabytes to zettabytes [138]. The real challenges in big data analytics are
gathering, storing large collections of data and extracting useful information
from these data set. Using advanced analytics techniques such as text analytics,
machine learning, predictive analytics, data mining, and statistics, researchers
and businesses can analyze previously unused data sources independently or
together with their existing enterprise data to gain new insights resulting in
significantly better and faster decisions. The traditional analytics techniques
are not scalable enough to support big data platform, only few machine learning
algorithms are available to process large data sets in a reasonable amount of
time. The following points are the challenges with the techniques proposed for
handling big data sets in this dissertation and to be tackled in future.
• The dimensionality reduction techniques such as PCA, SVD, EVD, GSVD
and GEVD, fail on large data sets due to the lack of computing resources
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such as memory space or, processing time. The big data technologies,
process large quantities of data within tolerable elapsed time. Therefore
in the future one can propose the implementation of these dimensionality
reduction techniques for these platform and overcome the technical
challenges with big data. One drawback of the RPCA approach is their
batch-processing nature. If the data set grows or changes over time, the
algorithm needs to run from scratch. This raises the question of how the
existing models can be extended to include the scalable data sets.
• In addition to class discovery, microarray experiments often aim to identify
individual genes that are differentially expressed under distinct conditions,
such as between two or more phenotypes, cell lines, under different
treatment types or diseased and healthy subjects [141]. As it is currently
largely unclear how molecular variants and their interactions determine
cancer pathogenesis and propensity, marker identification is valuable for
improving understanding of the molecular mechanisms of cancers and for
suggesting novel drug targets [189]. Kernel techniques help us to construct
different nonlinear versions of any algorithm which can be expressed in
terms of dot products, known as the kernel trick [147]. Thus, kernel
algorithms avoid the explicit usage of the input variables in the statistical
learning task. Kernel machines can be used to implement several learning
algorithms but they usually act as a black-box with respect to the input
variables[141]. Since biomarker signature discovery is an important area
in cancer studies, classification based on KPCA could be extended further
to uncover small sets of interpretable features/disease associated genes
from microarray data sets. For large data sets, the computation time
needed for matrix decomposition using the eigenvalue decomposition of
the kernel matrix may be excessive. Advanced techniques are required
to formulate the multivariate statistics, such as kernel PCA and kernel
regression, in matrix form over big data platforms.
• Besides the LS-SVM classifier that was used in this dissertation to improve
clinical decision support in cancer, the weighted LS-SVM classifier has
been investigated for data integration as well. In the future, our kernel
based integration method should be compared with other existing data
integration framework. Moreover, as these frameworks are complementary,
an ensemble approach can be applied. More accurate classifiers can be
obtained by not only combining different data types but also an outcome
of multiple classifiers. Furthermore the parameter optimization strategy,
especially for the bandwidth for kernel matrices and regularization term
can be improved. The work on novel chemoinformatics method for
identification of biofilm inhibitors can be further extended to screen
a set of compounds from PubChem, which are active in specific biological
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conditions prior to wet-laboratory testing. In addition, the current method
cannot address the questions such as the parameters which are important
for the activity of compound and how to modify molecules to improve the
activity in a specific biological condition etc. One can further extend this
method to answer such questions which helps medicinal chemist for the
discovery and development of new therapeutic agents.
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